

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Data from CENTRAL, Embase, ERIC, MEDLINE and PsycINFO

Treatment of Children with Mental Illness: Frequently Asked Questions about the Treatment of Mental Illness in Children.

(2009). (pp. 6): National Institute of Mental Health (NIMH). 6001 Executive Boulevard Room 8184 MSC 9663, Bethesda, MD 20892-9663.

Erratum: comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine (Human Psychopharmacology (2011) 26 (422-433) DOI: 10.1002/hup.1225). (2011). *Human psychopharmacology*, 26(7), 536. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/045/CN-01017045/frame.html> doi:10.1002/hup.1237

Aascher-Svanum, H., Novick, D., Haro, J., Bertsch, J., McDonnell, D., & Detke, H. (2014). Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection. *Neuropsychiatric Disease and Treatment*, 10, 1125-1131. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/543/CN-00995543/frame.html> doi:10.2147/NDT.S61409

Abu-Akel, A., & Abushua'leh, K. (2004). 'Theory of mind' in violent and nonviolent patients with paranoid schizophrenia. *Schizophrenia Research*, 69(1), 45-53. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/283/CN-00467283/frame.html> doi:10.1016/S0920-9964(03)00049-5

Abuzzahab, F. (1977). The treatment of schizophrenia with long-acting oral neuroleptics: a six-month double-blind investigation of penfluridol versus trifluoperazine. *Psychopharmacology bulletin*, 13(3), 26-27. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/448/CN-00016448/frame.html>

Addington, J., Epstein, I., Liu, L., French, P., Boydell, K. M., & Zipursky, R. B. (2011). A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. *Schizophrenia Research*, 125(1), 54-61. doi:<https://dx.doi.org/10.1016/j.schres.2010.10.015>

Aghotor, J., Pfueller, U., Moritz, S., Weisbrod, M., & Roesch-Ely, D. (2010). Metacognitive training for patients with schizophrenia (MCT): feasibility and preliminary evidence for its efficacy. *Journal of Behavior Therapy & Experimental Psychiatry*, 41(3), 207-211. doi:<https://dx.doi.org/10.1016/j.jbtep.2010.01.004>

Ahmed, A. O., Hunter, K. M., Goodrum, N. M., Batten, N. J., Birgenheir, D., Hardison, E., . . . Buckley, P. F. (2015). A randomized study of cognitive remediation for forensic and mental health patients with schizophrenia. *Journal of Psychiatric Research*, 68, 8-18. doi:<https://dx.doi.org/10.1016/j.jpsychires.2015.05.013>

Alexander, T. R., Crouch, K., Halstead, S., & Piachaud, J. (2006). Long-Term Outcome from a Medium Secure Service for People with Intellectual Disability. *Journal of Intellectual Disability Research*, 50(4), 305-315.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Allott, K., Alvarez-Jimenez, M., Killackey, E. J., Bendall, S., McGorry, P. D., & Jackson, H. J. (2011). Patient predictors of symptom and functional outcome following cognitive behaviour therapy or befriending in first-episode psychosis. *Schizophrenia Research*, 132(2-3), 125-130. doi:<https://dx.doi.org/10.1016/j.schres.2011.08.011>
- Almeida, O. P., MacLeod, C., Ford, A., Grafton, B., Hirani, V., Glance, D., & Holmes, E. (2014). Cognitive bias modification to prevent depression (COPE): study protocol for a randomised controlled trial. *Trials [Electronic Resource]*, 15, 282. doi:<https://dx.doi.org/10.1186/1745-6215-15-282>
- Alphs, L., Bossie, C., Fu, D., Ma, Y., & Kern, S. J. (2014). Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia. *Expert Opinion on Pharmacotherapy*, 15(7), 1029-1042. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/036/CN-01117036/frame.html> doi:10.1517/14656566.2014.909409
- Alphs, L., Bossie, C., Mao, L., Lee, E., & Starr, H. (2015). Treatment effect with paliperidone palmitate compared to oral antipsychotics in patients with early and more chronic schizophrenia. *Schizophrenia bulletin.*, 41, S299. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/793/CN-01087793/frame.html> doi:10.1093/schbul/sbv010
- Alphs, L., Bossie, C., Mao, L., Lee, E., & Starr, H. (2018). Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement. *Early intervention in psychiatry*, 12(1), 55-65. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/577/CN-01461577/frame.html> doi:10.1111/eip.12271
- Alphs, L., Bossie, C., Sliwa, J., Fu, D., Ma, Y., & Hulihan, J. (2013). Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. *Neuropsychiatric Disease and Treatment*, 9, 341-350. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/715/CN-01308715/frame.html> doi:10.2147/NDT.S36438
- Alphs, L., Bossie, C., Sliwa, J., Ma, Y.-W., & Turner, N. (2011). Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. *Annals of general psychiatry*, 10. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/528/CN-00887528/frame.html> doi:10.1186/1744-859X-10-12
- Alphs, L., Mao, L., Rodriguez, S., Hulihan, J., & Starr, H. (2014). Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia. *Journal of Clinical Psychiatry*, 75(12), 1388-1393. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/279/CN-01083279/frame.html> doi:10.4088/JCP.13m08965

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Alphs, L., Nasrallah, H., Bossie, C., Fu, D., Gopal, S., Hough, D., & Turkoz, I. (2016). Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. *International Clinical Psychopharmacology*, 31(4), 202-209. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/250/CN-01165250/frame.html> doi:10.1097/YIC.0000000000000125
- Alphs, L., Starr, H., Mao, L., Bossie, C., & Kim, E. (2015). Once-monthly paliperidone palmitate compared with oral conventional or oral atypical antipsychotic treatment in patients with schizophrenia. *European Neuropsychopharmacology*, 25, S524-s525. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/197/CN-01163197/frame.html>
- Alphs, L., Turkoz, I., & Fu, D.-J. (2015). Design of the schizophrenia disease recovery evaluation and modification (DREaM) study. *Biological psychiatry*, 77(9 suppl. 1), 202s. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/828/CN-01099828/frame.html>
- Alvarez-Jimenez, M., Gleeson, J. F., Cotton, S., Wade, D., Gee, D., Pearce, T., . . . McGorry, P. D. (2009). Predictors of adherence to cognitive-behavioural therapy in first-episode psychosis. *Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie*, 54(10), 710-718.
- Alvarez-Jimenez, M., Gleeson, J. F., Cotton, S. M., Wade, D., Crisp, K., Yap, M. B., & McGorry, P. D. (2010). Differential predictors of critical comments and emotional over-involvement in first-episode psychosis. *Psychological Medicine*, 40(1), 63-72. doi:<https://dx.doi.org/10.1017/S0033291708004765>
- Alvarez-Jimenez, M., Martinez-Garcia, O., Perez-Iglesias, R., Ramirez, M. L., Vazquez-Barquero, J. L., & Crespo-Facorro, B. (2010). Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. *Schizophrenia Research*, 116(1), 16-19. doi:<https://dx.doi.org/10.1016/j.schres.2009.10.012>
- Alvarez-Jimenez, M., Wade, D., Cotton, S., Gee, D., Pearce, T., Crisp, K., . . . Gleeson, J. F. (2008). Enhancing treatment fidelity in psychotherapy research: Novel approach to measure the components of cognitive behavioural therapy for relapse prevention in first-episode psychosis. *Australian and New Zealand Journal of Psychiatry*, 42(12), 1013-1020. doi:<http://dx.doi.org/10.1080/00048670802512057>
- Amado, I., Bourdel, M., Daban, C., Poirier, M., Loo, H., Bouhours, P., & Krebs, M. (2009). Preattentional processes and disorganization in schizophrenia: Influence of a 6-week risperidone treatment. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 33(7), 1107-1112. doi:<http://dx.doi.org/10.1016/j.pnpbp.2009.06.004>
- Amminger, G., Harris, M., McGorry, P., & Henry, L. (2013). Omega-3 fatty acids for indicated prevention: treatment results and pathomechanisms. *European archives of psychiatry and clinical neuroscience*, 263(1 suppl. 1), S44-s45. Retrieved

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/131/CN-01024131/frame.html> doi:10.1007/s00406-013-0433-0

Anand, E., Berggren, L., Landry, J., Popescu, M., Toth, A., & Detke, H. (2015). Clinical outcomes with olanzapine longacting injection: impact of the 3-hour observation period on patient satisfaction and well-being. *European neuropsychopharmacology*, 25, S535-s536. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/058/CN-01129058/frame.html>

Anand, E., Berggren, L., Landry, J., Toth, A., & Detke, H. (2016). Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being. *Neuropsychiatric Disease and Treatment*, 12, 2737-2743. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/297/CN-01246297/frame.html> doi:10.2147/NDT.S107266

Anderson, K. H., Ford, S., Robson, D., Cassis, J., Rodrigues, C., & Gray, R. (2010). An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia. *International Journal of Mental Health Nursing*, 19(5), 340-349. doi:<https://dx.doi.org/10.1111/j.1447-0349.2010.00681.x>

Andres, K., Pfammatter, M., Fries, A., & Brenner, H. D. (2003). The significance of coping as a therapeutic variable for the outcome of psychological therapy in schizophrenia. *European Psychiatry: the Journal of the Association of European Psychiatrists*, 18(4), 149-154.

Andrews, M., Baker, A. L., Halpin, S. A., Lewin, T. J., Richmond, R., Kay-Lambkin, F. J., . . . Callister, R. (2016). Early Therapeutic Alliance, Treatment Retention, and 12-Month Outcomes in a Healthy Lifestyles Intervention for People with Psychotic Disorders. *Journal of Nervous & Mental Disease*, 204(12), 894-902.

Anonymous. (2001). Pharmacogenomics: Can we predict response to antipsychotics? *Pharmaceutical Journal*, 267(7172), 658-659.

Anonymous. (2010). Metformin may be useful in managing atypical antipsychotic-induced metabolic problems. *Drugs and Therapy Perspectives*, 26(11), 14-17. doi:<http://dx.doi.org/10.2165/11206170-000000000-00000>

Appelbaum, P., Robbins, P., & Roth, L. (1999). Dimensional approach to delusions: comparison across types and diagnoses. *American Journal of Psychiatry*, 156(12), 1938-1943. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/722/CN-00264722/frame.html> doi:10.1176/ajp.156.12.1938

Appelbaum, P. S., Robbins, P. C., & Roth, L. H. (1999). Dimensional approach to delusions: comparison across types and diagnoses. *American Journal of Psychiatry*, 156(12), 1938-1943.

Apud, J., Tong, Y., Vargas, T., Rasetti, R., Callicott, J., Das, B., . . . Berman, K. (2016). Disease severity and the modulatory effect of tolcapone on cognitive information processing in patients with schizophrenia. *Neuropsychopharmacology. Conference: 55th annual meeting of the american college of neuropsychopharmacology, ACNP 2016. United states*.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Conference start: 20161204. Conference end: 20161208, 41, S226-s227. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/625/CN-01306625/frame.html> doi:10.1038/npp.2016.240

- Arango, C., Bombín, I., González-Salvador, T., García-Cabeza, I., & Bobes, J. (2006). Randomised clinical trial comparing oral versus depot formulations of zuclopentixol in patients with schizophrenia and previous violence. *European Psychiatry*, 21(1), 34-40. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/752/CN-00561752/frame.html> doi:10.1016/j.eurpsy.2005.07.006
- Arce, C. R., Eding, E., Marques-Teixeira, J., Milanova, V., Rancans, E., & Schreiner, A. (2012). Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). *European Archives of Psychiatry and Clinical Neuroscience*, 262(2), 139-149. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/404/CN-00843404/frame.html> doi:10.1007/s00406-011-0220-8
- Asarnow, J. R., Porta, G., Spirito, A., Emslie, G., Clarke, G., Wagner, K. D., . . . Brent, D. A. (2011). Suicide attempts and nonsuicidal self-injury in the Treatment of Resistant Depression in Adolescents: Findings from the TORDIA study. *Journal of the American Academy of Child & Adolescent Psychiatry*, 50(8), 772-781.
doi:<http://dx.doi.org/10.1016/j.jaac.2011.04.003>
- Ascher-Svanum, H., Novick, D., Haro, J., Bertsch, J., McDonnell, D., & Detke, H. (2012). Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long acting injection. *International journal of neuropsychopharmacology*, 15, 110. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/328/CN-01065328/frame.html> doi:10.1017/S1461145712000508
- Ascher-Svanum, H., Novick, D., Haro, J., Bertsch, J., McDonnell, D., & Detke, H. (2013). Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study. *BMC Psychiatry*, 13, 224. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/488/CN-01121488/frame.html> doi:10.1186/1471-244X-13-224
- Ascher-Svanum, H., Peng, X., Montgomery, W., Faries, D., Lawson, A., Witte, M., . . . McDonnell, D. (2011). Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. *European Psychiatry*, 26(5), 313-319. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/798/CN-00887798/frame.html> doi:10.1016/j.eurpsy.2010.03.015
- Ascher-Svanum, H., Zhao, F., Detke, H., Nyhuis, A., Lawson, A., Stauffer, V., . . . McDonnell, D. (2011). Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. *BMC Psychiatry*, 11, 152. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/675/CN-00805675/frame.html> doi:10.1186/1471-244X-11-152

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Au, D. W., Tsang, H. W., So, W. W., Bell, M. D., Cheung, V., Yiu, M. G., . . . Lee, G. T. (2015). Effects of integrated supported employment plus cognitive remediation training for people with schizophrenia and schizoaffective disorders. *Schizophrenia Research*, 166(1-3), 297-303. doi:<https://dx.doi.org/10.1016/j.schres.2015.05.013>
- Aymard, N., Viala, A., Stein, I., & Caroli, F. (1995). Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 19(7), 1119-1135. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/906/CN-00125906/frame.html>
- Bach, P., & Hayes, S. (2002). The use of acceptance and commitment therapy to prevent the rehospitalization of psychotic patients: a randomized controlled trial. *Journal of Consulting and Clinical Psychology*, 70(5), 1129-1139. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/272/CN-00398272/frame.html>
- Bach, P., & Hayes, S. C. (2002). The use of acceptance and commitment therapy to prevent the rehospitalization of psychotic patients: a randomized controlled trial. *Journal of Consulting & Clinical Psychology*, 70(5), 1129-1139.
- Bach, P., & Hayes, S. C. (2017). The use of acceptance and commitment therapy to prevent the rehospitalization of psychotic patients: A randomized controlled trial *Mindfulness: Clinical applications of mindfulness and acceptance: Specific interventions for psychiatric, behavioural, and physical health conditions*, Vol (pp. III (pp. 26-48). xii, 648). New York, NY: Routledge/Taylor & Francis Group; US.
- Bach, P., Hayes, S. C., & Gallop, R. (2012). Long-Term Effects of Brief Acceptance and Commitment Therapy for Psychosis. *Behavior Modification*, 36(2), 165-181.
- Bacon, T., Farhall, J., & Fossey, E. (2014). The active therapeutic processes of acceptance and commitment therapy for persistent symptoms of psychosis: clients' perspectives. *Behavioural & Cognitive Psychotherapy*, 42(4), 402-420. doi:<https://dx.doi.org/10.1017/S1352465813000209>
- Bacon, T., Farhall, J., & Fossey, E. (2014). The active therapeutic processes of acceptance and commitment therapy for persistent symptoms of psychosis: clients' perspectives. *Behavioural and Cognitive Psychotherapy*, 42(4), 402-420. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/941/CN-01123941/frame.html> doi:10.1017/S1352465813000209
- Bai, Y., Chen, T., Wu, B., Hung, C., Lin, W., Hu, T., . . . Chou, P. (2006). A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. *Pharmacopsychiatry*, 39(4), 135-141. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/599/CN-00571599/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Bai, Y., Ting, C. T., Chen, J., Chang, W., Wu, B., Hung, C., & Kuo, L. W. (2007). Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. *Journal of Clinical Psychiatry*, 68(8), 1218-1225. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/043/CN-00612043/frame.html>
- Baker, A., Bucci, S., Lewin, T. J., Kay-Lambkin, F., Constable, P. M., & Carr, V. J. (2006). Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial. *British Journal of Psychiatry*, 188, 439-448.
- Baker, A., Richmond, R., Haile, M., Lewin, T. J., Carr, V. J., Taylor, R. L., . . . Moeller-Saxone, K. (2007). Characteristics of smokers with a psychotic disorder and implications for smoking interventions. *Psychiatry Research*, 150(2), 141-152.
- Baker, A., Richmond, R., Haile, M., Lewin, T. J., Carr, V. J., Taylor, R. L., . . . Wilhelm, K. (2006). A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. *American Journal of Psychiatry*, 163(11), 1934-1942.
- Baker, A., Richmond, R., Lewin, T. J., & Kay-Lambkin, F. (2010). Cigarette smoking and psychosis: naturalistic follow up 4 years after an intervention trial. *Australian & New Zealand Journal of Psychiatry*, 44(4), 342-350.
doi:<https://dx.doi.org/10.3109/00048670903489841>
- Baker, A., Turner, A., Kay-Lambkin, F. J., & Lewin, T. J. (2009). The long and the short of treatments for alcohol or cannabis misuse among people with severe mental disorders. *Addictive Behaviors*, 34(10), 852-858.
doi:<https://dx.doi.org/10.1016/j.addbeh.2009.02.002>
- Baldwin, D., Hawley, C., Abed, R., Maragakis, B., White, A., Cox, J., . . . Frenkell, R. (1995). A Multicentre Comparison of Nefazodone and Paroxetine in Depressed Outpatients CONFERENCE ABSTRACT. *8th european college of neuropsychopharmacology congress. Venice, italy. 30th september - 4th october, 1995*. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/571/CN-00278571/frame.html>
- Ban, T. (1971). Systematic studies with long acting neuroleptics. *V world congress of psychiatry, ciudad de mexico. 28 november - 4 december 1971*. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/321/CN-00319321/frame.html>
- Barak, N., Beck, Y., & Albeck, J. (2016). Betahistine decreases olanzapine-induced weight gain and somnolence in humans. *Journal of psychopharmacology (oxford, england)*, 30(3), 237-241. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/189/CN-01138189/frame.html> doi:10.1177/0269881115626349
- Baran, B., Demanuele, C., Vuper, T., Seicol, B., Fowler, R., Correll, D., . . . Manoach, D. (2017). The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a double-blind randomized trial. *Sleep. Conference: 31st*

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

anniversary meeting of the associated professional sleep societies, LLC, SLEEP 2017. United states, 40, A415.

Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/392/CN-01375392/frame.html>

Bark, N., Revheim, N., Huq, F., Khalderov, V., Ganz, Z. W., & Medalia, A. (2003). The impact of cognitive remediation on psychiatric symptoms of schizophrenia. *Schizophrenia Research*, 63(3), 229-235.

Barnes, T., Drake, R., Dunn, G., Hayhurst, K., Jones, P., & Lewis, S. (2013). Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes. *British Journal of Psychiatry*, 203(3), 215-220.

Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/919/CN-00917919/frame.html>

doi:10.1192/bjp.bp.113.125807

Barnett, P., Scott, J., Krystal, J., & Rosenheck, R. (2012). Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. *Journal of Clinical Psychiatry*, 73(5), 696-702. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/314/CN-00840314/frame.html> doi:10.4088/JCP.11m07070

Barnett, P., Scott, J., & Rosenheck, R. (2011). How do clinical trial participants compare to other patients with schizophrenia? *Schizophrenia Research*, 130(1-3), 34-39. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/977/CN-00811977/frame.html> doi:10.1016/j.schres.2011.03.033

Barrett, B., Waheed, W., Farrelly, S., Birchwood, M., Dunn, G., Flach, C., . . . Byford, S. (2013). Randomised controlled trial of joint crisis plans to reduce compulsory treatment for people with psychosis: economic outcomes. *PLoS ONE [Electronic Resource]*, 8(11), e74210. doi:<https://dx.doi.org/10.1371/journal.pone.0074210>

Barrett, B., Waheed, W., Farrelly, S., Birchwood, M., Dunn, G., Flach, C., . . . Byford, S. (2013). Randomised controlled trial of joint crisis plans to reduce compulsory treatment for people with psychosis: economic outcomes. *PLoS ONE [Electronic Resource]*, 8(11), e74210. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/002/CN-01038002/frame.html> doi:10.1371/journal.pone.0074210

Barrowclough, C., Haddock, G., Lobban, F., Jones, S., Siddle, R., Roberts, C., & Gregg, L. (2006). Group cognitive-behavioural therapy for schizophrenia. Randomised controlled trial. *British Journal of Psychiatry*, 189, 527-532.

Barrowclough, C., Haddock, G., Tarrier, N., Lewis, S. W., Moring, J., O'Brien, R., . . . McGovern, J. (2001). Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. *American Journal of Psychiatry*, 158(10), 1706-1713.

Barrowclough, C., Haddock, G., Wykes, T., Beardmore, R., Conrod, P., Craig, T., . . . Tarrier, N. (2010). Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. *BMJ*, 341, c6325. doi:<https://dx.doi.org/10.1136/bmj.c6325>

Barrowclough, C., Marshall, M., Gregg, L., Fitzsimmons, M., Tomenson, B., Warburton, J., & Lobban, F. (2014). A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

randomized controlled trial. *Psychological Medicine*, 44(13), 2749-2761.

doi:<https://dx.doi.org/10.1017/S0033291714000208>

Barrowclough, C., Meier, P., Beardmore, R., & Emsley, R. (2010). Predicting therapeutic alliance in clients with psychosis and substance misuse. *Journal of Nervous & Mental Disease*, 198(5), 373-377.

doi:<https://dx.doi.org/10.1097/NMD.0b013e3181da4d4e>

Barton, G. R., Hodgekins, J., Mugford, M., Jones, P. B., Croudace, T., & Fowler, D. (2009). Cognitive behaviour therapy for improving social recovery in psychosis: cost-effectiveness analysis. *Schizophrenia Research*, 112(1-3), 158-163.

doi:<https://dx.doi.org/10.1016/j.schres.2009.03.041>

Bartzokis, G., Lu, P., Amar, C., Raven, E., Detore, N., Altshuler, L., . . . Nuechterlein, K. (2011). Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. *Schizophrenia Research*, 132(1), 35-41. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/630/CN-00810630/frame.html> doi:10.1016/j.schres.2011.06.029

Bartzokis, G., Lu, P., Raven, E., Amar, C., Detore, N., Couvrette, A., . . . Nuechterlein, K. (2012). Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. *Schizophrenia Research*, 140(1-3), 122-128. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/255/CN-00840255/frame.html> doi:10.1016/j.schres.2012.06.036

Bateman, K., Hansen, L., Turkington, D., & Kingdon, D. (2007). Cognitive behavioral therapy reduces suicidal ideation in schizophrenia: results from a randomized controlled trial. *Suicide & Life-Threatening Behavior*, 37(3), 284-290.

Beauchamp, M. C., Lecomte, T., Lecomte, C., Leclerc, C., & Corbiere, M. (2011). Personality traits in early psychosis: relationship with symptom and coping treatment outcomes. *Early intervention in psychiatry*, 5(1), 33-40.

doi:<https://dx.doi.org/10.1111/j.1751-7893.2010.00198.x>

Beauchamp, M. C., Lecomte, T., Lecomte, C., Leclerc, C., & Corbiere, M. (2013). Do personality traits matter when choosing a group therapy for early psychosis? *Psychology & Psychotherapy: Theory, Research & Practice*, 86(1), 19-32.

doi:<https://dx.doi.org/10.1111/j.2044-8341.2011.02052.x>

Bechdolf, A., Knost, B., Kuntermann, C., Schiller, S., Klosterkotter, J., Hambrecht, M., & Pukrop, R. (2004). A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia.[Erratum appears in Acta Psychiatr Scand. 2004 Dec;110(6):483]. *Acta Psychiatrica Scandinavica*, 110(1), 21-28.

Bechdolf, A., Knost, B., Nelson, B., Schneider, N., Veith, V., Yung, A. R., & Pukrop, R. (2010). Randomized comparison of group cognitive behaviour therapy and group psychoeducation in acute patients with schizophrenia: effects on subjective quality of life. *Australian & New Zealand Journal of Psychiatry*, 44(2), 144-150.

doi:<https://dx.doi.org/10.3109/00048670903393571>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Bechdolf, A., Kohn, D., Knost, B., Pukrop, R., & Klosterkotter, J. (2005). A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in acute patients with schizophrenia: outcome at 24 months. *Acta Psychiatrica Scandinavica*, 112(3), 173-179.
- Bechdolf, A., Muller, H., Stutzer, H., Wagner, M., Maier, W., Lautenschlager, M., . . . group, P. s. (2011). Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. *Schizophrenia Bulletin*, 37 Suppl 2, S111-121. doi:<https://dx.doi.org/10.1093/schbul/sbr083>
- Bechdolf, A., Phillips, L. J., Francey, S. M., Leicester, S., Morrison, A. P., Veith, V., . . . McGorry, P. D. (2006). Recent approaches to psychological interventions for people at risk of psychosis. *European Archives of Psychiatry & Clinical Neuroscience*, 256(3), 159-173.
- Bechdolf, A., Ruhrmann, S., Wagner, M., Kuhn, K. U., Janssen, B., Bottlender, R., . . . Klosterkotter, J. (2005). Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. *British Journal of Psychiatry - Supplementum*, 48, s45-48.
- Bechdolf, A., Wagner, M., Ruhrmann, S., Harrigan, S., Putzfeld, V., Pukrop, R., . . . Klosterkotter, J. (2012). Preventing progression to first-episode psychosis in early initial prodromal states. *British Journal of Psychiatry*, 200(1), 22-29. doi:<https://dx.doi.org/10.1192/bjp.bp.109.066357>
- Bechdolf, A., Wagner, M., Veith, V., Ruhrmann, S., Pukrop, R., Brockhaus-Dumke, A., . . . Klosterkotter, J. (2007). Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. *Early intervention in psychiatry*, 1(1), 71-78. doi:<https://dx.doi.org/10.1111/j.1751-7893.2007.00013.x>
- Bechelli, L., Iocco, M., Acioli, A., & Pontes, M. (1985). A double-blind trial of haloperidol decanoate and pipothiazine palmitate in the maintenance treatment of schizophrenics in a public out-patient clinic. *CURR. THER. Res., clin. EXP.*, 37(4), 662-671. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/150/CN-00183150/frame.html>
- Bechelli, L., & Navas-Filho, F. (1986). Short-term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia. *Encephale*, 12(3), 121-125. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/995/CN-00044995/frame.html>
- Bechi, M., Bosia, M., Spangaro, M., Buonocore, M., Cocchi, F., Pigoni, A., . . . Cavallaro, R. (2015). Combined social cognitive and neurocognitive rehabilitation strategies in schizophrenia: neuropsychological and psychopathological influences on Theory of Mind improvement. *Psychological Medicine*, 45(15), 3147-3157. doi:<https://dx.doi.org/10.1017/S0033291715001129>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Bechi, M., Riccaboni, R., Ali, S., Fresi, F., Buonocore, M., Bosia, M., . . . Cavallaro, R. (2012). Theory of mind and emotion processing training for patients with schizophrenia: preliminary findings. *Psychiatry Research*, 198(3), 371-377.
doi:<https://dx.doi.org/10.1016/j.psychres.2012.02.004>
- Bell, M., Bryson, G., & Wexler, B. E. (2003). Cognitive remediation of working memory deficits: durability of training effects in severely impaired and less severely impaired schizophrenia. *Acta Psychiatrica Scandinavica*, 108(2), 101-109.
- Bell, M., Fiszdon, J., Greig, T., Wexler, B., & Bryson, G. (2007). Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance. *Journal of Rehabilitation Research & Development*, 44(5), 761-770.
- Bell, M. D., Bryson, G. J., Greig, T. C., Fiszdon, J. M., & Wexler, B. E. (2005). Neurocognitive enhancement therapy with work therapy: Productivity outcomes at 6- and 12-month follow-ups. *Journal of Rehabilitation Research & Development*, 42(6), 829-838.
- Bell, M. D., Choi, K. H., Dyer, C., & Wexler, B. E. (2014). Benefits of cognitive remediation and supported employment for schizophrenia patients with poor community functioning. *Psychiatric Services*, 65(4), 469-475.
doi:<https://dx.doi.org/10.1176/appi.ps.201200505>
- Bell, M. D., Fiszdon, J. M., & Bryson, G. (2009). Attention training in schizophrenia: differing responses to similar tasks. *Journal of Psychiatric Research*, 43(4), 490-496. doi:<https://dx.doi.org/10.1016/j.jpsychires.2008.04.011>
- Bell, M. D., Zito, W., Greig, T., & Wexler, B. E. (2008). Neurocognitive enhancement therapy with vocational services: work outcomes at two-year follow-up. *Schizophrenia Research*, 105(1-3), 18-29.
doi:<https://dx.doi.org/10.1016/j.schres.2008.06.026>
- Bellnier, T., Janda, M., Ortega, T., Sundberg, J., Klajbor, K., & Insull, R. (2016). A pilot study to evaluate the risk of sexual dysfunction associated with long-term use of atypical long-acting injectable antipsychotics (LAIS) in the treatment of schizophrenia. *Journal of pharmacy practice. Conference: 19th annual meeting of the college of psychiatric and neurologic pharmacists, CPNP. United states*, 29(3), 275. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/015/CN-01362015/frame.html> doi:10.1177/0897190016645328
- Bellnier, T., Seeger, G., Ortega, T., Pierre, V., Patil, K., Strom, F., . . . Lennox, S. (2015). The potential role of aripiprazole long-acting injectable (LAI) for patients diagnosed with DSM-IV schizophrenia with comorbid substance abuse. *Journal of pharmacy practice. Conference: 18th annual meeting of the college of psychiatric and neurologic pharmacists, CPNP. United states*, 28(3), 330. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/042/CN-01362042/frame.html> doi:10.1177/0897190015582204
- Bellucci, D. M., Glaberman, K., & Haslam, N. (2003). Computer-assisted cognitive rehabilitation reduces negative symptoms in the severely mentally ill. *Schizophrenia Research*, 59(2-3), 225-232.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Bendall, S., Allott, K., Jovev, M., Marois, M. J., Killackey, E. J., Gleeson, J. F., . . . Jackson, H. J. (2015). Therapy contamination as a measure of therapist treatment adherence in a trial of cognitive behaviour therapy versus befriending for psychosis. *Behavioural & Cognitive Psychotherapy, 43*(3), 314-327. doi:<https://dx.doi.org/10.1017/S1352465813000921>
- Bennett, S., Heyman, I., Coughtrey, A., Simmonds, J., Varadkar, S., Stephenson, T., . . . Shafran, R. (2016). Guided self-help interventions for mental health disorders in children with neurological conditions: study protocol for a pilot randomised controlled trial. *Trials [Electronic Resource], 17*(1), 532.
- Berckel, B., Lipsch, C., Timp, S., Gispen, d. W. C., Wynne, H., Ree, J., & Kahn, R. (1996). Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects CONFERENCE ABSTRACT. *9th european college of neuropsychopharmacology congress. Amsterdam, the netherlands. 21st-25th september, 1996*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/263/CN-00285263/frame.html>
- Berry, K., Gregg, L., Hartwell, R., Haddock, G., Fitzsimmons, M., & Barrowclough, C. (2015). Therapist-client relationships in a psychological therapy trial for psychosis and substance misuse. *Drug & Alcohol Dependence, 152*, 170-176. doi:<https://dx.doi.org/10.1016/j.drugalcdep.2015.04.006>
- Berry, K., Gregg, L., Lobban, F., & Barrowclough, C. (2016). Therapeutic alliance in psychological therapy for people with recent onset psychosis who use cannabis. *Comprehensive Psychiatry, 67*, 73-80. doi:<https://dx.doi.org/10.1016/j.comppsych.2016.02.014>
- Berry, K., Gregg, L., Vasconcelos e Sa, D., Haddock, G., & Barrowclough, C. (2012). Staff-patient relationships and outcomes in schizophrenia: the role of staff attributions. *Behaviour Research & Therapy, 50*(3), 210-214. doi:<https://dx.doi.org/10.1016/j.brat.2012.01.004>
- Bertelsen, M., Jeppesen, P., Petersen, L., Thorup, A., Øhlenschlaeger, J., Quach, P., . . . Nordentoft, M. (2009). First episode of psychosis intensive early intervention programme versus standard treatment--secondary publication. *Ugeskrift for Laeger, 171*(41), 2992-2995. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/505/CN-00722505/frame.html>
- Berwaerts, J., Liu, Y., Gopal, S., Nuamah, I., Xu, H., Savitz, A., . . . Hough, D. (2015). Efficacy and safety of paliperidone palmitate 3 month formulation: a randomized, double-blind, placebo-controlled study. *Schizophrenia bulletin., 41*, S302. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/805/CN-01077805/frame.html> doi:[10.1093/schbul/sbv010](https://doi.org/10.1093/schbul/sbv010)
- Berwaerts, J., Liu, Y., Gopal, S., Nuamah, I., Xu, H., Savitz, A., . . . Hough, D. (2015). Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: a Randomized Clinical Trial. *JAMA Psychiatry, 72*(8), 830-839. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/723/CN-01086723/frame.html> doi:[10.1001/jamapsychiatry.2015.0241](https://doi.org/10.1001/jamapsychiatry.2015.0241)

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Bhatia, A., Bril, V., Brull, R., Perruccio, A., Wijeyesundara, D., Alvi, S., . . . Davis, A. (2016). Study protocol for a pilot, randomised, double-blinded, placebo controlled trial of perineural local anaesthetics and steroids for chronic post-traumatic neuropathic pain in the ankle and foot: the PREPLANS study. *BMJ Open*, 6(6) (no pagination). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/225/CN-01178225/frame.html>
doi:10.1136/bmjopen-2016-012293
- Bhattacharyya, S., Fusar-Poli, P., Borgwardt, S., Martin-Santos, R., Nosarti, C., O'Carroll, C., . . . McGuire, P. (2009). Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. *Archives of General Psychiatry*, 66(4), 442-451. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/575/CN-00687575/frame.html>
doi:10.1001/archgenpsychiatry.2009.17
- Biagi, E., Capuzzi, E., Colmegna, F., Mascalini, A., Brambilla, G., Ornaghi, A., . . . Clerici, M. (2017). Long-Acting Injectable Antipsychotics in Schizophrenia: literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. *Advances in therapy*, 1-13. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/785/CN-01366785/frame.html> doi:10.1007/s12325-017-0507-x
- Biederman, J., Gao, H., Rogers, A., & Spencer, T. (2006). Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. *Biological Psychiatry*, 60(10), 1106-1110. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/944/CN-00570944/frame.html> doi:10.1016/j.biopsych.2006.03.036
- Birchwood, M., Michail, M., Meaden, A., Lewis, S., Davies, L., Dunn, G., . . . Peters, E. (2014). The MRC command trial: results of a multi-centre, randomised controlled trial of cognitive therapy to prevent harmful compliance with command hallucinations. *Schizophrenia Research*, 153, S74. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/031/CN-01050031/frame.html>
- Birchwood, M., Michail, M., Meaden, A., Tarrier, N., Lewis, S., Wykes, T., . . . Peters, E. (2014). Cognitive behaviour therapy to prevent harmful compliance with command hallucinations (COMMAND): A randomised controlled trial. *The Lancet Psychiatry*, 1(1), 23-33. doi:<http://dx.doi.org/10.1016/S2215-0366%2814%2970247-0>
- Birchwood, M., Michail, M., Meaden, A., Tarrier, N., Lewis, S., Wykes, T., . . . Peters, E. (2014). Cognitive behaviour therapy to prevent harmful compliance with command hallucinations (COMMAND): a randomised controlled trial. *The Lancet Psychiatry*, 1(1), 23-33. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/211/CN-01040211/frame.html> doi:10.1016/S2215-0366%2814%2970247-0

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Birchwood, M., Peters, E., Tarrier, N., Dunn, G., Lewis, S., Wykes, T., . . . Michail, M. (2011). A multi-centre, randomised controlled trial of cognitive therapy to prevent harmful compliance with command hallucinations. *BMC Psychiatry*, 11, 155. doi:<https://dx.doi.org/10.1186/1471-244X-11-155>
- Bisol, L., Brunstein, M., Ottoni, G., Ramos, F., Borba, D., Daltio, C., . . . Lara, D. (2008). Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. *Journal of Clinical Psychiatry*, 69(10), 1572-1579. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/862/CN-00683862/frame.html>
- Bjerkenedt, L., Gullberg, B., Härnryd, C., & Sedvall, G. (1977). Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene. *Archiv für psychiatrie und nervenkrankheiten*, 224(2), 107-118. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/973/CN-00016973/frame.html>
- Blader, J. C., Pliszka, S. R., Kafantaris, V., Sauder, C., Posner, J., Foley, C. A., . . . Margulies, D. M. (2016). Prevalence and treatment outcomes of persistent negative mood among children with attention-deficit/hyperactivity disorder and aggressive behavior. *Journal of Child and Adolescent Psychopharmacology*, 26(2), 164-173. doi:<http://dx.doi.org/10.1089/cap.2015.0112>
- Blake, M., Schwartz, O., Waloszek, J. M., Raniti, M., Simmons, J. G., Murray, G., . . . Allen, N. B. (2017). The SENSE study: Treatment mechanisms of a cognitive behavioral and mindfulness-based group sleep improvement intervention for at-risk adolescents. *Sleep: Journal of Sleep and Sleep Disorders Research*, 40(6), 1-11. doi:<http://dx.doi.org/10.1093/sleep/zsx061>
- Blake, M., Waloszek, J. M., Schwartz, O., Raniti, M., Simmons, J. G., Blake, L., . . . Allen, N. B. (2016). The SENSE study: Post intervention effects of a randomized controlled trial of a cognitive-behavioral and mindfulness-based group sleep improvement intervention among at-risk adolescents. *Journal of Consulting and Clinical Psychology*, 84(12), 1039-1051. doi:<http://dx.doi.org/10.1037/ccp0000142>
- Blake, M. J., Snoep, L., Raniti, M., Schwartz, O., Waloszek, J. M., Simmons, J. G., . . . Allen, N. B. (2017). A cognitive-behavioral and mindfulness-based group sleep intervention improves behavior problems in at-risk adolescents by improving perceived sleep quality. *Behav Res Ther*, 99, 147-156. doi:<http://dx.doi.org/10.1016/j.brat.2017.10.006>
- Bloch, B., Reshef, A., Cohen, T., Tafla, A., Gathas, S., Israel, S., . . . Ebstein, R. P. (2010). Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia. *Psychiatry Research*, 175(1-2), 38-42. doi:<https://dx.doi.org/10.1016/j.psychres.2008.12.015>
- Boath, E., & Henshaw, C. (2001). The treatment of postnatal depression: A comprehensive literature review. *Journal of Reproductive and Infant Psychology*, 19(3), 215-248.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Boden, M., Gaudiano, B., Walser, R., Timko, C., Faustman, W., Yasmin, S., . . . McCarthy, J. (2016). Feasibility and challenges of inpatient psychotherapy for psychosis: lessons learned from a veterans health administration pilot randomized controlled trial. *BMC Research Notes*, 9, 376. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/254/CN-01165254/frame.html> doi:10.1186/s13104-016-2179-z
- Boden, M. T., Gaudiano, B. A., Walser, R. D., Timko, C., Faustman, W., Yasmin, S., . . . McCarthy, J. F. (2016). Feasibility and challenges of inpatient psychotherapy for psychosis: lessons learned from a veterans health administration pilot randomized controlled trial. *BMC Research Notes*, 9, 376. doi:<https://dx.doi.org/10.1186/s13104-016-2179-z>
- Bodick, N., & Offen, W. (1995). Xanomeline in Mild and Moderate Alzheimer's Disease; The Effects of a Novel M1 Agonist on Behavior CONFERENCE ABSTRACT. *8th european college of neuropsychopharmacology congress. Venice, italy. 30th september - 4th october, 1995*. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/895/CN-00278895/frame.html>
- Bodick, N., & Offen, W. (1996). The M1 Muscarinic Agonist Xanomeline Improves Both Cognitive and Behavioral Deficits in Alzheimer's Disease CONFERENCE ABSTRACT. *Xxth collegium internationale neuro-psychopharmacologicum. Melbourne, australia. 23rd-27th june, 1996*. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/892/CN-00278892/frame.html>
- Bolbecker, A., Hetrick, W., Johannessen, J., O'Donnell, B., Steinmetz, J., & Shekhar, A. (2009). Secretin effects on cerebellar-dependent motor learning in schizophrenia. *American Journal of Psychiatry*, 166(4), 460-466. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/292/CN-00688292/frame.html> doi:10.1176/appi.ajp.2008.08040597
- Bonsack, C., Gibellini Manetti, S., Favrod, J., Montagrin, Y., Besson, J., Bovet, P., & Conus, P. (2011). Motivational intervention to reduce cannabis use in young people with psychosis: a randomized controlled trial. *Psychotherapy & Psychosomatics*, 80(5), 287-297. doi:<https://dx.doi.org/10.1159/000323466>
- Bor, J., Brunelin, J., d'Amato, T., Costes, N., Suaud-Chagny, M. F., Saoud, M., & Poulet, E. (2011). How can cognitive remediation therapy modulate brain activations in schizophrenia? An fMRI study. *Psychiatry Research*, 192(3), 160-166. doi:<https://dx.doi.org/10.1016/j.psychresns.2010.12.004>
- Borras, L., Boucherie, M., Mohr, S., Lecomte, T., Perroud, N., & Huguelet, P. (2009). Increasing self-esteem: efficacy of a group intervention for individuals with severe mental disorders. *European Psychiatry: the Journal of the Association of European Psychiatrists*, 24(5), 307-316. doi:<https://dx.doi.org/10.1016/j.eurpsy.2009.01.003>
- Bosco, F. M., Bono, A., & Bara, B. G. (2012). Recognition and Repair of Communicative Failures: The Interaction between Theory of Mind and Cognitive Complexity in Schizophrenic Patients. *Journal of Communication Disorders*, 45(3), 181-197.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Bossie, C., Lasser, R., & Gharabawi, G. (2003). Low or absent pain and injection site effects with long-acting risperidone. *156th annual meeting of the american psychiatric association; 2003 may 17-22; san francisco, USA*. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/929/CN-00453929/frame.html>
- Bossie, C., Sliwa, J., Ma, Y., Fu, D., & Alphs, L. (2011). Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. *BMC Psychiatry*, 11, 79. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/506/CN-00843506/frame.html> doi:10.1186/1471-244X-11-79
- Bossie, C., Turkoz, I., Alphs, L., Mahalchick, L., & Fu, D. (2017). Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder. *Journal of Nervous and Mental Disease*, 205(4), 324-328. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/666/CN-01308666/frame.html> doi:10.1097/NMD.0000000000000646
- Bowie, C. R., McGurk, S. R., Mausbach, B., Patterson, T. L., & Harvey, P. D. (2012). Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior. *American Journal of Psychiatry*, 169(7), 710-718. doi:<https://dx.doi.org/10.1176/appi.ajp.2012.11091337>
- Bradford, A., Cully, J., Rhoades, H., Kunik, M., Kraus-Schuman, C., Wilson, N., & Stanley, M. (2011). Early response to psychotherapy and long-term change in worry symptoms in older adults with generalized anxiety disorder. *American Journal of Geriatric Psychiatry*, 19(4), 347-356. doi:<https://dx.doi.org/10.1097/JGP.0b013e3181f18061>
- Breier, A., Adler, C., Weisenfeld, N., Su, T.-P., Elman, I., Picken, L., . . . Pickar, D. (1998). Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. *Synapse (new york, N.Y.)*, 29(2), 142-147. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/201/CN-00352201/frame.html>
- Breier, A., Meehan, K., Birkett, M., David, S., Ferchland, I., Sutton, V., . . . Wright, P. (2002). A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. *Archives of General Psychiatry*, 59(5), 441-448. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/830/CN-00379830/frame.html>
- Breitborde, N. J., Bell, E. K., Dawley, D., Woolverton, C., Ceaser, A., Waters, A. C., . . . Harrison-Monroe, P. (2015). The Early Psychosis Intervention Center (EPICENTER): development and six-month outcomes of an American first-episode psychosis clinical service. *BMC Psychiatry*, 15, 266. doi:<https://dx.doi.org/10.1186/s12888-015-0650-3>
- Breitborde, N. J., Moreno, F. A., Mai-Dixon, N., Peterson, R., Durst, L., Bernstein, B., . . . McFarlane, W. R. (2011). Multifamily group psychoeducation and cognitive remediation for first-episode psychosis: a randomized controlled trial. *BMC Psychiatry*, 11, 9. doi:<https://dx.doi.org/10.1186/1471-244X-11-9>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Brenner, S. L., Burns, B. J., Curry, J. F., Silva, S. G., Kratochvil, C. J., & Domino, M. E. (2015). Mental health service use among adolescents following participation in a randomized clinical trial for depression. *Journal of Clinical Child & Adolescent Psychology*, 44(4), 551-558. doi:<https://dx.doi.org/10.1080/15374416.2014.881291>

Brent, D. A., Brunwasser, S. M., Hollon, S. D., Weersing, V., Clarke, G. N., Dickerson, J. F., . . . Garber, J. (2015). Effect of a cognitive-behavioral prevention program on depression 6 years after implementation among at-risk adolescents: A randomized clinical trial. *JAMA Psychiatry*, 72(11), 1110-1118.
doi:<http://dx.doi.org/10.1001/jamapsychiatry.2015.1559>

Brent, D. A., Emslie, G. J., Clarke, G. N., Asarnow, J., Spirito, A., Ritz, L., . . . Keller, M. B. (2009). Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. *The American Journal of Psychiatry*, 166(4), 418-426.
doi:<http://dx.doi.org/10.1176/appi.ajp.2008.08070976>

Briere, F. N., Rohde, P., Shaw, H., & Stice, E. (2014). Moderators of two indicated cognitive-behavioral depression prevention approaches for adolescents in a school-based effectiveness trial. *Behaviour Research & Therapy*, 53, 55-62.
doi:<https://dx.doi.org/10.1016/j.brat.2013.12.005>

Briki, M., Monnin, J., Haffen, E., Sechter, D., Favrod, J., Netillard, C., . . . Vandel, P. (2014). Metacognitive training for schizophrenia: a multicentre randomised controlled trial. *Schizophrenia Research*, 157(1-3), 99-106.
doi:<https://dx.doi.org/10.1016/j.schres.2014.06.005>

Brody, A. L., Zorick, T., Hubert, R., Hellemann, G. S., Balali, S., Kawasaki, S. S., . . . McCreary, C. (2017). Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial. *Nicotine & Tobacco Research*, 19(1), 68-76.

Brook, S., Krams, M., & Gunn, K. (1998). The efficacy and tolerability of intramuscular (im) ziprasidone versus im haloperidol in patients with acute, non-organic psychosis. *Xxist collegium internationale neuro-psychopharmacologicum, glasgow, scotland. 12th-16th july, 1998*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/910/CN-00656910/frame.html>

Brooman-White, R., Simpson, P., Hotham, J., & Das, M. (2013). Amisulpride augmentation of clozapine in violent schizophrenia patients: a case-series from the United Kingdom. *European neuropsychopharmacology*, 23, S487-s488. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/522/CN-01006522/frame.html> doi:10.1016/S0924-977X%2813%2970773-9

Brown, B., Turkoz, I., Mancevski, B., Mathews, M., & Reeve-Parker, K. (2017). Evaluation of paliperidone palmitate long-acting injectable therapy by duration of illness in patients with schizophrenia. *Australian and new zealand journal of psychiatry. Conference: royal australian and new zealand college of psychiatrists, RANZCP annual congress 2017*.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Australia, 51(1 Supplement 1), 161. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/726/CN-01375726/frame.html> doi:10.1177/0004867417702054

Brown, C., Goetz, J., Hamera, E., & Gajewski, B. (2014). Treatment response to the RENEW weight loss intervention in schizophrenia: impact of intervention setting. *Schizophrenia Research*, 159(2-3), 421-425.
doi:<https://dx.doi.org/10.1016/j.schres.2014.09.018>

Brown, C., Goetz, J., Hamera, E., & Gajewski, B. (2014). Treatment response to the RENEW weight loss intervention in schizophrenia: impact of intervention setting. *Schizophrenia Research*, 159(2-3), 421-425. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/283/CN-01077283/frame.html>
doi:10.1016/j.schres.2014.09.018

Brunnauer, A., & Laux, G. (2012). Driving ability under sertindole. *Pharmacopsychiatry*, 45(2), 47-50. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/213/CN-00843213/frame.html> doi:10.1055/s-0031-1287781

Bucci, P., Piegarì, G., Mucci, A., Merlotti, E., Chieffi, M., De Riso, F., . . . Galderisi, S. (2013). Neurocognitive individualized training versus social skills individualized training: a randomized trial in patients with schizophrenia. *Schizophrenia Research*, 150(1), 69-75. doi:<https://dx.doi.org/10.1016/j.schres.2013.07.053>

Bucci, S., Barrowclough, C., Ainsworth, J., Morris, R., Berry, K., Machin, M., . . . Haddock, G. (2015). Using mobile technology to deliver a cognitive behaviour therapy-informed intervention in early psychosis (Actissist): study protocol for a randomised controlled trial. *Trials [Electronic Resource]*, 16, 404. doi:<https://dx.doi.org/10.1186/s13063-015-0943-3>

Buchanan, R., Conley, R., Dickinson, D., Ball, M., Feldman, S., Gold, J., & McMahon, R. (2008). Galantamine for the treatment of cognitive impairments in people with schizophrenia. *American Journal of Psychiatry*, 165(1), 82-89. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/315/CN-00628315/frame.html>
doi:10.1176/appi.ajp.2007.07050724

Buchanan, R., Javitt, D., Marder, S., Schooler, N., Gold, J., McMahon, R., . . . Carpenter, W. (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. *American Journal of Psychiatry*, 164(10), 1593-1602. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/256/CN-00612256/frame.html> doi:10.1176/appi.ajp.2007.06081358

Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., . . . Carpenter, W. T. (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. *American Journal of Psychiatry*, 164(10), 1593-1602.

Buckley, P., Schooler, N., Goff, D., Hsiao, J., Kopelowicz, A., Lauriello, J., . . . Kane, J. (2013). PROA CTIVE (Preventing Relapse Oral Antipsychotics Compared to Injectables Evaluating Efficacy): relapse, symptoms, and medication profiles

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

over 30 months of study. *Schizophrenia bulletin.*, 39, S324. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/021/CN-01026021/frame.html> doi:10.1093/schbul/sbt011

Buckley, P., Schooler, N., Goff, D., Hsiao, J., Kopelowicz, A., Lauriello, J., . . . Kane, J. (2015). Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. *Schizophrenia Bulletin*, 41(2), 449-459. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/566/CN-01089566/frame.html> doi:10.1093/schbul/sbu067

Buckley, P., Schooler, N., Goff, D., Kopelowicz, A., Lauriello, J., Manschreck, T., . . . Looney, S. (2016). Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. *Psychiatric services (washington, D.C.)*, 67(12), 1370-1372. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/096/CN-01290096/frame.html> doi:10.1176/appi.ps.201500466

Buckley, P., Schooler, N., Goff, D., Kopelowicz, A., Lauriello, J., Manschreck, T., . . . Looney, S. (2015). Second and third relapses in a relapse prevention trial of long-acting injectable versus oral antipsychotics: a comparative analysis of successive relapses over 30 months. *Schizophrenia bulletin.*, 41, S305. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/800/CN-01077800/frame.html> doi:10.1093/schbul/sbv010

Buhmann, C., Nordentoft, M., Ekstroem, M., Carlsson, J., & Mortensen, E. (2016). The effect of flexible cognitive-behavioural therapy and medical treatment, including antidepressants on post-traumatic stress disorder and depression in traumatised refugees: pragmatic randomised controlled clinical trial. *British Journal of Psychiatry*, 208(3), 252-259. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/076/CN-01142076/frame.html> doi:10.1192/bjp.bp.114.150961

Buhmann, C. B., Nordentoft, M., Ekstroem, M., Carlsson, J., & Mortensen, E. L. (2016). The effect of flexible cognitive-behavioural therapy and medical treatment, including antidepressants on post-traumatic stress disorder and depression in traumatised refugees: Pragmatic randomised controlled clinical trial. *The British Journal of Psychiatry*, 208(3), 252-259. doi:<http://dx.doi.org/10.1192/bjp.bp.114.150961>

Buonocore, M., Bosia, M., Riccaboni, R., Bechi, M., Spangaro, M., Piantanida, M., . . . Cavallaro, R. (2015). Combined neurocognitive and metacognitive rehabilitation in schizophrenia: Effects on bias against disconfirmatory evidence. *European Psychiatry: the Journal of the Association of European Psychiatrists*, 30(5), 615-621. doi:<https://dx.doi.org/10.1016/j.eurpsy.2015.02.006>

Burns, T., & Catty, J. (2008). IPS in Europe: the EQOLISE trial. *Psychiatric Rehabilitation Journal*, 31(4), 313-317. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/894/CN-00638894/frame.html> doi:10.2975/31.4.2008.313.317

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Burns, T., Catty, J., & Group, E. (2008). IPS in Europe: the EQOLISE trial. *Psychiatric Rehabilitation Journal*, 31(4), 313-317.

doi:<https://dx.doi.org/10.2975/31.4.2008.313.317>

Burton, C. Z., Vella, L., & Twamley, E. W. (2011). Clinical and cognitive insight in a compensatory cognitive training intervention. *American Journal of Psychiatric Rehabilitation*, 14(4), 307-326.

doi:<http://dx.doi.org/10.1080/15487768.2011.622159>

Byerly, M., Nakonezny, P., Stroup, T., McEvoy, J., Hamer, R., Swartz, M., & Rosenheck, R. (2014). A single assessment with the brief adherence rating scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. *Neuropsychopharmacology*, 39, S381-s382. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/330/CN-01066330/frame.html> doi:10.1038/npp.2014.281

Byrne, R. E., & Morrison, A. P. (2014). Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. *Psychology & Psychotherapy: Theory, Research & Practice*, 87(3), 357-371. doi:<https://dx.doi.org/10.1111/papt.12013>

Cacciotti-Saija, C., Langdon, R., Ward, P. B., Hickie, I. B., Scott, E. M., Naismith, S. L., . . . Guastella, A. J. (2015). A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. *Schizophrenia Bulletin*, 41(2), 483-493. doi:<https://dx.doi.org/10.1093/schbul/sbu094>

Cain, C. K., McCue, M., Bello, I., Creedon, T., Tang, D. I., Laska, E., & Goff, D. C. (2014). d-Cycloserine augmentation of cognitive remediation in schizophrenia. *Schizophrenia Research*, 153(1-3), 177-183.
doi:<https://dx.doi.org/10.1016/j.schres.2014.01.016>

Calabrese, J., Sanchez, R., Jin, N., Amatniek, J., Cox, K., Johnson, B., . . . Carson, W. (2016). Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar i disorder: a double-blind, placebo-controlled, randomized withdrawal study. *Neuropsychopharmacology. Conference: 55th annual meeting of the american college of neuropsychopharmacology, ACNP 2016. United states. Conference start: 20161204. Conference end: 20161208*, 41, S360-s361. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/460/CN-01296460/frame.html> doi:10.1038/npp.2016.241

Canas, F., & Moller, H. (2010). Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. *Expert opinion on drug safety*, 9(5), 683-697. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/376/CN-00775376/frame.html>

Cañive, J., Lewine, J., Edgar, J., Davis, J., Miller, G., Torres, F., & Tuason, V. (1998). Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. *Psychopharmacology bulletin*, 34(1), 101-105. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/648/CN-00682648/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Canuso, C., Bossie, C., Lasser, R., & Gharabawi, G. (2003). Reduced Serum Prolactin Levels Following Long-Acting Treatment With Risperidone. *156th annual meeting of the american psychiatric association, may 17-22, san francisco CA*, Nr275. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/490/CN-00659490/frame.html>
- Canuso, C., Bossie, C., Lasser, R., & Gharabawi, G. (2003). Reduced serum prolactin levels following treatment with long-acting risperidone. *156th annual meeting of the american psychiatric association, may 17-22, san francisco CA*, 48. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/987/CN-00546987/frame.html>
- Canuso, C., Bossie, C., Zhu, Y., & Lasser, R. (2003). Long-acting risperidone reduces symptoms of depression and anxiety in patients with schizophrenia and schizoaffective disorder. *156th annual meeting of the american psychiatric association, may 17-22, san francisco CA*, 49. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/991/CN-00546991/frame.html>
- Canuso, C., Singh, J., Fedgchin, M., Alphs, L., Lane, R., Pinter, C., & Drevets, W. (2015). A novel study design to evaluate the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide. *Neuropsychopharmacology*, 40, S480. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/079/CN-01163079/frame.html> doi:10.1038/npp.2015.327
- Carpiniello, B., & Pinna, F. (2016). Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia. *Drug design, development and therapy*, 10, 1731-1742. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/270/CN-01158270/frame.html> doi:10.2147/DDDT.S86301
- Caspi, N., Modai, I., Barak, P., Waisbord, A., Zbarsky, H., Hirschmann, S., & Ritsner, M. (2001). Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. *International Clinical Psychopharmacology*, 16(2), 111-115. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/113/CN-00327113/frame.html>
- Cassady, S., Thaker, G., Moran, M., Birt, A., & Tamminga, C. (1992). GABA agonist-induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia. *Biological Psychiatry*, 32(4), 302-311. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/123/CN-00088123/frame.html>
- Cassella, J., Fishman, R., Kwentus, J., & Lesem, M. (2010). Inhaled loxapine (AZ-004, staccato loxapine) for rapid and acute treatment of agitation in patients with schizophrenia or bipolar disorder. *Academic emergency medicine*, 17, S142. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/720/CN-01055720/frame.html> doi:10.1111/j.1553-2712.2010.00743.x
- Cates, A., Sridharan, S., Ndebele, F., & Kunar, S. (2012). Use of paliperidone palmitate long-acting injection in dual diagnosis patients. *European Neuropsychopharmacology*, 22, S321-s322. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/331/CN-01004331/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Cather, C., Penn, D., Otto, M. W., Yovel, I., Mueser, K. T., & Goff, D. C. (2005). A pilot study of functional Cognitive Behavioral Therapy (fCBT) for schizophrenia. *Schizophrenia Research*, 74(2-3), 201-209.
- Cavallaro, R., Anselmetti, S., Poletti, S., Bechi, M., Ermoli, E., Cocchi, F., . . . Smeraldi, E. (2009). Computer-aided neurocognitive remediation as an enhancing strategy for schizophrenia rehabilitation. *Psychiatry Research*, 169(3), 191-196. doi:<https://dx.doi.org/10.1016/j.psychres.2008.06.027>
- Cella, M., Reeder, C., & Wykes, T. (2014). It is all in the factors: effects of cognitive remediation on symptom dimensions. *Schizophrenia Research*, 156(1), 60-62. doi:<https://dx.doi.org/10.1016/j.schres.2014.03.032>
- Chadwick, P., Hughes, S., Russell, D., Russell, I., & Dagnan, D. (2009). Mindfulness groups for distressing voices and paranoia: a replication and randomized feasibility trial. *Behavioural & Cognitive Psychotherapy*, 37(4), 403-412. doi:<https://dx.doi.org/10.1017/S1352465809990166>
- Chafetz, L., White, M., Collins-Bride, G., Cooper, B. A., & Nickens, J. (2008). Clinical trial of wellness training: health promotion for severely mentally ill adults. *Journal of Nervous & Mental Disease*, 196(6), 475-483. doi:<https://dx.doi.org/10.1097/NMD.0b013e31817738de>
- Challacombe, F., Salkovskis, P., Woolgar, M., Wilkinson, E., Read, J., & Acheson, R. (2017). A pilot randomized controlled trial of time-intensive cognitive-behaviour therapy for postpartum obsessive-compulsive disorder: Effects on maternal symptoms, mother-infant interactions and attachment. *Psychological Medicine*, 47(8), 1478-1488. doi:<http://dx.doi.org/10.1017/S0033291716003573>
- Chan, C. L., Ngai, E. K., Leung, P. K., & Wong, S. (2010). Effect of the adapted Virtual Reality cognitive training program among Chinese older adults with chronic schizophrenia: a pilot study. *International Journal of Geriatric Psychiatry*, 25(6), 643-649. doi:<https://dx.doi.org/10.1002/gps.2403>
- Chandrasena, R., Dvorakova, D., Lee, S., Loza, N., Mosolov, S., Osvath, P., . . . Treuer, T. (2009). Intramuscular olanzapine vs. Intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. *International journal of clinical practice*, 63(8), 1249-1258. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/287/CN-00775287/frame.html>
- Chang, W. C., Chan, G. H., Jim, O. T., Lau, E. S., Hui, C. L., Chan, S. K., . . . Chen, E. Y. (2015). Optimal duration of an early intervention programme for first-episode psychosis: randomised controlled trial. *British Journal of Psychiatry*, 206(6), 492-500. doi:<https://dx.doi.org/10.1192/bjp.bp.114.150144>
- Chawla, J., Pal, H., Lal, R., Jain, R., Schooler, N., & Balhara, Y. (2013). Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects. *Journal of opioid management*, 9(1), 35-41. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/762/CN-00858762/frame.html> doi:[10.5055/jom.2013.0145](https://doi.org/10.5055/jom.2013.0145)

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Chien, W. T., Bressington, D., Yip, A., & Karatzias, T. (2017). An international multi-site, randomized controlled trial of a mindfulness-based psychoeducation group programme for people with schizophrenia. *Psychological Medicine*, 47(12), 2081-2096. doi:<https://dx.doi.org/10.1017/S0033291717000526>
- Chien, W. T., & Lee, I. Y. (2013). The mindfulness-based psychoeducation program for Chinese patients with schizophrenia. *Psychiatric Services*, 64(4), 376-379. doi:<http://dx.doi.org/10.1176/appi.ps.002092012>
- Chien, W. T., Mui, J., Gray, R., & Cheung, E. (2016). Adherence therapy versus routine psychiatric care for people with schizophrenia spectrum disorders: a randomised controlled trial. *BMC Psychiatry*, 16, 42. doi:<https://dx.doi.org/10.1186/s12888-016-0744-6>
- Chien, W. T., & Thompson, D. R. (2014). Effects of a mindfulness-based psychoeducation programme for Chinese patients with schizophrenia: 2-year follow-up. *British Journal of Psychiatry*, 205(1), 52-59. doi:<https://dx.doi.org/10.1192/bjp.bp.113.134635>
- Choi, K. H., Fiszdon, J. M., & Bell, M. D. (2013). Beyond cognition: a longitudinal investigation of the role of motivation during a vocational rehabilitation program. *Journal of Nervous & Mental Disease*, 201(3), 173-178. doi:<https://dx.doi.org/10.1097/NMD.0b013e3182848bd4>
- Choi, K. H., & Kwon, J. H. (2006). Social cognition enhancement training for schizophrenia: a preliminary randomized controlled trial. *Community Mental Health Journal*, 42(2), 177-187.
- Chouinard, G., Annable, L., & Kropsky, M. (1978). A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. *Journal of clinical pharmacology*, 18(2-3), 148-154. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/581/CN-00017581/frame.html>
- Chouinard, G., Annable, L., & Steinberg, S. (1986). A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. *Journal of Clinical Psychopharmacology*, 6(1), 21-26. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/724/CN-00041724/frame.html>
- Chouinard, G., Annable, L., & Steinberg, S. (1986). A controlled trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. *Journal of Clinical Psychopharmacology*, 6(1), 21-26. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/898/CN-00187898/frame.html>
- Chouinard, G., Annable, L., Turnier, L., Holobow, N., & Szkrumelak, N. (1993). A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. *Canadian journal of psychiatry. Revue canadienne de psychiatrie*, 38 Suppl 4, S114-121. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/922/CN-00098922/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Christy, A., Poythress, N., Boothroyd, R., Petila, J., & Mehra, S. (2005). Evaluating the efficiency and community safety goals of the Broward County Mental Health Court. *Behavioral Sciences & the Law*, 23(2), 227-243. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/387/CN-00521387/frame.html> doi:10.1002/bls.647
- Chue, P., Eerdekins, M., Augustyns, I., Lachaux, B., Molcan, P., Eriksson, L., . . . David, A. (2005). Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. *European Neuropsychopharmacology*, 15(1), 111-117. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/850/CN-00504850/frame.html> doi:10.1016/j.euroneuro.2004.07.003
- Ciliberto, N., Bossie, C., Urioste, R., & Lasser, R. (2005). Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. *International Clinical Psychopharmacology*, 20(4), 207-212. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/294/CN-00522294/frame.html>
- Citrome, L. (2016). Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next? *CNS spectrums*, 21(S1), 4-11. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/030/CN-01301030/frame.html> doi:10.1017/S1092852916000729
- Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. (2016). Treatment of acute schizophrenia in adult patients using either brexpiprazole (OPC-34712) or aripiprazole, an exploratory study. *CNS spectrums. Conference: 11th annual neuroscience education institute psychopharmacology congress, NEI 2015. United states*, 21(1), 99. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/001/CN-01430001/frame.html> doi:10.1017/S1092852915000905
- Ciudad, A., Anand, E., Berggren, L., Casillas, M., Schacht, A., & Perrin, E. (2013). Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses. *Neuropsychiatric Disease and Treatment*, 9, 1737-1750. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/293/CN-00911293/frame.html> doi:10.2147/NDT.S50635
- Ciudad, A., San, L., Bernardo, M., Olivares, J., Polavieja, P., Valladares, A., & Gilaberte, I. (2012). Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia. *Progress in Neuropsychopharmacology & Biological Psychiatry*, 36(2), 245-250. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/293/CN-00901293/frame.html> doi:10.1016/j.pnpbp.2011.10.014
- Claghorn, J., Mathew, R., & Mirabi, M. (1979). Penfluridol: a long acting oral antipsychotic drug. *Journal of Clinical Psychiatry*, 40(2), 107-109. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/713/CN-00019713/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Clark, R., Teague, G., Ricketts, S., Bush, P., Xie, H., McGuire, T., . . . Zubkoff, M. (1998). Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders. *Health services research*, 33(5 Pt 1), 1285-1308. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/333/CN-00158333/frame.html>
- Clarke, G., DeBar, L. L., Pearson, J. A., Dickerson, J. F., Lynch, F. L., Gullion, C. M., & Leo, M. C. (2016). Cognitive behavioral therapy in primary care for youth declining antidepressants: A randomized trial. *Pediatrics*, 137(5), 1-13.
- Clarke, G., Herinckx, H., Kinney, R., Paulson, R., Cutler, D., Lewis, K., & Oxman, E. (2000). Psychiatric hospitalizations, arrests, emergency room visits, and homelessness of clients with serious and persistent mental illness: findings from a randomized trial of two ACT programs vs. usual care. *Mental Health Services Research*, 3(3), 155-164. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/116/CN-00583116/frame.html>
- Clarke, G., Herinckx, H., Kinney, R., Paulson, R., Cutler, D., Lewis, K., & Oxman, E. (2000). Psychiatric hospitalizations, arrests, emergency room visits, and homelessness of clients with serious and persistent mental illness: findings from a randomized trial of two ACT programs vs. usual care. *Mental Health Services Research*, 2(3), 155-164. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/247/CN-00327247/frame.html>
- Clarke, G. N., Herinckx, H. A., Kinney, R. F., Paulson, R. I., Cutler, D. L., Lewis, K., & Oxman, E. (2000). Psychiatric hospitalizations, arrests, emergency room visits, and homelessness of clients with serious and persistent mental illness: findings from a randomized trial of two ACT programs vs. usual care. *Mental Health Services Research*, 2(3), 155-164.
- Clayton, A. H. (2004). Postpartum mood disorders. *Primary Psychiatry*, 11(9), 20-21.
- Cleton, A., Rossenu, S., Crauwels, H., Berwaerts, J., Hough, D., Gopal, S., . . . Rosso, C. (2014). A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. *Journal of clinical pharmacology*, 54(9), 1048-1057. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/396/CN-00998396/frame.html>
doi:10.1002/jcph.295
- Coffey, H. S., & Wiener, L. L. (1967). GROUP TREATMENT OF AUTISTIC CHILDREN. PRENTICE-HALL PSYCHOLOGY SERIES (pp. 1).
- Cohen, J. A., Mannarino, A. P., & Iyengar, S. (2011). Community treatment of posttraumatic stress disorder for children exposed to intimate partner violence: a randomized controlled trial. *Archives of Pediatrics & Adolescent Medicine*, 165(1), 16-21. doi:<https://dx.doi.org/10.1001/archpediatrics.2010.247>
- Combs, D. R., Tosheva, A., Penn, D. L., Basso, M. R., Wanner, J. L., & Laib, K. (2008). Attentional-shaping as a means to improve emotion perception deficits in schizophrenia. *Schizophrenia Research*, 105(1-3), 68-77.
doi:<https://dx.doi.org/10.1016/j.schres.2008.05.018>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Combs, D. R., Tosheva, A., Wanner, J., & Basso, M. R. (2006). Remediation of emotion perception deficits in schizophrenia: the use of attentional prompts. *Schizophrenia Research*, 87(1-3), 340-341.
- Compas, B. E., Forehand, R., Thigpen, J., Hardcastle, E., Garai, E., McKee, L., . . . Sterba, S. (2015). Efficacy and moderators of a family group cognitive-behavioral preventive intervention for children of parents with depression. *Journal of Consulting and Clinical Psychology*, 83(3), 541-553. doi:<http://dx.doi.org/10.1037/a0039053>
- Comprone, J. J. (1982). Teaching Writing in the Condition of Secondary Orality (pp. 15).
- Condray, R., Dougherty, G., Keshavan, M., Reddy, R., Haas, G., Montrose, D., . . . Yao, J. (2011). 3-Hydroxykynurenone and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. *The international journal of neuropsychopharmacology*, 14(6), 756-767. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/820/CN-00801820/frame.html> doi:10.1017/S1461145710001689
- Constantine, R., Andel, R., McPherson, M., & Tandon, R. (2015). The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial. *Schizophrenia Research*, 166(1-3), 194-200. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/427/CN-01081427/frame.html> doi:10.1016/j.schres.2015.05.038
- Cooke, M. A., Peters, E. R., Greenwood, K. E., Fisher, P. L., Kumari, V., & Kuipers, E. (2007). Insight in psychosis: influence of cognitive ability and self-esteem. *British Journal of Psychiatry*, 191, 234-237.
- Correll, C. (2014). Comparative efficacy of LAIs versus oral antipsychotics in schizophrenia. *International journal of neuropsychopharmacology*, 17, 170. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/842/CN-01084842/frame.html> doi:10.1017/S1461145714000741
- Correll, C. (2014). The role of LAI antipsychotics in the maintenance treatment of schizophrenia. *European neuropsychopharmacology*, 24, S763. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/714/CN-01023714/frame.html>
- Correll, C., Citrome, L., Haddad, P., Lauriello, J., Olfson, M., Calloway, S., & Kane, J. (2016). The use of long-acting injectable antipsychotics in Schizophrenia: evaluating the evidence. *Journal of Clinical Psychiatry*, 77, 3-24. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/212/CN-01246212/frame.html> doi:10.4088/JCP.15032su1
- Corsini, G., Zompo, M., Spissu, A., Mangoni, A., & Gessa, G. (1978). Parkinsonism by haloperidol and piribedil. *Psychopharmacology*, 59(2), 139-141. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/803/CN-00238803/frame.html>
- Cosar, B., Candansayar, S., Taner, E., & Isik, E. (1999). Comparison of efficacy of clozapine, sulpiride, chlorpromazine and haloperidol in chronic schizophrenic patients therapy. *Journal of the european college of neuropsychopharmacology*,

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

9(Suppl 5), S287. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/119/CN-00656119/frame.html>

Cosden, M., Ellens, J., Schnell, J., & Yamini-Diouf, Y. (2005). Efficacy of a Mental Health Treatment Court with assertive community treatment. *Behavioral Sciences & the Law*, 23(2), 199-214.

Cosden, M., Ellens, J., Schnell, J., & Yamini-Diouf, Y. (2005). Efficacy of a Mental Health Treatment Court with assertive community treatment. *Behavioral Sciences & the Law*, 23(2), 199-214. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/389/CN-00521389/frame.html> doi:10.1002/bls.638

Covell, N., McEvoy, J., Schooler, N., Stroup, T., Jackson, C., Rojas, I., & Essock, S. (2012). Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. *Journal of Clinical Psychiatry*, 73(5), 669-675. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/433/CN-00842433/frame.html> doi:10.4088/JCP.11m07074

Crocq, M., Naber, D., Lader, M., Thibaut, F., Drici, M., Everitt, B., . . . Moore, N. (2010). Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. *European Neuropsychopharmacology*, 20(12), 829-838. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/546/CN-00802546/frame.html> doi:10.1016/j.euroneuro.2010.09.001

Crocq, M. A., Naber, D., Lader, M. H., Thibaut, F., Drici, M., Everitt, B., . . . Moore, N. D. (2010). Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. *European Neuropsychopharmacology*, 20(12), 829-838. doi:<https://dx.doi.org/10.1016/j.euroneuro.2010.09.001>

Ctri. (2015). Can transcranial direct current stimulation help attention in Lewy body dementia?

<Http://www.ctri.nic.in/clinicaltrials/pmaindet2.php?Trialid=11413>. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/116/CN-01308116/frame.html>

Cui, R., Haller, M., Skidmore, J. R., Goldsteinholz, K., Norman, S., & Tate, S. R. (2016). Treatment Attendance Among Veterans With Depression, Substance Use Disorder, and Trauma. *Journal of Dual Diagnosis*, 12(1), 15-26. doi:<https://dx.doi.org/10.1080/15504263.2016.1146384>

Cullen, A. E., Clarke, A. Y., Kuipers, E., Hodgins, S., Dean, K., & Fahy, T. (2012). A multi-site randomized controlled trial of a cognitive skills programme for male mentally disordered offenders: social-cognitive outcomes. *Psychological Medicine*, 42(3), 557-569. doi:<https://dx.doi.org/10.1017/S0033291711001553>

Cullen, A. E., Clarke, A. Y., Kuipers, E., Hodgins, S., Dean, K., & Fahy, T. (2012). A multisite randomized trial of a cognitive skills program for male mentally disordered offenders: violence and antisocial behavior outcomes. *Journal of Consulting & Clinical Psychology*, 80(6), 1114-1120. doi:<https://dx.doi.org/10.1037/a0030291>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Curry, J., Silva, S., Rohde, P., Ginsburg, G., Kratochvil, C., Simons, A., . . . March, J. (2011). Recovery and recurrence following treatment for adolescent major depression. *Archives of General Psychiatry*, 68(3), 263-269.
doi:<https://dx.doi.org/10.1001/archgenpsychiatry.2010.150>
- Daniel, D., Potkin, S., Reeves, K., Swift, R., & Harrigan, E. (2001). Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. *Psychopharmacology*, 155(2), 128-134. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/874/CN-00355874/frame.html>
- Daniel, G., Berman, F., Fawcett, R., & Weinberger, R. (1988). Admorphine and RCBF in Schizophrenia CONFERENCE ABSTRACT. *141st annual meeting of the american psychiatric association. Quebec, canada. 7-12th may, 1988.* Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/727/CN-00279727/frame.html>
- Davis, L. W., Lysaker, P. H., Kristeller, J. L., Salyers, M. P., Kovach, A. C., & Woller, S. (2015). Effect of mindfulness on vocational rehabilitation outcomes in stable phase schizophrenia. *Psychological Services*, 12(3), 303-312.
doi:<https://dx.doi.org/10.1037/ser0000028>
- Davis, L. W., Ringer, J. M., Strasburger, A. M., & Lysaker, P. H. (2008). Participant evaluation of a CBT program for enhancing work function in schizophrenia. *Psychiatric Rehabilitation Journal*, 32(1), 55-58.
doi:<https://dx.doi.org/10.2975/32.1.2008.55.58>
- Davis, M. C., Green, M. F., Lee, J., Horan, W. P., Senturk, D., Clarke, A. D., & Marder, S. R. (2014). Oxytocin-augmented social cognitive skills training in schizophrenia. *Neuropsychopharmacology*, 39(9), 2070-2077.
doi:<https://dx.doi.org/10.1038/npp.2014.68>
- Davis, R., Vanover, K., & Mates, S. (2014). ITI-007: a novel treatment for behavioral disturbances associated with dementia and related disorders. *Annals of neurology*, 76, S90. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/190/CN-01055190/frame.html> doi:10.1002/ana.24247
- Dekker, J., Wijdenes, W., Koning, Y., Gardien, R., Hermandes-Willenborg, L., & Nusselder, H. (2002). Assertive community treatment in Amsterdam. *Community Mental Health Journal*, 38(5), 425-434. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/054/CN-00410054/frame.html>
- Dekker, J., Wijdenes, W., Koning, Y. A., Gardien, R., Hermandes-Willenborg, L., & Nusselder, H. (2002). Assertive community treatment in Amsterdam. *Community Mental Health Journal*, 38(5), 425-434.
- Demant, K. M., Vinberg, M., Kessing, L. V., & Miskowiak, K. W. (2015). Effects of Short-Term Cognitive Remediation on Cognitive Dysfunction in Partially or Fully Remitted Individuals with Bipolar Disorder: Results of a Randomised Controlled Trial. *PLoS ONE [Electronic Resource]*, 10(6), e0127955.
doi:<https://dx.doi.org/10.1371/journal.pone.0127955>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Detke, H., McDonnell, D., Andersen, S., & Watson, S. (2008). Olanzapine long-acting injection in patients with schizophrenia at risk of relapse: 12-week switching data. *European Neuropsychopharmacology*, 18, S435. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/937/CN-00690937/frame.html>

Detke, H., McDonnell, D., Kane, J., Naber, D., Sethuraman, G., & Lin, D. (2008). Efficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophrenia. *European Neuropsychopharmacology*, 18, S393-s394. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/151/CN-00690151/frame.html>

Detke, H., Weiden, P., Llorca, P., Choukour, M., Watson, S., Brunner, E., & Ascher-Svanum, H. (2014). Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia. *Journal of Clinical Psychopharmacology*, 34(4), 426-434. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/981/CN-00994981/frame.html> doi:10.1097/JCP.0000000000000140

Detke, H., Zhao, F., Garhyan, P., Carlson, J., & McDonnell, D. (2011). Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. *International Clinical Psychopharmacology*, 26(1), 35-42. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/337/CN-00781337/frame.html> doi:10.1097/YIC.0b013e32834093d1

Detke, H., Zhao, F., & Witte, M. (2012). Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data. *BMC Psychiatry*, 12(1). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/788/CN-01036788/frame.html> doi:10.1186/1471-244X-12-51

Dickinson, E. A. *Constructing, Consuming, and Complicating the Human-Nature Binary: Communication Practices in Forest Environmental Education*. Retrieved from <http://ez.library.latrobe.edu.au/login?url=https://search.proquest.com/docview/870289859?accountid=12001>
http://ap01.alma.exlibrisgroup.com/view/uresolver/61LATROBE_INST/openurl?ctx_enc=info:ofi/enc:UTF-8&ctx_ver=Z39.88-2004&url_ctx_fmt=info:ofi/fmt:kev:mtx:ctx&url_ver=Z39.88-2004&rft.genre=unknown&rft.atitle=&rft.jtitle=&rft.btitle=&rft.aulast=Dickinson&rft.auinitm=A.&rft.usuffix=&rft.au=Dickinson%2C+Elizabeth+A.&rft.date=2010&rft.volume=&rft.issue=&rft.quarter=&rft.ssn=&rft.spage=&rft.epage=&rft.pages=&rft.artnum=&rft.issn=&rft.eissn=&rft.isbn=9781124067094&rft.sici=&rft.coden=&rft_id=info:doi/&rft.object_id=&rft.eisbn=&rft.edition=&rft.pub=Constructing%2C+Consuming%2C+and+Complicating+the+Human-Nature+Binary%3A+Communication+Practices+in+Forest+Environmental+Education&rft.place=&rft.series=&rft.stil=e=&rft.bici=&rft_id=info:bibcode/&rft_id=info:hdl/&rft_id=info:lccn/&rft_id=info:oclcnum/&rft_id=info:pmid/&rft_id=info:eric/ED518442 ERIC database

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Dieterich, M., Irving, C., Bergman, H., Khokhar, M., Park, B., & Marshall, M. (2017). Intensive case management for severe mental illness. *Cochrane database of systematic reviews (Online)*, 2017(1) (no pagination). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/267/CN-01299267/frame.html> doi:10.1002/14651858.CD007906.pub3

Dilla, T., Moller, J., O'Donohoe, P., Alvarez, M., Sacristan, J., & Happich, M. (2014). Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison. *BMC Psychiatry*, 14, 298. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/305/CN-01104305/frame.html> doi:10.1186/s12888-014-0298-4

Dillenkoffer, R., George, R., Bishop, M., & Gallant, D. (1971). Electrocardiographic Effects of Thiothixene: a double-blind comparison with thioridazine. *V world congress of psychiatry, ciudad de mexico. 28 november - 4 december 1971.* Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/233/CN-00656233/frame.html>

Dimond, S., Scammell, R., Pryce, I., Huws, D., & Gray, C. (1979). Some effects of piracetam (UCB 6215, Nootropyl) on chronic schizophrenia. *Psychopharmacology*, 64(3), 341-348. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/801/CN-00238801/frame.html>

Ditye, T., Jacobson, L., Walsh, V., & Lavidor, M. (2012). Modulating behavioral inhibition by tDCS combined with cognitive training. *Experimental Brain Research*, 219(3), 363-368. doi:<https://dx.doi.org/10.1007/s00221-012-3098-4>

Doknic, M., Maric, N., Britvic, D., Pekic, S., Damjanovic, A., Miljic, D., . . . Popovic, V. (2011). Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. *Neuroendocrinology*, 94(3), 246-254. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/878/CN-00889878/frame.html> doi:10.1159/000329391

Dom, R., Lommel, R., & Baro, F. (1971). A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dextetimide, a potent and long-acting antiparkinsonian agent. *Acta Psychiatrica Scandinavica*, 47(4), 399-410. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/992/CN-00006992/frame.html>

Doyle, O., Simoni, S., Schwarz, A., Brittain, C., O'Daly, O., Williams, S., & Mehta, M. (2013). Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents. *Journal of pharmacology and experimental therapeutics*, 345(1), 151-160. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/513/CN-00877513/frame.html> doi:10.1124/jpet.112.201665

Drake, R., McHugo, G., Clark, R., Teague, G., Xie, H., Miles, K., & Ackerson, T. (1998). Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. *American Journal of*

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Orthopsychiatry, 68(2), 201-215. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/160/CN-00686160/frame.html>

Drake, R. J., Day, C. J., Picucci, R., Warburton, J., Larkin, W., Husain, N., . . . Marshall, M. (2014). A naturalistic, randomized, controlled trial combining cognitive remediation with cognitive-behavioural therapy after first-episode non-affective psychosis. *Psychological Medicine*, 44(9), 1889-1899. doi:<https://dx.doi.org/10.1017/S0033291713002559>

Druais, S., Doutriaux, A., Cognet, M., Godet, A., Lancon, C., Levy, P., . . . Guillou, P. (2016). Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France. *Encephale. (no pagination)*, 2016, Date of Publication: July 21. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/209/CN-01247209/frame.html> doi:10.1016/j.encep.2016.02.021

Drukker, M., Maarschalkerweerd, M., Bak, M., Driessen, G., à, C. J., Bie, A., . . . Delespaul, P. (2008). A real-life observational study of the effectiveness of FACT in a Dutch mental health region. *BMC Psychiatry*, 8, 93. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/213/CN-00685213/frame.html> doi:10.1186/1471-244X-8-93

Drury, V., Birchwood, M., & Cochrane, R. (2000). Cognitive therapy and recovery from acute psychosis: a controlled trial. 3. Five-year follow-up. *British Journal of Psychiatry*, 177, 8-14.

D'Souza, D. C., Radhakrishnan, R., Perry, E., Bhakta, S., Singh, N. M., Yadav, R., . . . Andrade, C. (2013). Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. *Neuropsychopharmacology*, 38(3), 492-503. doi:<https://dx.doi.org/10.1038/npp.2012.208>

Ducasse, D., Courtet, P., Sénèque, M., Genty, C., Picot, M., Schwan, R., & Olié, E. (2015). Effectiveness of the first French psychoeducational program on unipolar depression: study protocol for a randomized controlled trial. *BMC Psychiatry*, 15, 294. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/947/CN-01168947/frame.html> doi:10.1186/s12888-015-0667-7

Dunn, G., & Bentall, R. (2007). Modelling treatment-effect heterogeneity in randomized controlled trials of complex interventions (psychological treatments). *Statistics in Medicine*, 26(26), 4719-4745.

Dunn, G., Fowler, D., Rollinson, R., Freeman, D., Kuipers, E., Smith, B., . . . Bebbington, P. (2012). Effective elements of cognitive behaviour therapy for psychosis: results of a novel type of subgroup analysis based on principal stratification. *Psychological Medicine*, 42(5), 1057-1068. doi:<https://dx.doi.org/10.1017/S0033291711001954>

Durham, R. C., Guthrie, M., Morton, R. V., Reid, D. A., Treliving, L. R., Fowler, D., & Macdonald, R. R. (2003). Tayside-Fife clinical trial of cognitive-behavioural therapy for medication-resistant psychotic symptoms. Results to 3-month follow-up. *British Journal of Psychiatry*, 182, 303-311.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Eack, S. M., George, M. M., Prasad, K. M., & Keshavan, M. S. (2008). Neuroanatomical substrates of foresight in schizophrenia.

Schizophrenia Research, 103(1-3), 62-70. doi:<https://dx.doi.org/10.1016/j.schres.2008.05.012>

Eack, S. M., Greenwald, D. P., Hogarty, S. S., Cooley, S. J., DiBarry, A. L., Montrose, D. M., & Keshavan, M. S. (2009).

Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial.

Psychiatric Services, 60(11), 1468-1476. doi:<https://dx.doi.org/10.1176/appi.ps.60.11.1468>

Eack, S. M., Hogarty, G. E., Cho, R. Y., Prasad, K. M., Greenwald, D. P., Hogarty, S. S., & Keshavan, M. S. (2010).

Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. *Archives of General Psychiatry*, 67(7), 674-682.

doi:<https://dx.doi.org/10.1001/archgenpsychiatry.2010.63>

Eack, S. M., Hogarty, G. E., Greenwald, D. P., Hogarty, S. S., & Keshavan, M. S. (2007). Cognitive enhancement therapy improves emotional intelligence in early course schizophrenia: preliminary effects. *Schizophrenia Research*, 89(1-3), 308-311.

Eack, S. M., Hogarty, S. S., Bangalore, S. S., Keshavan, M. S., & Cornelius, J. R. (2016). Patterns of Substance Use During Cognitive Enhancement Therapy: An 18-Month Randomized Feasibility Study. *Journal of Dual Diagnosis*, 12(1), 74-82. doi:<https://dx.doi.org/10.1080/15504263.2016.1145778>

Eack, S. M., Hogarty, S. S., Greenwald, D. P., Litschge, M. Y., McKnight, S. A., Bangalore, S. S., . . . Cornelius, J. R. (2015). Cognitive Enhancement Therapy in substance misusing schizophrenia: results of an 18-month feasibility trial. *Schizophrenia Research*, 161(2-3), 478-483. doi:<https://dx.doi.org/10.1016/j.schres.2014.11.017>

Eack, S. M., Mesholam-Gately, R. I., Greenwald, D. P., Hogarty, S. S., & Keshavan, M. S. (2013). Negative symptom improvement during cognitive rehabilitation: results from a 2-year trial of Cognitive Enhancement Therapy. *Psychiatry Research*, 209(1), 21-26. doi:<https://dx.doi.org/10.1016/j.psychres.2013.03.020>

Eack, S. M., Pogue-Geile, M. F., Greenwald, D. P., Hogarty, S. S., & Keshavan, M. S. (2011). Mechanisms of functional improvement in a 2-year trial of cognitive enhancement therapy for early schizophrenia. *Psychological Medicine*, 41(6), 1253-1261. doi:<https://dx.doi.org/10.1017/S0033291710001765>

Eberharter-Maki, E. (1996). Students with Serious Emotional Disturbance. A Legal Guide to Identification (pp. 55).

Edwards, J., Cocks, J., Burnett, P., Maud, D., Wong, L., Yuen, H. P., . . . McGorry, P. D. (2011). Randomized controlled trial of clozapine and CBT for first-episode psychosis with enduring positive symptoms: A pilot study. *Schizophrenia Research and Treatment*, (no pagination)(394896). doi:<http://dx.doi.org/10.1155/2011/394896>

Eerdeken, M., Hove, I., Remmerie, B., & Mannaert, E. (2004). Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. *Schizophrenia Research*, 70(1), 91-100. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/200/CN-00516200/frame.html> doi:[10.1016/j.schres.2003.11.001](https://dx.doi.org/10.1016/j.schres.2003.11.001)

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Einarsen, T. (2011). Comparing the effectiveness of paliperidone palmitate versus olanzapine pamoate for relapse prevention in schizophrenia: post HOC indirect analysis using published placebo-controlled studies. *Value in health.*, 14(7), A560. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/808/CN-01020808/frame.html> doi:10.1016/j.jval.2011.08.1666

Ellila, H. T., Sourander, A., Valimaki, M., Warne, T., & Kaivosoja, M. (2008). The Involuntary Treatment of Adolescent Psychiatric Inpatients--A Nation-Wide Survey from Finland. *Journal of Adolescence*, 31(3), 407-419.

Emmerson, L. C., Granholm, E., Link, P. C., McQuaid, J. R., & Jeste, D. V. (2009). Insight and treatment outcome with cognitive-behavioral social skills training for older people with schizophrenia. *Journal of Rehabilitation Research & Development*, 46(8), 1053-1058.

Emsley, R., Asmal, L., Chiliza, B., du, P. S., Carr, J., Kidd, M., . . . Kahn, R. (2015). Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia. *Psychiatry Research*, 233(2), 186-193. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/632/CN-01164632/frame.html> doi:10.1016/j.psychresns.2015.06.014

Emsley, R., Asmal, L., du, P. S., Chiliza, B., Kidd, M., Carr, J., & Vink, M. (2015). Dorsal striatal volumes in never-treated patients with first-episode schizophrenia before and during acute treatment. *Schizophrenia Research*, 169(1-3), 89-94. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/688/CN-01127688/frame.html> doi:10.1016/j.schres.2015.09.014

Emslie, G. J., Kennard, B. D., Mayes, T. L., Nakonezny, P. A., Moore, J., Jones, J. M., . . . King, J. (2015). Continued effectiveness of relapse prevention cognitive-behavioral therapy following fluoxetine treatment in youth with major depressive disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, 54(12), 991-998. doi:<http://dx.doi.org/10.1016/j.jaac.2015.09.014>

Engdahl, B. E. (1987). Psychological Consequences of the World War II Prisoner of War Experience: Implications for Treatment (pp. 23).

England, M. (2007). Efficacy of cognitive nursing intervention for voice hearing. *Perspectives in Psychiatric Care*, 43(2), 69-76.

Erickson, D. H. (2010). Cognitive-behaviour therapy for medication-resistant positive symptoms in early psychosis: A case series. *Early intervention in psychiatry*, 4(3), 251-256. doi:<http://dx.doi.org/10.1111/j.1751-7893.2010.00184.x>

Erickson, D. H., Janeck, A. S., & Tallman, K. (2007). A cognitive-behavioral group for patients with various anxiety disorders. *Psychiatric Services*, 58(9), 1205-1211.

Esposito-Smythers, C., Spirito, A., Kahler, C. W., Hunt, J., & Monti, P. (2011). Treatment of co-occurring substance abuse and suicidality among adolescents: a randomized trial. *Journal of Consulting & Clinical Psychology*, 79(6), 728-739. doi:<https://dx.doi.org/10.1037/a0026074>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Essock, S., Frisman, L., & Kontos, N. (1998). Cost-effectiveness of assertive community treatment teams. *American Journal of Orthopsychiatry*, 68(2), 179-190. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/161/CN-00686161/frame.html>
- Essock, S., Mueser, K., Drake, R., Covell, N., McHugo, G., Frisman, L., . . . Swain, K. (2006). Comparison of ACT and standard case management for delivering integrated treatment for co-occurring disorders. *Psychiatric services (washington, D.C.)*, 57(2), 185-196. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/438/CN-00562438/frame.html> doi:10.1176/appi.ps.57.2.185
- eudract_number. (2013). A study to see how effective and safe two doses of the study drug, LND101001 are compared to a placebo when given to patients with Mild to Moderate Alzheimer's Disease. A placebo is a dummy medication - looks like the study drug but has no active ingredient. Https://www.clinicaltrialsregister.eu/ctr-search/search?Query=eudract_number:2013-001851-11. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/140/CN-01308140/frame.html>
- eudract_number. (2015). A 12 week, multicentre, study investigating the efficacy of ORM-12741 on agitation/aggression symptoms in patients with Alzheimer's Disease. Https://www.clinicaltrialsregister.eu/ctr-search/search?Query=eudract_number:2014-000217-30. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/139/CN-01308139/frame.html>
- Evins, A. E., Cather, C., Pratt, S. A., Pachas, G. N., Hoeppner, S. S., Goff, D. C., . . . Schoenfeld, D. A. (2014). Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. *JAMA*, 311(2), 145-154. doi:<https://dx.doi.org/10.1001/jama.2013.285113>
- Evins, A. E., Hoeppner, S. S., Schoenfeld, D. A., Hoeppner, B. B., Cather, C., Pachas, G. N., . . . Maravic, M. C. (2017). Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder. *Schizophrenia Research*, 183, 124-129. doi:<https://dx.doi.org/10.1016/j.schres.2016.11.018>
- Evins, A. E., Mays, V. K., Rigotti, N. A., Tisdale, T., Cather, C., & Goff, D. C. (2001). A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. *Nicotine & Tobacco Research*, 3(4), 397-403.
- Fakhri, A., Pakseresht, S., Haghdoost, M., Hekmatkhah, N., Torkashvand, M., & Ghorbanzadeh, B. (2016). Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: a Randomized, Placebo-Controlled Study. *Acta medica iranica*, 54(11), 696-703. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/978/CN-01262978/frame.html>
- Fakra, E., Salgado-Pineda, P., Besnier, N., Azorin, J., & Blin, O. (2009). Risperidone versus haloperidol for facial affect recognition in schizophrenia: findings from a randomised study. *World Journal of Biological Psychiatry*, 10(4 Pt 3),

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

719-728. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/713/CN-00729713/frame.html>

doi:10.1080/15622970701432536

Fakra, E., Salgado-Pineda, P., Besnier, N., Azorin, J. M., & Blin, O. (2009). Risperidone versus haloperidol for facial affect recognition in schizophrenia: findings from a randomised study. *World Journal of Biological Psychiatry*, 10(4 Pt 3), 719-728.

Falkai, P., Leweke, F., Ruhrmann, S., & Woelwer, W. (2014). Enhancing Schizophrenia prevention and recovery through innovative treatments - a new network approach in Germany. *Early intervention in psychiatry*, 8, 20. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/921/CN-01049921/frame.html> doi:10.1111/eip.12185

Farhall, J., Freeman, N. C., Shawyer, F., & Trauer, T. (2009). An effectiveness trial of cognitive behaviour therapy in a representative sample of outpatients with psychosis. *British Journal of Clinical Psychology*, 48(Pt 1), 47-62. doi:<https://dx.doi.org/10.1348/014466608X360727>

Farrelly, S., Thornicroft, G., Birchwood, M., Marshall, M., Szumukler, G., & Waheed, W. (2011). CRIMSON: RCT of joint crisis plans for individuals with psychosis. *Psychiatrische praxis*, 38. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/831/CN-01005831/frame.html> doi:10.1055/s-0031-1277812

Farreny, A., Aguado, J., Ochoa, S., Haro, J. M., & Usall, J. (2013). The role of negative symptoms in the context of cognitive remediation for schizophrenia. *Schizophrenia Research*, 150(1), 58-63. doi:<https://dx.doi.org/10.1016/j.schres.2013.08.008>

Farreny, A., Aguado, J., Ochoa, S., Huerta-Ramos, E., Marsa, F., Lopez-Carrilero, R., . . . Usall, J. (2012). REPYFLEC cognitive remediation group training in schizophrenia: Looking for an integrative approach. *Schizophrenia Research*, 142(1-3), 137-144. doi:<https://dx.doi.org/10.1016/j.schres.2012.08.035>

Favrod, J., Rexhaj, S., Bardy, S., Ferrari, P., Hayoz, C., Moritz, S., . . . Bonsack, C. (2014). Sustained antipsychotic effect of metacognitive training in psychosis: a randomized-controlled study. *European Psychiatry: the Journal of the Association of European Psychiatrists*, 29(5), 275-281. doi:<https://dx.doi.org/10.1016/j.eurpsy.2013.08.003>

Fenger, M., Lindschou, J., Gluud, C., Winkel, P., Jorgensen, L., Kruse-Blinkenberg, S., & Lau, M. (2016). Internet-based self-help therapy with FearFighterTM versus no intervention for anxiety disorders in adults: study protocol for a randomised controlled trial. *Trials [Electronic Resource]*, 17(1), 525.

Ferrier, I., Johnstone, E., & Crow, T. (1984). Hormonal effects of apomorphine in schizophrenia. *British Journal of Psychiatry*, 144(4), 349-357. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/484/CN-00188484/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Fialko, L., Freeman, D., Bebbington, P. E., Kuipers, E., Garety, P. A., Dunn, G., & Fowler, D. (2006). Understanding suicidal ideation in psychosis: findings from the Psychological Prevention of Relapse in Psychosis (PRP) trial. *Acta Psychiatrica Scandinavica*, 114(3), 177-186.
- Findling, R. L., Frazier, J. A., Kafantaris, V., Kowatch, R., McClellan, J., Pavuluri, M., . . . Taylor-Zapata, P. (2008). The Collaborative Lithium Trials (CoLT): Specific aims, methods, and implementation. *Child and Adolescent Psychiatry and Mental Health Vol 2 2008, ArtID 21*, 2. doi:<http://dx.doi.org/10.1186/1753-2000-2-21>
- Fisher, M., Loewy, R., Carter, C., Lee, A., Ragland, J. D., Niendam, T., . . . Vinogradov, S. (2015). Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia. *Schizophrenia Bulletin*, 41(1), 250-258. doi:<https://dx.doi.org/10.1093/schbul/sbt232>
- Fisher, M., Mellon, S. H., Wolkowitz, O., & Vinogradov, S. (2016). Neuroscience-informed auditory training in schizophrenia: A final report of the effects on cognition and serum brain-derived neurotrophic factor. *Schizophrenia Research: Cognition*, 3, 1-7. doi:<http://dx.doi.org/10.1016/j.scog.2015.10.006>
- Fiszdon, J. M., Bryson, G. J., Wexler, B. E., & Bell, M. D. (2004). Durability of cognitive remediation training in schizophrenia: performance on two memory tasks at 6-month and 12-month follow-up. *Psychiatry Research*, 125(1), 1-7.
- Fiszdon, J. M., Choi, J., Goulet, J., & Bell, M. D. (2008). Temporal relationship between change in cognition and change in functioning in schizophrenia. *Schizophrenia Research*, 105(1-3), 105-113. doi:<https://dx.doi.org/10.1016/j.schres.2008.06.010>
- Fiszdon, J. M., & Johannesen, J. K. (2010). Comparison of computational methods for the evaluation of learning potential in schizophrenia. *Journal of the International Neuropsychological Society*, 16(4), 613-620. doi:<https://dx.doi.org/10.1017/S1355617710000317>
- Flach, C., French, P., Dunn, G., Fowler, D., Gumley, A., Birchwood, M., . . . Morrison, A. (2015). Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE-2 trial. *British Journal of Psychiatry*, 207(2), 123-129. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/544/CN-01089544/frame.html> doi:[10.1192/bjp.bp.114.153320](https://doi.org/10.1192/bjp.bp.114.153320)
- Flach, C., French, P., Dunn, G., Fowler, D., Gumley, A. I., Birchwood, M., . . . Morrison, A. P. (2015). Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE-2 trial. *British Journal of Psychiatry*, 207(2), 123-129. doi:<https://doi.org/10.1192/bjp.bp.114.153320>
- Fleischhacker, W. (2013). Making sense of diverging results of studies comparing depot to oral antipsychotics. *Schizophrenia bulletin*, 39, S330. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/235/CN-01007235/frame.html> doi:[10.1093/schbul/sbt011](https://doi.org/10.1093/schbul/sbt011)

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Fleischhacker, W., Eerdekins, M., Karcher, K., Remington, G., Llorca, P., Chrzanowski, W., . . . Gefvert, O. (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. *Journal of Clinical Psychiatry*, 64(10), 1250-1257. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/411/CN-00559411/frame.html>
- Fleischhacker, W., Gopal, S., Lane, R., Gassmann-Mayer, C., Lim, P., Hough, D., . . . Eerdekins, M. (2012). Erratum: a randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia-Corrigendum (*International Journal of Neuropsychopharmacology* (2011) DOI 10.1017/S1461145711001076). *International journal of neuropsychopharmacology*, 15(1), 119. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/808/CN-01018808/frame.html> doi:10.1017/S146114571100160X
- Fleischhacker, W., Gopal, S., Lane, R., Gassmann-Mayer, C., Lim, P., Hough, D., . . . Eerdekins, M. (2012). A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. *The international journal of neuropsychopharmacology*, 15(1), 107-118. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/830/CN-00897830/frame.html> doi:10.1017/S1461145711001076
- Fleischhacker, W., Sanchez, R., Jin, N., Peters-Strickland, T., Johnson, B., Eramo, A., . . . Kane, J. (2013). Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole. *European neuropsychopharmacology*, 23, S474-s475. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/765/CN-01024765/frame.html> doi:10.1016/S0924-977X%2813%2970751-X
- Fleischhacker, W., Sanchez, R., Perry, P., Jin, N., Peters-Strickland, T., Johnson, B., . . . Kane, J. (2014). Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. *British Journal of Psychiatry*, 205(2), 135-144. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/844/CN-01002844/frame.html> doi:10.1192/bjp.bp.113.134213
- Fletcher, P., Frith, C., Grasby, P., Friston, K., & Dolan, R. (1996). Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. *Journal of neuroscience*, 16(21), 7055-7062. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/505/CN-00130505/frame.html>
- Föcking, M., Dicker, P., Lopez, L., Cannon, M., Schafer, M., McGorry, P., . . . Amminger, G. (2016). Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder? *BMC Psychiatry*, 16(1) (no pagination). Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/327/CN-01208327/frame.html> doi:10.1186/s12888-016-1039-7
- Föcking, M., Dicker, P., Lopez, L., Cannon, M., Schäfer, M., McGorry, P., . . . Amminger, G. (2016). Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- disorder? *BMC Psychiatry*, 16(1), 326. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/462/CN-01379462/frame.html> doi:10.1186/s12888-016-1039-7
- Focking, M., Dicker, P., Lopez, L. M., Cannon, M., Schafer, M. R., McGorry, P. D., . . . Amminger, G. (2016). Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: A predictor of transition to psychotic disorder? *BMC Psychiatry* Vol 16 2016, ArtID 326, 16.
- Focking, M., Dicker, P., Lopez, L. M., Cannon, M., Schafer, M. R., McGorry, P. D., . . . Amminger, G. P. (2016). Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder? *BMC Psychiatry*, 16(1), 326. doi:<https://dx.doi.org/10.1186/s12888-016-1039-7>
- Forbes, E. E., Olino, T. M., Ryan, N. D., Birmaher, B., Axelson, D., Moyles, D. L., & Dahl, R. E. (2010). Reward-related brain function as a predictor of treatment response in adolescents with major depressive disorder. *Cognitive, Affective & Behavioral Neuroscience*, 10(1), 107-118. doi:<http://dx.doi.org/10.3758/CABN.10.1.107>
- Fortney, J. C., Pyne, J. M., Kimbrell, T. A., Hudson, T. J., Robinson, D. E., Schneider, R., . . . Schnurr, P. P. (2015). Telemedicine-based collaborative care for posttraumatic stress disorder: a randomized clinical trial.[Erratum appears in *JAMA Psychiatry*. 2015 Jan;72(1):96]. *JAMA Psychiatry*, 72(1), 58-67. doi:<https://dx.doi.org/10.1001/jamapsychiatry.2014.1575>
- Foster, A., Buckley, P., Lauriello, J., Looney, S., & Schooler, N. (2017). Combination Antipsychotic Therapies: an Analysis from a Longitudinal Pragmatic Trial. *Journal of Clinical Psychopharmacology*, 37(5), 595-599. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/989/CN-01430989/frame.html> doi:10.1097/JCP.0000000000000766
- Fowler, D., Freeman, D., Smith, B., Kuipers, E., Bebbington, P., Bashforth, H., . . . Garety, P. (2006). The Brief Core Schema Scales (BCSS): psychometric properties and associations with paranoia and grandiosity in non-clinical and psychosis samples. *Psychological Medicine*, 36(6), 749-759.
- Fowler, D., Hodgekins, J., Painter, M., Reilly, T., Crane, C., Macmillan, I., . . . Jones, P. B. (2009). Cognitive behaviour therapy for improving social recovery in psychosis: a report from the ISREP MRC Trial Platform Study (Improving Social Recovery in Early Psychosis). *Psychological Medicine*, 39(10), 1627-1636. doi:<https://dx.doi.org/10.1017/S0033291709005467>
- Fredrick, M. M., Mintz, J., Roberts, D. L., Maples, N. J., Sarkar, S., Li, X., & Velligan, D. I. (2015). Is cognitive adaptation training (CAT) compensatory, restorative, or both? *Schizophrenia Research*, 166(1-3), 290-296. doi:<https://dx.doi.org/10.1016/j.schres.2015.06.003>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Freeman, D., Dunn, G., Garety, P., Weinman, J., Kuipers, E., Fowler, D., . . . Bebbington, P. (2013). Patients' beliefs about the causes, persistence and control of psychotic experiences predict take-up of effective cognitive behaviour therapy for psychosis. *Psychological Medicine*, 43(2), 269-277. doi:<https://dx.doi.org/10.1017/S0033291712001225>
- Freeman, D., Dunn, G., Startup, H., & Kingdon, D. (2012). The effects of reducing worry in patients with persecutory delusions: study protocol for a randomized controlled trial. *Trials [Electronic Resource]*, 13, 223. doi:<https://dx.doi.org/10.1186/1745-6215-13-223>
- Freeman, D., Dunn, G., Startup, H., Pugh, K., Cordwell, J., Mander, H., . . . Kingdon, D. (2015). Effects of cognitive behaviour therapy for worry on persecutory delusions in patients with psychosis (WIT): a parallel, single-blind, randomised controlled trial with a mediation analysis. *The Lancet. Psychiatry*, 2(4), 305-313. doi:[https://dx.doi.org/10.1016/S2215-0366\(15\)00039-5](https://dx.doi.org/10.1016/S2215-0366(15)00039-5)
- Freeman, D., Garety, P. A., Fowler, D., Kuipers, E., Bebbington, P. E., & Dunn, G. (2004). Why do people with delusions fail to choose more realistic explanations for their experiences? An empirical investigation. *Journal of Consulting & Clinical Psychology*, 72(4), 671-680.
- Freeman, D., Pugh, K., Dunn, G., Evans, N., Sheaves, B., Waite, F., . . . Fowler, D. (2014). An early Phase II randomised controlled trial testing the effect on persecutory delusions of using CBT to reduce negative cognitions about the self: the potential benefits of enhancing self confidence. *Schizophrenia Research*, 160(1-3), 186-192. doi:<https://dx.doi.org/10.1016/j.schres.2014.10.038>
- Freeman, D., Startup, H., Myers, E., Harvey, A., Geddes, J., Yu, L. M., . . . Lister, R. (2013). The effects of using cognitive behavioural therapy to improve sleep for patients with delusions and hallucinations (the BEST study): study protocol for a randomized controlled trial. *Trials [Electronic Resource]*, 14, 214. doi:<https://dx.doi.org/10.1186/1745-6215-14-214>
- Freeman, D., Waite, F., Emsley, R., Kingdon, D., Davies, L., Fitzpatrick, R., & Dunn, G. (2016). The efficacy of a new translational treatment for persecutory delusions: study protocol for a randomised controlled trial (The Feeling Safe Study). *Trials [Electronic Resource]*, 17(1), 134. doi:<https://dx.doi.org/10.1186/s13063-016-1245-0>
- Freeman, D., Waite, F., Startup, H., Myers, E., Lister, R., McInerney, J., . . . Yu, L.-M. (2015). Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): A prospective, assessor-blind, randomised controlled pilot trial. *The Lancet Psychiatry*, 2(11), 975-983.
- Freeman, D., Waite, F., Startup, H., Myers, E., Lister, R., McInerney, J., . . . Yu, L. M. (2015). Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial. *The Lancet. Psychiatry*, 2(11), 975-983. doi:[https://dx.doi.org/10.1016/S2215-0366\(15\)00314-4](https://dx.doi.org/10.1016/S2215-0366(15)00314-4)

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- French, P., Shryane, N., Bentall, R. P., Lewis, S. W., & Morrison, A. P. (2007). Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. *British Journal of Psychiatry - Supplementum*, 51, s82-87. doi:<https://dx.doi.org/10.1192/bjp.191.51.s82>
- Fricchione, P. V., Addeo, L., Laezza, R., Balletta, G., & Manna, G. (2016). Long-acting injectable antipsychotics: second-generation compared to first-generation drugs. Clinical outcomes and reflections. *European neuropsychopharmacology. Conference: 29th european college of neuropsychopharmacology congress, ECNP 2016. Austria. Conference start: 20160917. Conference end: 20160920, 26, S535-s536*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/834/CN-01303834/frame.html>
- Fritzen, F., & Bloch, M. (2014). N-acetylcysteine for the treatment of obsessive-compulsive disorder. *Current psychiatry reviews*, 10(4 // (AACAP) *American Academy of Child and Adolescent Psychiatry* // 1K23MH091240-01 (NIH) *American Academy of Child and Adolescent Psychiatry* // UL1 RR024139 (NCRR) *American Academy of Child and Adolescent Psychiatry* // (NIMH) *American Academy of Child and Adolescent Psychiatry*), 308-316. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/858/CN-01079858/frame.html>
- Fu, D., Alphs, L., Lindenmayer, J., Schooler, N., Simonson, R., Turkoz, I., & Walling, D. (2014). Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder. *European neuropsychopharmacology.*, 24, S534-s535. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/724/CN-01054724/frame.html>
- Fu, D., Bossie, C., Kern, S. J., Ma, Y., & Alphs, L. (2014). Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. *Clinical schizophrenia & related psychoses*, 8(2), 101-109, 109a. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/422/CN-01076422/frame.html> doi:10.3371/CSRP.FUBO.022213
- Fu, D., Bossie, C., Sliwa, J., Ma, Y., & Alphs, L. (2014). Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. *International Clinical Psychopharmacology*, 29(1), 45-55. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/046/CN-01121046/frame.html> doi:10.1097/YIC.0000000000000006
- Fu, D.-J., Bossie, C., Sliwa, J., Ma, Y.-W., & Alphs, L. (2014). Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. *Clinical schizophrenia & related psychoses*, 8(2), 101-109a. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/634/CN-00998634/frame.html> doi:10.3371/CSRP.FUBO.022213
- Fu, D.-J., Turkoz, I., Simonson, R., Walling, D., Schooler, N., Lindenmayer, J., & Alphs, L. (2013). Paliperidone palmitate long-acting injectable in acute exacerbation of schizoaffective disorder. *Schizophrenia bulletin.*, 39, S331. Retrieved from

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

<http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/017/CN-01026017/frame.html>

doi:10.1093/schbul/sbt011

Fu, D.-J., Turkoz, I., Simonson, R., Walling, D., Schooler, N., Lindenmayer, J.-P., & Alphs, L. (2014). Paliperidone palmitate delays relapse in patients with schizoaffective disorder. *Biological psychiatry.*, 75(9 suppl. 1), 263s. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/461/CN-01060461/frame.html>
doi:10.1016/j.biopsych.2014.03.015

Fung, K. M., Tsang, H. W., & Cheung, W. M. (2011). Randomized controlled trial of the self-stigma reduction program among individuals with schizophrenia. *Psychiatry Research*, 189(2), 208-214.
doi:<https://dx.doi.org/10.1016/j.psychres.2011.02.013>

Furre, A., Sandvik, L., Heyerdahl, S., Friis, S., Knutzen, M., & Hanssen-Bauer, K. (2014). Characteristics of adolescents subjected to restraint in acute psychiatric units in Norway: a case-control study. *Psychiatric services (washington, D.C.)*, 65(11), 1367-1372. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/964/CN-01021964/frame.html>

Gaag, M., Nieman, D., Wunderink, L., Klaassen, R., Rietdijk, J., Dragt, S., . . . Linszen, D. (2012). The results of a specific CBT intervention in young help-seeking patients with social decline and an ultra-high risk for developing a first-episode of psychosis. *Early intervention in psychiatry*, 6, 12. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/037/CN-01004037/frame.html> doi:10.1111/j.1751-7893.2012.00392.x

Gaebel, W., Riesbeck, M., Wolwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., . . . German Study Group on First-Episode, S. (2011). Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. *Journal of Clinical Psychiatry*, 72(2), 205-218. doi:<https://dx.doi.org/10.4088/JCP.09m05459yel>

Gaebel, W., Schreiner, A., Bergmans, P., Arce, R., Rouillon, F., & Cordes, J. (2011). Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial (vol 35, pg 2367, 2010). *Neuropsychopharmacology*, 36(2), 548. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/080/CN-00776080/frame.html>

Gaebel, W., Schreiner, A., Bergmans, P., Arce, R., Rouillon, F., Cordes, J., . . . Smeraldi, E. (2010). Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. *Neuropsychopharmacology*, 35(12), 2367-2377. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/919/CN-00769919/frame.html>
doi:10.1038/npp.2010.111

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Galderisi, S., Piegari, G., Mucci, A., Acerra, A., Luciano, L., Rabasca, A. F., . . . Maj, M. (2010). Social skills and neurocognitive individualized training in schizophrenia: comparison with structured leisure activities. *European Archives of Psychiatry & Clinical Neuroscience*, 260(4), 305-315. doi:<https://dx.doi.org/10.1007/s00406-009-0078-1>
- Gallant, D., Mielke, D., Spirtes, M., Swanson, W., & Bost, R. (1974). Penfluridol: an efficacious long-acting oral antipsychotic compound. *American Journal of Psychiatry*, 131(6), 699-702. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/251/CN-00010251/frame.html> doi:10.1176/ajp.131.6.699
- Garety, P., Waller, H., Emsley, R., Jolley, S., Kuipers, E., Bebbington, P., . . . Freeman, D. (2015). Cognitive mechanisms of change in delusions: an experimental investigation targeting reasoning to effect change in paranoia. *Schizophrenia Bulletin*, 41(2), 400-410. doi:<https://dx.doi.org/10.1093/schbul/sbu103>
- Garety, P. A., Fowler, D. G., Freeman, D., Bebbington, P., Dunn, G., & Kuipers, E. (2008). Cognitive--behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. *British Journal of Psychiatry*, 192(6), 412-423. doi:<https://dx.doi.org/10.1192/bjp.bp.107.043570>
- Garety, P. A., Freeman, D., Jolley, S., Dunn, G., Bebbington, P. E., Fowler, D. G., . . . Dudley, R. (2005). Reasoning, emotions, and delusional conviction in psychosis. *Journal of Abnormal Psychology*, 114(3), 373-384. doi:<https://dx.doi.org/10.1037/0021-843X.114.3.373>
- Garrido, G., Barrios, M., Penades, R., Enriquez, M., Garolera, M., Aragay, N., . . . Vendrell, J. M. (2013). Computer-assisted cognitive remediation therapy: cognition, self-esteem and quality of life in schizophrenia. *Schizophrenia Research*, 150(2-3), 563-569. doi:<https://dx.doi.org/10.1016/j.schres.2013.08.025>
- Garrido, G., Penades, R., Barrios, M., Aragay, N., Ramos, I., Valles, V., . . . Vendrell, J. M. (2017). Computer-assisted cognitive remediation therapy in schizophrenia: Durability of the effects and cost-utility analysis. *Psychiatry Research*, 254, 198-204. doi:<https://dx.doi.org/10.1016/j.psychres.2017.04.065>
- Gaudiano, B., Busch, A., Wenze, S., Nowlan, K., Epstein-Lubow, G., & Miller, I. (2015). Acceptance-based Behavior Therapy for Depression With Psychosis: results From a Pilot Feasibility Randomized Controlled Trial. *Journal of Psychiatric Practice*, 21(5), 320-333. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/561/CN-01089561/frame.html> doi:10.1097/PRA.0000000000000092
- Gaudiano, B., Davis, C., Epstein-Lubow, G., Johnson, J., Mueser, K., & Miller, I. (2017). Acceptance and Commitment Therapy for Inpatients with Psychosis (the REACH Study): protocol for Treatment Development and Pilot Testing. *Healthcare (basel, switzerland)*, 5(2). Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/416/CN-01380416/frame.html> doi:10.3390/healthcare5020023

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Gaudiano, B., & Herbert, J. (2006). Acute treatment of inpatients with psychotic symptoms using Acceptance and Commitment Therapy: pilot results. *Behav Res Ther*, 44(3), 415-437. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/702/CN-00560702/frame.html> doi:10.1016/j.brat.2005.02.007
- Gaudiano, B., Herbert, J., & Hayes, S. (2010). Is It the Symptom or the Relation to It? Investigating Potential Mediators of Change in Acceptance and Commitment Therapy for Psychosis. *Behavior Therapy*, 41(4), 543-554. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/328/CN-00775328/frame.html>
- Gaudiano, B. A., Busch, A. M., Wenze, S. J., Nowlan, K., Epstein-Lubow, G., & Miller, I. W. (2015). Acceptance-based Behavior Therapy for Depression With Psychosis: Results From a Pilot Feasibility Randomized Controlled Trial. *Journal of Psychiatric Practice*, 21(5), 320-333. doi:<https://dx.doi.org/10.1097/PRA.0000000000000092>
- Gaudiano, B. A., & Herbert, J. D. (2006). Acute treatment of inpatients with psychotic symptoms using Acceptance and Commitment Therapy: pilot results. *Behaviour Research & Therapy*, 44(3), 415-437.
- Gaudiano, B. A., Nowlan, K., Brown, L. A., Epstein-Lubow, G., & Miller, I. W. (2013). An Open Trial of a New Acceptance-Based Behavioral Treatment for Major Depression with Psychotic Features. *Behavior Modification*, 37(3), 324-355.
- Gaughran, F., Stahl, D., Ismail, K., Atakan, Z., Lally, J., Gardner-Sood, P., . . . Smith, S. (2013). Improving physical health and reducing substance use in psychosis--randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial. *BMC Psychiatry*, 13, 263. doi:<https://dx.doi.org/10.1186/1471-244X-13-263>
- Gefvert, O., Nyberg, S., Persson, P., Helklin, L., & Bjorner, A. (2001). Pharmacokinetics, D2 receptor occupancy, and clinical effects of a long-acting injectable formulation of risperidone in patients with schizophrenia. *2001 annual meeting of the american psychiatric association; 2001 may 5-10; new orleans; LA, USA*. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/615/CN-00655615/frame.html>
- Gerlach, J., Kramp, P., Kristjansen, P., Lauritsen, B., Lühdorf, K., & Munkvad, I. (1975). Peroral and parenteral administration of long-acting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia. *Acta Psychiatrica Scandinavica*, 52(2), 132-144. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/544/CN-00705544/frame.html>
- Gerlach, J., Rasmussen, P., Hansen, L., & Kristjansen, P. (1977). Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety. *Acta Psychiatrica Scandinavica*, 55(4), 251-260. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/014/CN-00016014/frame.html>
- Ghahari, S., Hassani, H., & Purmofrad, M. (2017). Pragmatic Competency and Obsessive-Compulsive Disorder: A Comparative Assessment with Normal Controls. *Journal of Psycholinguistic Research*, 46(4), 863-875.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Gharabawi, G., Bossie, C., Turkoz, I., Kujawa, M., Mahmoud, R., & Simpson, G. (2007). The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. *Journal of Nervous and Mental Disease, 195*(12), 976-982. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/883/CN-00621883/frame.html> doi:10.1097/NMD.0b013e31815c1982
- Ghouchani, S., Molavi, N., Massah, O., Sadeghi, M., Mousavi, S., Noroozi, M., . . . Farhoudian, A. (2018). Effectiveness of Acceptance and Commitment Therapy (ACT) on aggression of patients with psychosis due to methamphetamine use: a pilot study. *Journal of Substance Use, 1*-6. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/131/CN-01461131/frame.html> doi:10.1080/14659891.2018.1436602
- Ghouchani, S., Molavi, N., Massah, O., Sadeghi, M., Mousavi, S. H., Noroozi, M., . . . Farhoudian, A. (2018). Effectiveness of Acceptance and Commitment Therapy (ACT) on aggression of patients with psychosis due to methamphetamine use: A pilot study. *Journal of Substance Use, 23*(4), 402-407. doi:<http://dx.doi.org/10.1080/14659891.2018.1436602>
- Gibbs, A., Naudts, K., Spencer, E., & David, A. (2007). The role of dopamine in attentional and memory biases for emotional information. *American Journal of Psychiatry, 164*(10), 1603-1609; quiz 1624. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/257/CN-00612257/frame.html> doi:10.1176/appi.ajp.2007.06081241
- Gibbs, A. A., Naudts, K. H., Spencer, E. P., & David, A. S. (2007). The role of dopamine in attentional and memory biases for emotional information. *American Journal of Psychiatry, 164*(10), 1603-1609; quiz 1624.
- Gil Sanz, D., Diego Lorenzo, M., Bengochea Seco, R., Arrieta Rodriguez, M., Lastra Martinez, I., Sanchez Calleja, R., & Alvarez Soltero, A. (2009). Efficacy of a social cognition training program for schizophrenic patients: a pilot study. *Spanish Journal of Psychology, 12*(1), 184-191.
- Gilboa-Schechtman, E., Foa, E. B., Shafran, N., Aderka, I. M., Powers, M. B., Rachamim, L., . . . Apter, A. (2010). Prolonged exposure versus dynamic therapy for adolescent PTSD: A pilot randomized controlled trial. *Journal of the American Academy of Child & Adolescent Psychiatry, 49*(10), 1034-1042. doi:<http://dx.doi.org/10.1016/j.jaac.2010.07.014>
- Gilden, J., Wierdsma, A., Beveren, J., Hakkaart, L., Westrhenen, R., Feltz-Cornelis, C., . . . Mulder, C. (2015). Acemap, a long acting oral antipsychotic agent as a way of improving treatment engagement and outcomes? *European archives of psychiatry and clinical neuroscience, 265*(1 suppl. 1), S59-s60. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/561/CN-01139561/frame.html>
- Girgis, R., Slifstein, M., D'Souza, D., Lee, Y., Periclou, A., Ghahramani, P., . . . Rakhit, A. (2016). Preferential binding to dopamine D₃ receptors by cariprazine in patients with schizophrenia using PET with the D₃/D₂ receptor ligand -(+)-PHNO. *Psychopharmacology, 233*(19-20), 3503-3512. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/798/CN-01209798/frame.html> doi:10.1007/s00213-016-4382-y

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Gitlin, M., Gerner, R., & Rosenblatt, M. (1981). Assessment of naltrexone in the treatment of schizophrenia.

Psychopharmacology, 74(1), 51-53. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/787/CN-00025787/frame.html>

Gleeson, J. F., Chanen, A., Cotton, S. M., Pearce, T., Newman, B., & McCutcheon, L. (2012). Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial. *Early intervention in psychiatry*, 6(1), 21-29.

Gleeson, J. F., Cotton, S. M., Alvarez-Jimenez, M., Wade, D., Crisp, K., Newman, B., . . . McGorry, P. D. (2010). Family outcomes from a randomized control trial of relapse prevention therapy in first-episode psychosis. *Journal of Clinical Psychiatry*, 71(4), 475-483. doi:<https://dx.doi.org/10.4088/JCP.08m04672yel>

Gleeson, J. F., Cotton, S. M., Alvarez-Jimenez, M., Wade, D., Gee, D., Crisp, K., . . . McGorry, P. D. (2009). A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. *Journal of Clinical Psychiatry*, 70(4), 477-486.

Gleeson, J. F., Cotton, S. M., Alvarez-Jimenez, M., Wade, D., Gee, D., Crisp, K., . . . McGorry, P. D. (2013). A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up. *Schizophrenia Bulletin*, 39(2), 436-448. doi:<https://dx.doi.org/10.1093/schbul/sbr165>

Gobbi, G., Comai, S., & Debonnel, G. (2014). Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: a pilot randomized, open-label, comparative study. *Neuropsychiatric Disease and Treatment*, 10, 757-765. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/508/CN-00993508/frame.html> doi:10.2147/NDT.S59968

Göder, R., Fritzer, G., Gottwald, B., Lippmann, B., Seeck-Hirschner, M., Serafin, I., & Aldenhoff, J. (2008). Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia. *Pharmacopsychiatry*, 41(3), 92-99. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/535/CN-00648535/frame.html> doi:10.1055/s-2007-1004592

Goethals, K., Buitelaar, J., & van Marle, H. (2008). The Role of Substance Abuse in Psychotic versus Personality Disordered Offenders Detained under the Dutch Entrustment Act (TBS): An Exploratory Study. *International Journal of Mental Health and Addiction*, 6(3), 389-401.

Goff, D., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D., . . . Coyle, J. (1999). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. *Archives of General Psychiatry*, 56(1), 21-27. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/868/CN-00158868/frame.html>

Goff, D., Tsai, G., Levitt, J., Amico, E., Schoenfeld, D., McCarley, R., & Coyle, J. (1998). D-Cycloserine Added to Neuroleptics in Schizophrenia. *151st annual meeting of the american psychiatric association. Toronto, ontario, canada. 30th may-*

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

4th june 1998., (Nr210). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/357/CN-00654357/frame.html>

Gohar, S. M., Hamdi, E., El Ray, L. A., Horan, W. P., & Green, M. F. (2013). Adapting and evaluating a social cognitive remediation program for schizophrenia in Arabic. *Schizophrenia Research*, 148(1-3), 12-17.
doi:<https://dx.doi.org/10.1016/j.schres.2013.05.008>

Gold, P., Meisler, N., Santos, A., Carnemolla, M., Williams, O., & Keleher, J. (2006). Randomized trial of supported employment integrated with assertive community treatment for rural adults with severe mental illness. *Schizophrenia Bulletin*, 32(2), 378-395. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/158/CN-00561158/frame.html> doi:10.1093/schbul/sbi056

Gold, P. B., Meisler, N., Santos, A. B., Carnemolla, M. A., Williams, O. H., & Keleher, J. (2006). Randomized trial of supported employment integrated with assertive community treatment for rural adults with severe mental illness. *Schizophrenia Bulletin*, 32(2), 378-395.

Goldberg, S., Schooler, N., Hogarty, G., & Roper, M. (1977). Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. *Archives of General Psychiatry*, 34(2), 171-184. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/710/CN-00015710/frame.html>

Goldsmith, L. P., Lewis, S. W., Dunn, G., & Bentall, R. P. (2015). Psychological treatments for early psychosis can be beneficial or harmful, depending on the therapeutic alliance: an instrumental variable analysis. *Psychological Medicine*, 45(11), 2365-2373. doi:<https://dx.doi.org/10.1017/S003329171500032X>

Goldstein, B. I., Shamseddeen, W., Spirito, A., Emslie, G., Clarke, G., Wagner, K. D., . . . Brent, D. A. (2009). Substance use and the treatment of resistant depression in adolescents. *Journal of the American Academy of Child & Adolescent Psychiatry*, 48(12), 1182-1192. doi:<https://dx.doi.org/10.1097/CHI.0b013e3181bef6e8>

Goldstein, T. R., Axelson, D. A., Birmaher, B., & Brent, D. A. (2007). Dialectical behavior therapy for adolescents with bipolar disorder: A 1-years open trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, 46(7), 820-830.
doi:<http://dx.doi.org/10.1097/chi.0b013e31805c1613>

Gomar, J. J., Valls, E., Radua, J., Mareca, C., Tristany, J., del Olmo, F., . . . Cognitive Rehabilitation Study, G. (2015). A Multisite, Randomized Controlled Clinical Trial of Computerized Cognitive Remediation Therapy for Schizophrenia. *Schizophrenia Bulletin*, 41(6), 1387-1396. doi:<https://dx.doi.org/10.1093/schbul/sbv059>

Gomeni, R., Heidbreder, C., Fudala, P., & Nasser, A. (2013). A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone. *Journal of clinical pharmacology*, 53(10), 1010-1019. Retrieved

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/053/CN-00914053/frame.html>

doi:10.1002/jcpb.141

Gomez, S.-L. C., Reina, G. R., Moreno, D. L. F., Severac, C. A., Mateos, C. E., & Gonzalez, M. A. (2016). Twenty-four months experience of paliperidone long-acting injection in a Spanish psychiatric service: a mirror image analysis. *European psychiatry.*, 33, S541. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/381/CN-01160381/frame.html> doi:10.1016/j.eurpsy.2016.01.1999

Gonzalez-Ortega, I., Echeburua, E., Garcia-Alocen, A., Vega, P., & Gonzalez-Pinto, A. (2016). Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial. *Trials [Electronic Resource]*, 17, 372. doi:<https://dx.doi.org/10.1186/s13063-016-1507-x>

Goodyer, I., Dubicka, B., Wilkinson, P., Kelvin, R., Roberts, C., Byford, S., . . . Harrington, R. (2007). Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. *BMJ*, 335(7611), 142.

Goodyer, I. M., Reynolds, S., Barrett, B., Byford, S., Dubicka, B., Hill, J., . . . Fonagy, P. (2017). Cognitive behavioural therapy and short-term psychoanalytical psychotherapy versus a brief psychosocial intervention in adolescents with unipolar major depressive disorder (IMPACT): A multicentre, pragmatic, observer-blind, randomised controlled superiority trial. *The Lancet Psychiatry*, 4(2), 109-119. doi:<http://dx.doi.org/10.1016/S2215-0366%2816%2930378-9>

Goodyer, I. M., Reynolds, S., Barrett, B., Byford, S., Dubicka, B., Hill, J., . . . Fonagy, P. (2017). Cognitive-behavioural therapy and short-term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled trial. *Health Technology Assessment (Winchester, England)*, 21(12), 1-94. doi:<https://dx.doi.org/10.3310/hta21120>

Gopal, S., Liu, Y., Alphs, L., Savitz, A., Nuamah, I., & Hough, D. (2012). Rates and time course of extrapyramidal symptoms: a comparison of oral and long-acting intramuscular (LAI) paliperidone randomized controlled studies. *Schizophrenia Research.*, 136, S257. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/056/CN-01050056/frame.html>

Gopal, S., Liu, Y., Alphs, L., Savitz, A., Nuamah, I., & Hough, D. (2013). Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. *Neuropsychiatric Disease and Treatment*, 9, 1381-1392. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/122/CN-00914122/frame.html> doi:10.2147/NDT.S49944

Gopal, S., Pandina, G., Lane, R., Nuamah, I., Remmerie, B., Coppola, D., & Hough, D. (2011). A post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

schizophrenia. *Innovations in clinical neuroscience*, 8(8), 26-33. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/878/CN-00893878/frame.html>

Gopal, S., Xu, H., McQuarrie, K., Savitz, A., Nuamah, I., Woodruff, K., & Mathews, M. (2016). Caregiver burden in schizophrenia: pooled analysis of the involvement evaluation questionnaire data for paliperidone palmitate 3-month formulation. *Value in health. Conference: ISPOR 21st annual international meeting research. Washington, DC united states. Conference start: 20160521. Conference end: 20160525. Conference publication: (var.pagings)*, 19(3), A191. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/605/CN-01266605/frame.html>

Gopal, S., Xu, H., McQuarrie, K., Savitz, A., Nuamah, I., Woodruff, K., & Mathews, M. (2017). Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. *npj Schizophrenia*, 3(1), 23. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/338/CN-01415338/frame.html> doi:10.1038/s41537-017-0025-5

Gottdiener, W. H., & Haslam, N. (2002). The benefits of individual psychotherapy for people diagnosed with schizophrenia: A meta-analytic review. *Ethical Human Sciences and Services*, 4(3), 163-187.

Gottlieb, J. D., Cather, C., Shanahan, M., Creedon, T., Macklin, E. A., & Goff, D. C. (2011). D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. *Schizophrenia Research*, 131(1-3), 69-74. doi:<https://dx.doi.org/10.1016/j.schres.2011.05.029>

Gottlieb, J. D., Gidugu, V., Maru, M., Tepper, M. C., Davis, M. J., Greenwold, J., . . . Mueser, K. T. (2017). Randomized controlled trial of an internet cognitive behavioral skills-based program for auditory hallucinations in persons with psychosis. *Psychiatric Rehabilitation Journal*, 40(3), 283-292. doi:<http://dx.doi.org/10.1037/prj0000258>

Gottlieb, J. D., Mueser, K. T., Rosenberg, S. D., Xie, H., & Wolfe, R. S. (2011). Psychotic depression, posttraumatic stress disorder, and engagement in cognitive-behavioral therapy within an outpatient sample of adults with serious mental illness. *Comprehensive Psychiatry*, 52(1), 41-49. doi:<https://dx.doi.org/10.1016/j.comppsych.2010.04.012>

Gouzoulis-Mayfrank, E., Konig, S., Koebke, S., Schnell, T., Schmitz-Buhl, M., & Daumann, J. (2015). Trans-sector integrated treatment in psychosis and addiction: A randomized controlled study of a motivational, cognitive behavioral therapy program under standard hospital treatment conditions. *Deutsches Arzteblatt International*, 112(41), 683-691.

Grabe, H. J., Wolf, T., Gratz, S., & Laux, G. (1999). The influence of clozapine and typical neuroleptics on information processing of the central nervous system under clinical conditions in schizophrenic disorders: Implications for fitness to drive. *Neuropsychobiology*, 40(4), 196-201. doi:<http://dx.doi.org/10.1159/000026619>

Granholm, E., Holden, J., Link, P. C., & McQuaid, J. R. (2014). Randomized clinical trial of cognitive behavioral social skills training for schizophrenia: improvement in functioning and experiential negative symptoms. *Journal of Consulting & Clinical Psychology*, 82(6), 1173-1185. doi:<https://dx.doi.org/10.1037/a0037098>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Granholm, E., Holden, J., Link, P. C., McQuaid, J. R., & Jeste, D. V. (2013). Randomized controlled trial of cognitive behavioral social skills training for older consumers with schizophrenia: defeatist performance attitudes and functional outcome. *American Journal of Geriatric Psychiatry, 21*(3), 251-262. doi:<https://dx.doi.org/10.1016/j.jagp.2012.10.014>
- Granholm, E., Holden, J., Sommerfeld, D., Rufener, C., Perivoliotis, D., Mueser, K., & Aarons, G. (2015). Enhancing assertive community treatment with cognitive behavioral social skills training for schizophrenia: study protocol for a randomized controlled trial. *Trials [Electronic Resource], 16*, 438. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/294/CN-01096294/frame.html> doi:10.1186/s13063-015-0967-8
- Granholm, E., Holden, J., & Worley, M. (2018). Improvement in negative symptoms and functioning in cognitive-behavioral social skills training for schizophrenia: Mediation by defeatist performance attitudes and asocial beliefs. *Schizophrenia Bulletin, 44*(3), 653-661. doi:<http://dx.doi.org/10.1093/schbul/sbx099>
- Granholm, E., Holden, J. L., Sommerfeld, D., Rufener, C., Perivoliotis, D., Mueser, K., & Aarons, G. A. (2015). Enhancing assertive community treatment with cognitive behavioral social skills training for schizophrenia: study protocol for a randomized controlled trial. *Trials [Electronic Resource], 16*, 438. doi:<https://dx.doi.org/10.1186/s13063-015-0967-8>
- Granholm, E., McQuaid, J. R., Link, P. C., Fish, S., Patterson, T., & Jeste, D. V. (2008). Neuropsychological predictors of functional outcome in Cognitive Behavioral Social Skills Training for older people with schizophrenia. *Schizophrenia Research, 100*(1-3), 133-143. doi:<https://dx.doi.org/10.1016/j.schres.2007.11.032>
- Granholm, E., McQuaid, J. R., McClure, F. S., Auslander, L. A., Perivoliotis, D., Pedrelli, P., . . . Jeste, D. V. (2005). A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia. *American Journal of Psychiatry, 162*(3), 520-529.
- Granholm, E., McQuaid, J. R., McClure, F. S., Link, P. C., Perivoliotis, D., Gottlieb, J. D., . . . Jeste, D. V. (2007). Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up. *Journal of Clinical Psychiatry, 68*(5), 730-737.
- Granholm, E., McQuaid, J. R., McClure, F. S., Pedrelli, P., & Jeste, D. V. (2002). A randomized controlled pilot study of cognitive behavioral social skills training for older patients with schizophrenia. *Schizophrenia Research, 53*(1-2), 167-169.
- Grant, P. M., Huh, G. A., Perivoliotis, D., Stolar, N. M., & Beck, A. T. (2012). Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. *Archives of General Psychiatry, 69*(2), 121-127. doi:<https://dx.doi.org/10.1001/archgenpsychiatry.2011.129>
- Grawe, R. W., Falloon, I. R., Widen, J. H., & Skogvoll, E. (2006). Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study. *Acta Psychiatrica Scandinavica, 114*(5), 328-336.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Green, A., Brunette, M., Dawson, R., Buckley, P., Wallace, A., Hafez, H., . . . Weeks, M. (2015). Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. *Journal of Clinical Psychiatry*, 76(10), 1359-1365. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/570/CN-01105570/frame.html> doi:10.4088/JCP.13m08838
- Green, M. (2011). Social cognition and schizophrenia. *European archives of psychiatry and clinical neuroscience.*, 261, S7-s8. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/891/CN-01005891/frame.html> doi:10.1007/s00406-011-0229-z
- Greenwood, K., Hung, C. F., Tropeano, M., McGuffin, P., & Wykes, T. (2011). No association between the Catechol-O-Methyltransferase (COMT) val158met polymorphism and cognitive improvement following cognitive remediation therapy (CRT) in schizophrenia.[Erratum appears in Neurosci Lett. 2011 Jul 15;499(1):57]. *Neuroscience Letters*, 496(2), 65-69. doi:<https://dx.doi.org/10.1016/j.neulet.2011.03.075>
- Greig, T. C., Zito, W., Wexler, B. E., Fiszdon, J., & Bell, M. D. (2007). Improved cognitive function in schizophrenia after one year of cognitive training and vocational services. *Schizophrenia Research*, 96(1-3), 156-161.
- Grote, N., Katon, W., & Lohr, M. (2013). Momcare: culturally relevant treatment services for perinatal depression. *Archives of women's mental health.*, 16, S4. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/120/CN-01058120/frame.html> doi:10.1007/s00737-013-0355-x
- Gumley, A., O'Grady, M., McNay, L., Reilly, J., Power, K., & Norrie, J. (2003). Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy. *Psychological Medicine*, 33(3), 419-431.
- Gumley, A., White, R., Briggs, A., Ford, I., Barry, S., Stewart, C., . . . McLeod, H. (2017). A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: pilot trial outcomes (ADAPT). *Schizophrenia Research*, 183, 143-150. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/430/CN-01373430/frame.html> doi:10.1016/j.schres.2016.11.026
- Gumley, A., White, R., Briggs, A., Ford, I., Barry, S., Stewart, C., . . . McLeod, H. (2017). A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: Pilot trial outcomes (ADAPT). *Schizophrenia Research*, 183, 143-150. doi:<https://dx.doi.org/10.1016/j.schres.2016.11.026>
- Gumley, A. I., MacBeth, A., Reilly, J. D., O'Grady, M., White, R. G., McLeod, H., . . . Power, K. G. (2015). Fear of recurrence: results of a randomized trial of relapse detection in schizophrenia. *British Journal of Clinical Psychology*, 54(1), 49-62. doi:<https://dx.doi.org/10.1111/bjcp.12060>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Guo, X., Zhai, J., Liu, Z., Fang, M., Wang, B., Wang, C., . . . Zhao, J. (2010). Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study. *Archives of General Psychiatry*, 67(9), 895-904. doi:<https://dx.doi.org/10.1001/archgenpsychiatry.2010.105>
- Guo, Z. H., Li, Z. J., Ma, Y., Sun, J., Guo, J. H., Li, W. X., . . . Kingdon, D. (2017). Brief cognitive-behavioural therapy for patients in the community with schizophrenia: randomised controlled trial in Beijing, China. *British Journal of Psychiatry*, 210(3), 223-229. doi:<https://dx.doi.org/10.1192/bjp.bp.116.183285>
- Guo, Z.-H., Li, Z.-J., Ma, Y., Sun, J., Guo, J.-H., Li, W.-X., . . . Kingdon, D. (2017). Brief cognitive-behavioural therapy for patients in the community with schizophrenia: Randomised controlled trial in Beijing, China. *The British Journal of Psychiatry*, 210(3), 223-229. doi:<http://dx.doi.org/10.1192/bjp.bp.116.183285>
- Gupta, M., Bassett, E., Iftene, F., & Bowie, C. R. (2012). Functional outcomes in schizophrenia: understanding the competence-performance discrepancy. *Journal of Psychiatric Research*, 46(2), 205-211.
doi:<https://dx.doi.org/10.1016/j.jpsychires.2011.09.002>
- Habib, N., Dawood, S., Kingdon, D., & Naeem, F. (2015). Preliminary evaluation of culturally adapted CBT for psychosis (CA-CBT): findings from developing culturally-sensitive CBT project (DCCP). *Behavioural & Cognitive Psychotherapy*, 43(2), 200-208. doi:<https://dx.doi.org/10.1017/S1352465813000829>
- Hadas-Lidor, N., Katz, N., Tyano, S., & Weizman, A. (2001). Effectiveness of dynamic cognitive intervention in rehabilitation of clients with schizophrenia. *Clinical Rehabilitation*, 15(4), 349-359.
- Haddock, G., Barrowclough, C., Shaw, J. J., Dunn, G., Novaco, R. W., & Tarrier, N. (2009). Cognitive-behavioural therapy v. social activity therapy for people with psychosis and a history of violence: randomised controlled trial. *British Journal of Psychiatry*, 194(2), 152-157. doi:<https://dx.doi.org/10.1192/bjp.bp.107.039859>
- Haddock, G., Barrowclough, C., Tarrier, N., Moring, J., O'Brien, R., Schofield, N., . . . Lewis, S. (2003). Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. *British Journal of Psychiatry*, 183, 418-426.
- Haddock, G., Lewis, S., Bentall, R., Dunn, G., Drake, R., & Tarrier, N. (2006). Influence of age on outcome of psychological treatments in first-episode psychosis. *British Journal of Psychiatry*, 188, 250-254.
- Hagan, R., Evans, S. F., & Pope, S. (2004). Preventing postnatal depression in mothers of very preterm infants: a randomised controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*, 111(7), 641-647.
- Hall, P. L., & Tarrier, N. (2003). The cognitive-behavioural treatment of low self-esteem in psychotic patients: a pilot study. *Behaviour Research & Therapy*, 41(3), 317-332.
- Hallak, J., Maia-de-Oliveira, J., Abrao, J., Evora, P., Zuardi, A., Crippa, J., . . . Dursun, S. (2013). Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

JAMA Psychiatry, 70(7), 668-676. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/509/CN-00876509/frame.html> doi:10.1001/jamapsychiatry.2013.1292

Halperin, S., Nathan, P., Drummond, P., & Castle, D. (2000). A cognitive-behavioural, group-based intervention for social anxiety in schizophrenia. *Australian & New Zealand Journal of Psychiatry*, 34(5), 809-813.

Hammer, T., Oranje, B., & Glenthøj, B. (2007). The effects of imipramine on P50 suppression, prepulse inhibition and habituation of the startle response in humans. *The international journal of neuropsychopharmacology*, 10(6), 787-795. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/643/CN-00617643/frame.html> doi:10.1017/S1461145706007504

Hammersley, P., Dias, A., Todd, G., Bowen-Jones, K., Reilly, B., & Bentall, R. P. (2003). Childhood trauma and hallucinations in bipolar affective disorder: preliminary investigation. *British Journal of Psychiatry*, 182, 543-547.

Handley, R., Zelaya, F., Reinders, A., Marques, T., Mehta, M., O'Gorman, R., . . . Dazzan, P. (2013). Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. *Human Brain Mapping*, 34(2), 272-282. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/759/CN-00880759/frame.html> doi:10.1002/hbm.21436

Handley, R., Zelaya, F. O., Reinders, A. A., Marques, T. R., Mehta, M. A., O'Gorman, R., . . . Dazzan, P. (2013). Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. *Human Brain Mapping*, 34(2), 272-282. doi:<https://dx.doi.org/10.1002/hbm.21436>

Hansen, J., Østergaard, B., Nordentoft, M., & Hounsgaard, L. (2012). Cognitive adaptation training combined with assertive community treatment: a randomised longitudinal trial. *Schizophrenia Research*, 135(1-3), 105-111. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/505/CN-00836505/frame.html> doi:10.1016/j.schres.2011.12.014

Hansen, J. P., Ostergaard, B., Nordentoft, M., & Hounsgaard, L. (2012). Cognitive adaptation training combined with assertive community treatment: a randomised longitudinal trial. *Schizophrenia Research*, 135(1-3), 105-111. doi:<https://dx.doi.org/10.1016/j.schres.2011.12.014>

Hansen, J. P., Ostergaard, B., Nordentoft, M., & Hounsgaard, L. (2013). The feasibility of cognitive adaptation training for outpatients with schizophrenia in integrated treatment. *Community Mental Health Journal*, 49(6), 630-635. doi:<https://dx.doi.org/10.1007/s10597-012-9557-3>

Hansson, K., Allebeck, P., & Malm, U. (2001). Event recording in psychiatric care: development of an instrument and 1-year results. *Nordic Journal of Psychiatry*, 55(1), 25-31. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/655/CN-00377655/frame.html> doi:10.1080/080394801750093689

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Hansson, K. S., Allebeck, P., & Malm, U. (2001). Event recording in psychiatric care: development of an instrument and 1-year results. *Nordic Journal of Psychiatry*, 55(1), 25-31.
- Hard, M., Mills, R., Sadler, B., Turncliff, R., & Citrome, L. (2017). Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. *Journal of Clinical Psychopharmacology*, 37(3), 289-295. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/158/CN-01374158/frame.html>
doi:10.1097/JCP.0000000000000691
- Hard, M., Mills, R., Sadler, B., Wehr, A., Weiden, P., & Moltke, L. (2017). Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: a Phase I Study and a Population Pharmacokinetic Model. *CNS drugs*, 31(7), 617-624. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/805/CN-01380805/frame.html>
doi:10.1007/s40263-017-0447-7
- Hard, M., Stankovic, S., Risinger, R., Bose, A., Du, Y., Zummo, J., . . . Ehrich, E. (2014). Efficacy of aripiprazole lauroxil, a new long-acting injectable atypical antipsychotic, across three geographic regions. *Neuropsychopharmacology*, 39, S359-S360. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/347/CN-01066347/frame.html>
doi:10.1038/npp.2014.281
- Hargarter, L., Bergmans, P., Usankova, I., & Cherubin, P. (2017). Paliperidone palmitate 3-monthly formulation in schizophrenia—baseline interim analysis of a naturalistic, 52-week, prospective study. *European neuropsychopharmacology*. Conference: 30th european college of neuropsychopharmacology congress, ECNP 2017. France, 27(Supplement 4), S950. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/532/CN-01428532/frame.html>
- Hargarter, L., Cherubin, P., Bergmans, P., Keim, S., Rancans, E., Bez, Y., . . . Schreiner, A. (2015). Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 58, 1-7. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/770/CN-01130770/frame.html> doi:10.1016/j.pnpbp.2014.11.006
- Haut, K. M., Lim, K. O., & MacDonald, A., 3rd. (2010). Prefrontal cortical changes following cognitive training in patients with chronic schizophrenia: effects of practice, generalization, and specificity. *Neuropsychopharmacology*, 35(9), 1850-1859. doi:<https://dx.doi.org/10.1038/npp.2010.52>
- Hawkins, R. D. (2013). Possible Contributions of a Novel Form of Synaptic Plasticity in "Aplysia" to Reward, Memory, and Their Dysfunctions in Mammalian Brain. *Learning & Memory*, 20(10), 580-591.
- Hawkins, T., & Berman, B. (2017). Pimavanserin. *Neurology: clinical practice*, 7(2), 157-162. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/221/CN-01371221/frame.html>
doi:10.1212/CPJ.0000000000000342

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Hayward, M., Strauss, C., & Bogen-Johnston, L. (2014). Relating therapy for voices (the R2V study): study protocol for a pilot randomized controlled trial. *Trials [Electronic Resource]*, 15, 325. doi:<https://dx.doi.org/10.1186/1745-6215-15-325>
- Hazell, C. M., Hayward, M., Cavanagh, K., Jones, A. M., & Strauss, C. (2016). Guided self-help cognitive behavioral intervention for VoicEs (GiVE): study protocol for a pilot randomized controlled trial. *Trials [Electronic Resource]*, 17(1), 351. doi:<https://dx.doi.org/10.1186/s13063-016-1494-y>
- Hedges, S., El-Mallakh, R., Issa, F., Elkashaf, A., Bigelow, L., & Wyatt, R. (1998). Clonidine does not potentiate the antipsychotic effects of neuroleptics in chronically ill patients. *Annals of clinical psychiatry*, 10(1), 3-7. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/516/CN-00151516/frame.html>
- Henderson, C., Farrelly, S., Flach, C., Borschmann, R., Birchwood, M., Thornicroft, G., . . . Szumukler, G. (2017). Informed, advance refusals of treatment by people with severe mental illness in a randomised controlled trial of joint crisis plans: Demand, content and correlates. *BMC Psychiatry* Vol 17 2017, ArtID 376, 17.
- Henderson, C., Farrelly, S., Flach, C., Borschmann, R., Birchwood, M., Thornicroft, G., . . . Szumukler, G. (2017). Informed, advance refusals of treatment by people with severe mental illness in a randomised controlled trial of joint crisis plans: demand, content and correlates. *BMC Psychiatry*, 17(1), 376. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/483/CN-01448483/frame.html> doi:10.1186/s12888-017-1542-5
- Henderson, C., Flood, C., Leese, M., Thornicroft, G., Sutherby, K., & Szumukler, G. (2004). Effect of joint crisis plans on use of compulsory treatment in psychiatry: single blind randomised controlled trial. *BMJ*, 329(7458), 136.
- Henderson, C., Flood, C., Leese, M., Thornicroft, G., Sutherby, K., & Szumukler, G. (2004). Effect of joint crisis plans on use of compulsory treatment in psychiatry: single blind randomised controlled trial. *BMJ (Clinical research ed.)*, 329(7458), 136. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/160/CN-00481160/frame.html> doi:10.1136/bmj.38155.585046.63
- Hendriks, L., Kleine, R. A., Heyvaert, M., Becker, E. S., Hendriks, G.-J., & Minnen, A. (2017). Intensive prolonged exposure treatment for adolescent complex posttraumatic stress disorder: A single-trial design. *Journal of Child Psychology and Psychiatry*, 58(11), 1229-1238. doi:<http://dx.doi.org/10.1111/jcpp.12756>
- Heres, S. (2012). What are the clinical implications of long-acting antipsychotics for psychiatrists? *European Neuropsychopharmacology*, 22, S449. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/324/CN-01004324/frame.html>
- Heresco-Levy, U., Javitt, D., Gelfin, Y., Kaufman, Y., Levin, R., Korn-Lubetzki, I., . . . Kremer, I. (2009). D-serine adjuvant treatment alleviates motor and behavioural symptoms in Idiopathic Parkinson's disease. *European neuropsychopharmacology*, 19, S255-s256. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/598/CN-01029598/frame.html> doi:10.1016/S0924-977X%2809%2970368-2

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Herrmann, W., Schärer, E., Wendt, G., & Delini-Stula, A. (1991). Pharmaco-EEG profile of maroxepine: third example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs. *Pharmacopsychiatry*, 24(6), 214-224. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/881/CN-00083881/frame.html> doi:10.1055/s-2007-1014471
- Hill, A., Sun, B., Karagianis, J., Watson, S., & McDonnell, D. (2011). Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. *BMC Psychiatry*, 11. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/593/CN-01016593/frame.html> doi:10.1186/1471-244X-11-28
- Hill, A., Sun, B., & McDonnell, D. (2014). Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine. *Clinical schizophrenia & related psychoses*, 7(4), 216-222. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/769/CN-00983769/frame.html> doi:10.3371/CSRP.HISU.020813
- Hirsch, S., Bowen, J., Emami, J., Cramer, P., Jolley, A., Haw, C., & Dickinson, M. (1996). A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse. *British Journal of Psychiatry*, 168(1), 49-56. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/984/CN-00128984/frame.html>
- Hirsch, S., Gaind, R., Rohde, P., Stevens, B., & Wing, J. (1973). Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. *British medical journal*, 1(5854), 633-637. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/335/CN-00008335/frame.html>
- Hjorthoj, C. R., Fohlmann, A., Larsen, A. M., Gluud, C., Arendt, M., & Nordentoft, M. (2013). Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. *Psychological Medicine*, 43(7), 1499-1510.
doi:<https://dx.doi.org/10.1017/S0033291712002255>
- Hjorthoj, C. R., Orlovska, S., Fohlmann, A., & Nordentoft, M. (2013). Psychiatric treatment following participation in the CapOpus randomized trial for patients with comorbid cannabis use disorder and psychosis. *Schizophrenia Research*, 151(1-3), 191-196. doi:<https://dx.doi.org/10.1016/j.schres.2013.10.014>
- Hodgekins, J., & Fowler, D. (2010). CBT and recovery from psychosis in the ISREP trial: mediating effects of hope and positive beliefs on activity. *Psychiatric Services*, 61(3), 321-324. doi:<https://dx.doi.org/10.1176/ps.2010.61.3.321>
- Hoffer, A., Goetsche, R., & Linden, F. (1980). A psychoanalytic approach to a therapeutic impasse with an impulsive adolescent: permission to speak the unspeakable. *Am-j-psychiatry*, 137(11), 1404-1409. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/284/CN-00302284/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Hoffman, R. (2008). Auditory/Verbal hallucinations, speech perception neurocircuitry, and the social deafferentation hypothesis. *Clinical EEG and neuroscience*, 39(2), 87-90. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/344/CN-00639344/frame.html> doi:10.1177/155005940803900213
- Hoflich, A., Hahn, A., Winkler, D., Atanelov, J., Losak, J., Baldinger, P., . . . Lanzenberger, R. (2012). Ketamine affects brain activation during a visual integration task: a double-blind placebo-controlled pharmaco-fMRI study. *European Neuropsychopharmacology*, 22, S201. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/224/CN-01030224/frame.html>
- Hogarty, G., McEvoy, J., Ulrich, R., DiBarry, A., Bartone, P., Cooley, S., . . . Perel, J. (1995). Pharmacotherapy of impaired affect in recovering schizophrenic patients. *Archives of General Psychiatry*, 52(1), 29. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/756/CN-00108756/frame.html>
- Hogarty, G., Schooler, N., Ulrich, R., Mussare, F., Ferro, P., & Herron, E. (1979). Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. *Archives of General Psychiatry*, 36(12), 1283-1294. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/414/CN-00021414/frame.html>
- Hogarty, G. E., Flesher, S., Ulrich, R., Carter, M., Greenwald, D., Pogue-Geile, M., . . . Zoretich, R. (2004). Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. *Archives of General Psychiatry*, 61(9), 866-876.
- Hogarty, G. E., Greenwald, D. P., & Eack, S. M. (2006). Durability and mechanism of effects of cognitive enhancement therapy. *Psychiatric Services*, 57(12), 1751-1757.
- Hojgaard, D. R., Hybel, K. A., Ivarsson, T., Skarphedinsson, G., Becker Nissen, J., Weidle, B., . . . Thomsen, P. H. (2017). One-year outcome for responders of cognitive-behavioral therapy for pediatric obsessive-compulsive disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, 56(11), 940-947. doi:<http://dx.doi.org/10.1016/j.jaac.2017.09.002>
- Holt, R., Barnett, A., & Bailey, C. (2010). Bromocriptine: old drug, new formulation and new indication. *Diabetes, obesity & metabolism*, 12(12), 1048-1057. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/828/CN-00905828/frame.html> doi:10.1111/j.1463-1326.2010.01304.x
- Holzer, L., Urben, S., Passini, C. M., Jaugey, L., Herzog, M. H., Halfon, O., & Pihet, S. (2014). A randomized controlled trial of the effectiveness of computer-assisted cognitive remediation (CACR) in adolescents with psychosis or at high risk of psychosis. *Behavioural & Cognitive Psychotherapy*, 42(4), 421-434. doi:<https://dx.doi.org/10.1017/S1352465813000313>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Hooker, C. I., Bruce, L., Fisher, M., Verosky, S. C., Miyakawa, A., D'Esposito, M., & Vinogradov, S. (2013). The influence of combined cognitive plus social-cognitive training on amygdala response during face emotion recognition in schizophrenia. *Psychiatry Research*, 213(2), 99-107. doi:<https://dx.doi.org/10.1016/j.psychresns.2013.04.001>
- Hooker, C. I., Bruce, L., Fisher, M., Verosky, S. C., Miyakawa, A., & Vinogradov, S. (2012). Neural activity during emotion recognition after combined cognitive plus social cognitive training in schizophrenia. *Schizophrenia Research*, 139(1-3), 53-59. doi:<https://dx.doi.org/10.1016/j.schres.2012.05.009>
- Horan, W. P., Kern, R. S., Tripp, C., Hellemann, G., Wynn, J. K., Bell, M., . . . Green, M. F. (2011). Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. *Journal of Psychiatric Research*, 45(8), 1113-1122. doi:<https://dx.doi.org/10.1016/j.jpsychires.2011.01.015>
- Hornung, W. P., Feldmann, R., Klingberg, S., Buchkremer, G., & Reker, T. (1999). Long-term effects of a psychoeducational psychotherapeutic intervention for schizophrenic outpatients and their key-persons--results of a five-year follow-up. *European Archives of Psychiatry & Clinical Neuroscience*, 249(3), 162-167.
- Hough, D., Karcher, K., Nuamah, I., Palumbo, J., Berlin, J., Baseman, A., . . . Kent, J. (2011). Risk of cardiovascular morbidity and sudden death with risperidone and paliperidone treatment: analysis of 64 randomized. *Journal of pharmacy practice*, 24(2), 257. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/582/CN-01034582/frame.html> doi:10.1177/0897190011403437
- Huerta-Ramos, E., Iniesta, R., Ochoa, S., Cobo, J., Miquel, E., Roca, M., . . . Usall, J. (2014). Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. *European Neuropsychopharmacology*, 24(2), 223-231. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/008/CN-00979008/frame.html> doi:10.1016/j.euroneuro.2013.11.012
- Huerta-Ramos, E., Iniesta, R., Ochoa, S., Cobo, J., Miquel, E., Roca, M., . . . Usall, J. (2014). Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.[Erratum appears in Eur Neuropsychopharmacol. 2015 Jun;25(6):966]. *European Neuropsychopharmacology*, 24(2), 223-231. doi:<https://dx.doi.org/10.1016/j.euroneuro.2013.11.012>
- Huerta-Ramos, M., Usall, J., Iniesta, R., Cobo, J., Araya, S., Roca, M., . . . Ochoa, S. (2011). Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: neuropsychological effects. *Archives of women's mental health*, 14, S160. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/891/CN-01032891/frame.html> doi:10.1007/s00737-011-0238-y
- Huf, G., Coutinho, E., & Adams, C. (2012). Physical restraints versus seclusion room for management of people with acute aggression or agitation due to psychotic illness (TREC-SAVE): a randomized trial. *Psychological Medicine*, 42(11),

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

2265-2273. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/804/CN-01124804/frame.html> doi:10.1017/S0033291712000372

Huss, M., Ginsberg, Y., Arngrim, T., Philipsen, A., Carter, K., Chen, C., . . . Kumar, V. (2014). Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial. *Clinical Drug Investigation*, 34(9), 639-649. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/664/CN-01041664/frame.html> doi:10.1007/s40261-014-0213-2

Hutton, P., Morrison, A. P., Wardle, M., & Wells, A. (2014). Metacognitive therapy in treatment-resistant psychosis: a multiple-baseline study. *Behavioural & Cognitive Psychotherapy*, 42(2), 166-185.
doi:<https://dx.doi.org/10.1017/S1352465812001026>

Hvid, M., Vangborg, K., Sørensen, H., Nielsen, I., Stenborg, J., & Wang, A. (2011). Preventing repetition of attempted suicide--II. The Amager project, a randomized controlled trial. *Nordic Journal of Psychiatry*, 65(5), 292-298. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/914/CN-00812914/frame.html>
doi:10.3109/08039488.2010.544404

Innis, R., Bunney, B., Charney, D., Price, L., Glazer, W., Sternberg, D., . . . Heninger, G. (1986). Does the cholecystokinin antagonist proglumide possess antipsychotic activity? *Psychiatry Research*, 18(1), 1-7. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/989/CN-00043989/frame.html>

Ionescu, D., Luckenbaugh, D., Nicu, M., Richards, E., Slonena, E., Vande, V. J., . . . Zarate, C. (2014). Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. *Journal of Clinical Psychiatry*, 75(9), e932-938. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/263/CN-01048263/frame.html>
doi:10.4088/JCP.14m09049

Iqbal, M., Young, M., Charles, J., Elgart, B., Greiff, H., & Simpson, G. (1978). A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients. *Journal of Clinical Psychiatry*, 39(4), 375-379. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/807/CN-00017807/frame.html>

Ishigooka, J., Nakamura, J., & Shimizu, N. (2014). Efficacy of aripiprazole once-monthly in Asian patients with schizophrenia: secondary efficacy outcomes in a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. *International journal of neuropsychopharmacology*, 17, 62. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/784/CN-01100784/frame.html> doi:10.1017/S1461145714000741

Ishoy, P., Fagerlund, B., Broberg, B., Bak, N., Knop, F., Glenthøj, B., & Ebdrup, B. (2017). No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. *Acta Psychiatrica Scandinavica*, (no pagination). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/433/CN-01340433/frame.html> doi:10.1111/acps.12711

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Ishøy, P., Fagerlund, B., Broberg, B., Bak, N., Knop, F., Glenthøj, B., & Ebdrup, B. (2017). No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. *Acta Psychiatrica Scandinavica*, 136(1), 52-62. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/481/CN-01383481/frame.html> doi:10.1111/acps.12711
- Ising, H., Smit, F., Veling, W., Rietdijk, J., Dragt, S., Klaassen, R., . . . van der Gaag, M. (2015). Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: Multi-centre randomized controlled trial. *Psychological Medicine*, 45(7), 1435-1446. doi:<http://dx.doi.org/10.1017/S0033291714002530>
- Ising, H. K., Kraan, T. C., Rietdijk, J., Dragt, S., Klaassen, R. M., Boonstra, N., . . . van der Gaag, M. (2016). Four-Year Follow-up of Cognitive Behavioral Therapy in Persons at Ultra-High Risk for Developing Psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial. *Schizophrenia Bulletin*, 42(5), 1243-1252. doi:<https://dx.doi.org/10.1093/schbul/sbw018>
- Ising, H. K., Lokkerbol, J., Rietdijk, J., Dragt, S., Klaassen, R. M., Kraan, T., . . . van der Gaag, M. (2017). Four-Year Cost-effectiveness of Cognitive Behavior Therapy for Preventing First-episode Psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial. *Schizophrenia Bulletin*, 43(2), 365-374. doi:<https://dx.doi.org/10.1093/schbul/sbw084>
- Ising, H. K., Smit, F., Veling, W., Rietdijk, J., Dragt, S., Klaassen, R. M., . . . van der Gaag, M. (2015). Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial. *Psychological Medicine*, 45(7), 1435-1446. doi:<https://dx.doi.org/10.1017/S0033291714002530>
- Isitt, J., Nadipelli, V., Kouassi, A., Fava, M., & Heidbreder, C. (2016). Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. *Schizophrenia Research*, 174(1-3), 126-131. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/597/CN-01164597/frame.html> doi:10.1016/j.schres.2016.03.020
- Ismail, Z., Peters-Strickland, T., Miguel, M., Baker, R., Hertel, P., Eramo, A., . . . Kane, J. (2017). Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores. *Journal of Clinical Psychopharmacology*, 37(3), 347-350. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/546/CN-01400546/frame.html> doi:10.1097/JCP.0000000000000710
- Itoh, H., Miura, S., Yagi, G., Ogita, K., Ohtsuka, N., & Koga, Y. (1976). Comparison of clinical effects of Penfluridol, a long-acting oral neuroleptic, and perphenazine in schizophrenia using double-blind technique. *Rinsho hyoka*, 4(1). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/861/CN-00267861/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Ivaturi, V., Gopalakrishnan, M., Gobburu, J., Zhang, W., Liu, Y., Heidbreder, C., & Laffont, C. (2017). Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone. *British journal of clinical pharmacology*, 83(7), 1476-1498. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/144/CN-01459144/frame.html> doi:10.1111/bcp.13246
- Jackson, C., Trower, P., Reid, I., Smith, J., Hall, M., Townend, M., . . . Birchwood, M. (2009). Improving psychological adjustment following a first episode of psychosis: a randomised controlled trial of cognitive therapy to reduce post psychotic trauma symptoms. *Behaviour Research & Therapy*, 47(6), 454-462.
doi:<https://dx.doi.org/10.1016/j.brat.2009.02.009>
- Jackson, H., McGorry, P., Edwards, J., Hulbert, C., Henry, L., Harrigan, S., . . . Power, P. (2005). A controlled trial of cognitively oriented psychotherapy for early psychosis (COPE) with four-year follow-up readmission data. *Psychological Medicine*, 35(9), 1295-1306.
- Jackson, H. J., McGorry, P. D., Killackey, E., Bendall, S., Allott, K., Dudgeon, P., . . . Harrigan, S. (2008). Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project. *Psychological Medicine*, 38(5), 725-735.
- Jakobsen, J., Gluud, C., Kongerslev, M., Larsen, K., Sorensen, P., Winkel, P., . . . Simonsen, E. (2014). Third-wave cognitive therapy versus mentalisation-based treatment for major depressive disorder: a randomised clinical trial. *BMJ Open*, 4(8). Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/575/CN-01002575/frame.html> doi:10.1136/bmjopen-2014-004903
- Jakobsen, J., Gluud, C., Kongerslev, M., Larsen, K., Sørensen, P., Winkel, P., . . . Simonsen, E. (2014). Third-wave cognitive therapy versus mentalisation-based treatment for major depressive disorder: a randomised clinical trial. *BMJ Open*, 4(8), e004903. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/380/CN-01114380/frame.html> doi:10.1136/bmjopen-2014-004903
- Jans, T., Jacob, C., Warnke, A., Zwanzger, U., Gros-Lesch, S., Matthies, S., . . . Philipsen, A. (2015). Does intensive multimodal treatment for maternal ADHD improve the efficacy of parent training for children with ADHD? A randomized controlled multicenter trial. *Journal of Child Psychology and Psychiatry*, 56(12), 1298-1313.
doi:<http://dx.doi.org/10.1111/jcpp.12443>
- Jarungsuccess, S., Srisaksakul, E., Ruangdechanan, A., Sanichwankul, K., Pumpaisalchai, W., Suwan, S., . . . Udombhornprabha, A. (2014). Pharmacokinetics predictive of risperidone in man with clinical implications. *European neuropsychopharmacology*, 24, S748-s749. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/702/CN-01054702/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Jean-Baptiste, M., Tek, C., Liskov, E., Chakunta, U. R., Nicholls, S., Hassan, A. Q., . . . Wexler, B. E. (2007). A pilot study of a weight management program with food provision in schizophrenia. *Schizophrenia Research*, 96(1-3), 198-205.
doi:<http://dx.doi.org/10.1016/j.schres.2007.05.022>

Jenner, J. A., Nienhuis, F. J., van de Willige, G., & Wiersma, D. (2006). "Hitting" voices of schizophrenia patients may lastingly reduce persistent auditory hallucinations and their burden: 18-month outcome of a randomized controlled trial. *Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie*, 51(3), 169-177.

Jenner, J. A., Nienhuis, F. J., Wiersma, D., & van de Willige, G. (2004). Hallucination focused integrative treatment: a randomized controlled trial. *Schizophrenia Bulletin*, 30(1), 133-145.

Johns, L. C., Gregg, L., Vythelingum, N., & McGuire, P. K. (2003). Establishing the reliability of a verbal self-monitoring paradigm. *Psychopathology*, 36(6), 299-303.

Johnson, D. P., Penn, D. L., Bauer, D. J., Meyer, P., & Evans, E. (2008). Predictors of the therapeutic alliance in group therapy for individuals with treatment-resistant auditory hallucinations. *British Journal of Clinical Psychology*, 47(Pt 2), 171-183.

Johnson, S., Leese, M., Brooks, L., Clarkson, P., Guite, H., Thornicroft, G., . . . Wykes, T. (1998). Frequency and predictors of adverse events. PRISM Psychosis Study. 3. *British Journal of Psychiatry*, 173, 376-384. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/392/CN-00332392/frame.html>

Jolley, S., Garety, P., Dunn, G., White, J., Aitken, M., Challacombe, F., . . . Craig, T. (2005). A pilot validation study of a new measure of activity in psychosis. *Social Psychiatry & Psychiatric Epidemiology*, 40(11), 905-911.

Jolley, S., Garety, P. A., Ellett, L., Kuipers, E., Freeman, D., Bebbington, P. E., . . . Dunn, G. (2006). A validation of a new measure of activity in psychosis. *Schizophrenia Research*, 85(1-3), 288-295.

Jones, B., Griffiths, K., Christensen, H., Ellwood, D., Bennett, K., & Bennett, A. (2013). Online cognitive behaviour training for the prevention of postnatal depression in at-risk mothers: a randomised controlled trial protocol. *BMC Psychiatry*, 13. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/269/CN-00909269/frame.html>
doi:10.1186/1471-244X-13-265

Jones, B., Taylor, C., & Meehan, K. (2001). The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. *Journal of Clinical Psychiatry*, 62 Suppl 2, 22-24. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/838/CN-00328838/frame.html>

Jones, B. A., Griffiths, K. M., Christensen, H., Ellwood, D., Bennett, K., & Bennett, A. (2013). Online cognitive behaviour training for the prevention of postnatal depression in at-risk mothers: a randomised controlled trial protocol. *BMC Psychiatry*, 13, 265. doi:<https://dx.doi.org/10.1186/1471-244X-13-265>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Jones, R., Lasser, R., & Bossie, C. (2003). Clinical Improvement With Long-Acting Risperidone in Patients Previously Receiving Oral Olanzapine. *156th annual meeting of the american psychiatric association, may 17-22, san francisco CA*, Nr224. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/558/CN-00658558/frame.html>
- Jung, E., Wiesjahn, M., & Lincoln, T. M. (2014). Negative, not positive symptoms predict the early therapeutic alliance in cognitive behavioral therapy for psychosis. *Psychotherapy Research*, 24(2), 171-183.
doi:<https://dx.doi.org/10.1080/10503307.2013.851425>
- Jus, A., Pineau, R., Jus, K., Villeneuve, A., Gautier, J., Pires, P., . . . Villeneuve, R. (1974). Penfluridol: a long-acting oral neuroleptic as therapeutic agent in chronic schizophrenia. *Current therapeutic research, clinical and experimental*, 16(10), 1041-1058. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/281/CN-00011281/frame.html>
- Kalali, A., Geffen, Y., Davidson, M., Hufford, M., Gendreau, R., Rao, S., . . . Kranzler, J. (2011). Methodological challenges of demonstrating cognitive improvements with broad spectrum agents: a novel approach. *European archives of psychiatry and clinical neuroscience.*, 261, S17. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/127/CN-01035127/frame.html> doi:10.1007/s00406-011-0229-z
- Kane, J. (2003). The latest advance in long-acting antipsychotic therapy. *156th annual meeting of the american psychiatric association, may 17-22, san francisco CA*, No. 1B. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/088/CN-00655088/frame.html>
- Kane, J. (2012). Methodologic challenges in clinical trials in schizophrenia. *Schizophrenia Research.*, 136, S60. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/063/CN-01050063/frame.html>
- Kane, J. (2014). Differences among long-acting antipsychotics in the maintenance treatment of schizophrenia. *International journal of neuropsychopharmacology.*, 17, 170. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/841/CN-01084841/frame.html> doi:10.1017/S1461145714000741
- Kane, J., Detke, H., Naber, D., Sethuraman, G., Lin, D., Bergstrom, R., & McDonnell, D. (2010). Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. *American Journal of Psychiatry*, 167(2), 181-189. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/788/CN-00732788/frame.html> doi:10.1176/appi.ajp.2009.07081221
- Kane, J., Eerdekins, M., Keith, S., Lesem, M., Karcher, K., & Lindenmayer, J. (2002). Long-acting injectable risperidone: efficacy and safety. *European neuropsychopharmacology; 15th international congress of the european college of neuropsychopharmacology, october 5-9, barcelona, spain*, 12(Suppl 3), S325. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/438/CN-00659438/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Kane, J., Eerdekins, M., Lindenmayer, J., Keith, S., Lesem, M., & Karcher, K. (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. *American Journal of Psychiatry, 160*(6), 1125-1132. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/930/CN-00437930/frame.html> doi:10.1176/appi.ajp.160.6.1125
- Kane, J., Peters-Strickland, T., Baker, R., Hertel, P., Eramo, A., Jin, N., . . . Sanchez, R. (2014). Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. *Journal of Clinical Psychiatry, 75*(11), 1254-1260. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/277/CN-01083277/frame.html> doi:10.4088/JCP.14m09168
- Kane, J., Schooler, N., Marcy, P., Correll, C., Brunette, M., Mueser, K., . . . Robinson, D. (2015). The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. *Journal of Clinical Psychiatry, 76*(3), 240-246. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/560/CN-01132560/frame.html> doi:10.4088/JCP.14m09289
- Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Brunette, M. F., Mueser, K. T., . . . Robinson, D. G. (2015). The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. *Journal of Clinical Psychiatry, 76*(3), 240-246. doi:<https://dx.doi.org/10.4088/JCP.14m09289>
- Kaneno, S., Ohkuma, T., Yamashita, I., Mori, A., Yagi, G., Kudo, Y., . . . Nakane, Y. (1991). A Double-blind Comparative Study on the Efficacy and Safety of Fluphenazine Decanoate (SQ10, 733) and Oral Haloperidol in the Treatment of Schizophrenic Patients. *Rinsho hyoka (clinical evaluation), 19*(1), 15-45. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/360/CN-00655360/frame.html>
- Kariofillis, D., Sartory, G., Kargel, C., & Muller, B. W. (2014). The effect of cognitive training on evoked potentials in schizophrenia. *Schizophrenia Research: Cognition, 1*(4), 180-186. doi:<http://dx.doi.org/10.1016/j.scog.2014.07.001>
- Karow, A., Reimer, J., Konig, H., Heider, D., Bock, T., Huber, C., . . . Lambert, M. (2012). Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). *Journal of Clinical Psychiatry, 73*(3), e402-e408. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/155/CN-01018155/frame.html> doi:10.4088/JCP.11m06875
- Karow, A., Reimer, J., König, H., Heider, D., Bock, T., Huber, C., . . . Lambert, M. (2012). Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). *Journal of Clinical Psychiatry, 73*(3), e402-408. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/422/CN-00842422/frame.html> doi:10.4088/JCP.11m06875

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Kasckow, J., Haas, G., Cornelius, J., & Luther, J. (2013). Telehealth monitoring of suicidal ideation in patients schizophrenia.

Schizophrenia bulletin., 39, S336-s337. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/013/CN-01026013/frame.html> doi:10.1093/schbul/sbt011

Katagiri, H., Fujikoshi, S., Suzuki, T., Fujita, K., Sugiyama, N., Takahashi, M., & Gomez, J. (2013). A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. *BMC Psychiatry*, 13, 20. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/253/CN-00864253/frame.html> doi:10.1186/1471-244X-13-20

Katagiri, H., Fujikoshi, S., Suzuki, T., Fujita, K., Sugiyama, N., Takahashi, M., & Gomez, J.-C. (2014). Erratum to A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. *BMC Psychiatry*, 14(1). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/768/CN-01077768/frame.html> doi:10.1186/s12888-014-0313-9

Katz, E., Hauber, B., Gopal, S., Fairchild, A., Pugh, A., Weinstein, R., & Levitan, B. (2016). Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials. *Patient preference and adherence*, 10, 2127-2139. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/269/CN-01246269/frame.html> doi:10.2147/PPA.S114172

Katz, G., Durst, R., & Knobler, H. Y. (2001). Exogenous melatonin, jet lag and psychosis: Preliminary case results. *Journal of Clinical Psychopharmacology*, 21(3), 349-351. doi:<http://dx.doi.org/10.1097/00004714-200106000-00021>

Keks, N., Ingham, M., Khan, A., & Karcher, K. (2007). Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. *British Journal of Psychiatry*, 191, 131-139. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/677/CN-00618677/frame.html> doi:10.1192/bjp.bp.105.017020

Kelly, D., McMahon, R., Weiner, E., Boggs, D., Dickinson, D., Conley, R., & Buchanan, R. (2008). Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. *Schizophrenia Research*, 103(1-3), 161-168. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/004/CN-00649004/frame.html> doi:10.1016/j.schres.2008.04.027

Kelly, F. J. (1965). TOWARD A WORKING TYPOLOGY OF DELINQUENT CHILDREN (pp. 4).

Kemp, R., Harris, A., Vurel, E., & Sitharthan, T. (2007). Stop Using Stuff: trial of a drug and alcohol intervention for young people with comorbid mental illness and drug and alcohol problems. *Australasian Psychiatry*, 15(6), 490-493.

Kennedy, S., Avedisova, A., Picarel-Blanchot, F., & Bodinat, C. (2014). Efficacy of 3 agomelatine dose regimens versus placebo on the core symptoms of depression and functioning. *European neuropsychopharmacology.*, 24, S405-s406. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/744/CN-01054744/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Kern, R. S., Green, M. F., Mintz, J., & Liberman, R. P. (2003). Does 'errorless learning' compensate for neurocognitive impairments in the work rehabilitation of persons with schizophrenia? *Psychological Medicine*, 33(3), 433-442.
- Kersten, L., Pratzlich, M., Mannstadt, S., Ackermann, K., Kohls, G., Oldenhof, H., . . . Stadler, C. (2016). START NOW - a comprehensive skills training programme for female adolescents with oppositional defiant and conduct disorders: study protocol for a cluster-randomised controlled trial.[Erratum appears in Trials. 2017 Mar 2;18(1):95; PMID: 28253890]. *Trials [Electronic Resource]*, 17(1), 568.
- Keshavan, M. S., Eack, S. M., Wojtalik, J. A., Prasad, K. M., Francis, A. N., Bhojraj, T. S., . . . Hogarty, S. S. (2011). A broad cortical reserve accelerates response to cognitive enhancement therapy in early course schizophrenia. *Schizophrenia Research*, 130(1-3), 123-129. doi:<https://dx.doi.org/10.1016/j.schres.2011.05.001>
- Keskiner, A., Simeon, J., Fink, M., & Itil, T. (1968). Long-acting phenothiazine (fluphenazine decanoate) treatment of psychosis. *Archives of General Psychiatry*, 18(4), 477-481. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/867/CN-00001867/frame.html>
- Keuthen, N. J., Rothbaum, B. O., Welch, S. S., Taylor, C., Falkenstein, M., Heekin, M., . . . Jenike, M. A. (2010). Pilot trial of dialectical behavior therapy-enhanced habit reversal for trichotillomania. *Depression and Anxiety*, 27(10), 953-959. doi:<http://dx.doi.org/10.1002/da.20732>
- Khazaal, Y., Chatton, A., Dieben, K., Huguet, P., Boucherie, M., Monney, G., . . . Favrod, J. (2015). Reducing delusional conviction through a cognitive-based group training game: A multicentre randomized controlled trial. *Frontiers in Psychiatry*, 6 (APR) (no pagination)(66). doi:<http://dx.doi.org/10.3389/fpsy.2015.00066>
- Khazaie, H., & Shakeri, J. (2005). Comparative efficacy of every 2 weeks versus every 6 weeks injections of fluphenazine decanoate. *Archives of iranian medicine*, 8(2), 109-114. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/290/CN-00569290/frame.html>
- Kidd, S. A., Herman, Y., Barbic, S., Ganguli, R., George, T. P., Hassan, S., . . . Velligan, D. (2014). Testing a modification of cognitive adaptation training: streamlining the model for broader implementation. *Schizophrenia Research*, 156(1), 46-50. doi:<https://dx.doi.org/10.1016/j.schres.2014.03.026>
- Kidd, S. A., Kaur, J., Virdee, G., George, T. P., McKenzie, K., & Herman, Y. (2014). Cognitive remediation for individuals with psychosis in a supported education setting: a randomized controlled trial. *Schizophrenia Research*, 157(1-3), 90-98. doi:<https://dx.doi.org/10.1016/j.schres.2014.05.007>
- Kim, B., Lee, S., Choi, T., Suh, S., Kim, Y., Lee, E., & Yook, K. (2008). Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 32(5), 1231-1235. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/285/CN-00648285/frame.html> doi:[10.1016/j.pnpbp.2008.03.012](https://doi.org/10.1016/j.pnpbp.2008.03.012)

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Kim, E., Starr, H., Bossie, C., Mao, L., & Alphs, L. (2015). Once-monthly paliperidone palmitate compared with oral atypical antipsychotic treatment in patients with schizophrenia. *Schizophrenia bulletin.*, 41, S318. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/794/CN-01077794/frame.html>
doi:10.1093/schbul/sbv010

Kim, H., & Lee, K. (2012). Escitalopram for chronic tension-type headache in patients with major depressive disorder. *European Neuropsychopharmacology*, 22, S255. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/219/CN-01030219/frame.html>

Kimura, H., Kanahara, N., Komatsu, N., Ishige, M., Muneoka, K., Yoshimura, M., . . . Iyo, M. (2014). A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. *Schizophrenia Research*, 155(1-3), 52-58. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/819/CN-00988819/frame.html> doi:10.1016/j.schres.2014.02.022

Kindler, J., Homan, P., Jann, K., Federspiel, A., Flury, R., Hauf, M., . . . Hubl, D. (2013). Reduced neuronal activity in language-related regions after transcranial magnetic stimulation therapy for auditory verbal hallucinations. *Biological Psychiatry*, 73(6), 518-524. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/413/CN-00968413/frame.html> doi:10.1016/j.biopsych.2012.06.019

King, C., & Goldstein, M. (1979). Therapist ratings of achievement of objectives in psychotherapy with acute schizophrenics. *Schizophrenia Bulletin*, 5(1), 118-129. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/376/CN-00020376/frame.html>

Kissling, W., Glue, P., Medori, R., & Simpson, S. (2007). Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. *Human psychopharmacology*, 22(8), 505-513. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/936/CN-00627936/frame.html> doi:10.1002/hup.877

Kittipeerachon, M., & Chaichan, W. (2016). Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: a pragmatic double-blind randomized trial. *Schizophrenia Research*, 176(2-3), 231-238. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/975/CN-01291975/frame.html>
doi:10.1016/j.schres.2016.07.017

Klingberg, S., Buchkremer, G., Holle, R., Schulze Monking, H., & Hornung, W. P. (1999). Differential therapy effects of psychoeducational psychotherapy for schizophrenic patients--results of a 2-year follow-up. *European Archives of Psychiatry & Clinical Neuroscience*, 249(2), 66-72.

Klingberg, S., Herrlich, J., Wiedemann, G., Wolwer, W., Meisner, C., Engel, C., . . . Wittorf, A. (2012). Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study. *Journal of Nervous & Mental Disease*, 200(7), 569-576. doi:<https://dx.doi.org/10.1097/NMD.0b013e31825bfa1d>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Klingberg, S., Wittorf, A., Fischer, A., Jakob-Deters, K., Buchkremer, G., & Wiedemann, G. (2010). Evaluation of a cognitive behaviourally oriented service for relapse prevention in schizophrenia. *Acta Psychiatrica Scandinavica*, 121(5), 340-350. doi:<https://dx.doi.org/10.1111/j.1600-0447.2009.01479.x>

Klingberg, S., Wittorf, A., Herrlich, J., Wiedemann, G., Meisner, C., Buchkremer, G., . . . Wolwer, W. (2009). Cognitive behavioural treatment of negative symptoms in schizophrenia patients: study design of the TONES study, feasibility and safety of treatment. *European Archives of Psychiatry & Clinical Neuroscience*, 259 Suppl 2, S149-154. doi:<https://dx.doi.org/10.1007/s00406-009-0047-8>

Klingberg, S., Wittorf, A., Meisner, C., Wolwer, W., Wiedemann, G., Herrlich, J., . . . Buchkremer, G. (2010). Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: the POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical trial. *Trials [Electronic Resource]*, 11, 123. doi:<https://dx.doi.org/10.1186/1745-6215-11-123>

Klingberg, S., Wolwer, W., Engel, C., Wittorf, A., Herrlich, J., Meisner, C., . . . Wiedemann, G. (2011). Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. *Schizophrenia Bulletin*, 37 Suppl 2, S98-110. doi:<https://dx.doi.org/10.1093/schbul/sbr073>

Knapp, M., Beecham, J., Koutsogeorgopoulou, V., Hallam, A., Fenyo, A., Marks, I., . . . Muijen, M. (1994). Service use and costs of home-based versus hospital-based care for people with serious mental illness. *British Journal of Psychiatry*, 165(2), 195-203. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/130/CN-00106130/frame.html>

Koch, H. (2016). Interpretation of depot risperidone concentration vs. time data using a piecewise polynomial regression model. *Archives of psychiatry and psychotherapy*, 18(1), 5-7. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/773/CN-01154773/frame.html> doi:10.12740/APP/61725

Kolko, D. J., Campo, J. V., Kilbourne, A. M., & Kelleher, K. (2012). Doctor-office collaborative care for pediatric behavioral problems: a preliminary clinical trial. *Archives of Pediatrics & Adolescent Medicine*, 166(3), 224-231. doi:<https://dx.doi.org/10.1001/archpediatrics.2011.201>

Kommescher, M., Wagner, M., Putzfeld, V., Berning, J., Janssen, B., Decker, P., . . . Bechdolf, A. (2016). Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. *Early intervention in psychiatry*, 10(1), 17-27. doi:<https://dx.doi.org/10.1111/eip.12130>

Konicki, P., Owen, R., Litman, R., & Pickar, D. (1991). The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients. *Life sciences*, 48(14), 1411-1416. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/072/CN-00307072/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Kontis, D., Huddy, V., Reeder, C., Landau, S., & Wykes, T. (2013). Effects of age and cognitive reserve on cognitive remediation therapy outcome in patients with schizophrenia. *American Journal of Geriatric Psychiatry*, 21(3), 218-230.
doi:<https://dx.doi.org/10.1016/j.jagp.2012.12.013>
- Koshikawa, Y., Takekita, Y., Kato, M., Sakai, S., Onohara, A., Sunada, N., . . . Kinoshita, T. (2015). The effects of risperidone long-acting injection versus paliperidone palmitate on cognitive and social function in schizophrenia - An open pilot randomised controlled trial. *European neuropsychopharmacology*, 25, S500-s501. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/060/CN-01129060/frame.html>
- Koshikawa, Y., Takekita, Y., Kato, M., Sakai, S., Onohara, A., Sunada, N., . . . Kinoshita, T. (2016). The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: a 6-Month, Open-Label, Randomized Controlled Pilot Trial. *Neuropsychobiology*, 73(1), 35-42. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/570/CN-01154570/frame.html> doi:10.1159/000442209
- Krakvik, B., Grawe, R. W., Hagen, R., & Stiles, T. C. (2013). Cognitive behaviour therapy for psychotic symptoms: a randomized controlled effectiveness trial. *Behavioural & Cognitive Psychotherapy*, 41(5), 511-524.
doi:<https://dx.doi.org/10.1017/S1352465813000258>
- Kramer, M., Litman, R., Hough, D., Lane, R., Lim, P., & Liu, Y. (2009). Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. *International journal of neuropsychopharmacology*, 13(5), 1-13. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/534/CN-00747534/frame.html>
- Kramer, M., Litman, R., Hough, D., Lane, R., Lim, P., Liu, Y., & Eerdekkens, M. (2010). Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. *The international journal of neuropsychopharmacology*, 13(5), 635-647. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/195/CN-00768195/frame.html>
doi:10.1017/S1461145709990988
- Krystal, J., Madonick, S., Perry, E., Gueorguieva, R., Brush, L., Wray, Y., . . . D'Souza, D. (2006). Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism. *Neuropsychopharmacology*, 31(8), 1793-1800. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/949/CN-00561949/frame.html> doi:10.1038/sj.npp.1300994
- Kuipers, E., Watson, P., Onwumere, J., Bebbington, P., Dunn, G., Weinman, J., . . . Garety, P. (2007). Discrepant illness perceptions, affect and expressed emotion in people with psychosis and their carers. *Social Psychiatry & Psychiatric Epidemiology*, 42(4), 277-283.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Kukla, M., Davis, L. W., & Lysaker, P. H. (2014). Cognitive behavioral therapy and work outcomes: correlates of treatment engagement and full and partial success in schizophrenia. *Behavioural & Cognitive Psychotherapy*, 42(5), 577-592.
doi:<https://dx.doi.org/10.1017/S1352465813000428>

Kulkarni, J., Castella, A., Smith, D., Taffe, J., Keks, N., & Copolov, D. (1996). A clinical trial of the effects of estrogen in acutely psychotic women. *Schizophrenia Research*, 20(3), 247-252. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/608/CN-00130608/frame.html>

Kulkarni, J., Gurvich, C., Lee, S., Gilbert, H., Gavrilidis, E., Castella, A., . . . Davis, S. (2010). Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. *Psychoneuroendocrinology*, 35(8), 1142-1147. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/520/CN-00767520/frame.html> doi:10.1016/j.psyneuen.2010.01.014

Kumar, P., Waiter, G., Ahearn, T., Milders, M., Reid, I., & Steele, D. J. (2008). Abnormal Temporal Difference Reward-Learning Signals in Major Depression. *Brain*, 131(8), 2084-2093.

Kumar, P., Waiter, G., Ahearn, T., Milders, M., Reid, I., & Steele, J. (2008). Abnormal temporal difference reward-learning signals in major depression. *Brain*, 131(Pt 8), 2084-2093. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/319/CN-00649319/frame.html> doi:10.1093/brain/awn136

Kumar, P., Waiter, G., Ahearn, T., Milders, M., Reid, I., & Steele, J. D. (2008). Abnormal temporal difference reward-learning signals in major depression. *Brain*, 131(Pt 8), 2084-2093. doi:<https://dx.doi.org/10.1093/brain/awn136>

Kuokkanen, R., Lappalainen, R., Repo-Tiihonen, E., & Tiihonen, J. (2014). Metacognitive group training for forensic and dangerous non-forensic patients with schizophrenia: a randomised controlled feasibility trial. *Criminal Behaviour & Mental Health*, 24(5), 345-357. doi:<https://dx.doi.org/10.1002/cbm.1905>

Kurland, A., Ota, K., & Slotnick, V. (1975). Penfluridol: a long-acting oral neuroleptic. A controlled study. *Journal of clinical pharmacology*, 15(8-9), 611-621. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/214/CN-00699214/frame.html>

Kurland, A., & Richardson, J. (1966). A comparative study of two long acting phenothiazine preparations, fluphenazine-enanthate and fluphenazine-decanoate. *Psychopharmacologia*, 9(4), 320-327. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/030/CN-00002030/frame.html>

Kurtz, M. M., Mueser, K. T., Thime, W. R., Corbera, S., & Wexler, B. E. (2015). Social skills training and computer-assisted cognitive remediation in schizophrenia. *Schizophrenia Research*, 162(1-3), 35-41.
doi:<https://dx.doi.org/10.1016/j.schres.2015.01.020>

Kwon, J., Kim, S., Han, J., Lee, S., Chang, J., Choi, J., . . . Lee, E. (2015). Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. *International Clinical*

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Psychopharmacology, 30(6), 320-328. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/303/CN-01096303/frame.html> doi:10.1097/YIC.0000000000000093

Kwon, J. S., Choi, J. S., Bahk, W. M., Yoon Kim, C., Hyung Kim, C., Chul Shin, Y., . . . Geun Oh, C. (2006). Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. *Journal of Clinical Psychiatry*, 67(4), 547-553.

Laffont, C., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P., & Nasser, A. (2015). Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. *Journal of clinical pharmacology*, 55(1), 93-103. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/062/CN-01115062/frame.html> doi:10.1002/jcph.366

Lalova, M., Bayle, F., Grillon, M. L., Houet, L., Moreau, E., Rouam, F., . . . Piolino, P. (2013). Mechanisms of insight in schizophrenia and impact of cognitive remediation therapy. *Comprehensive Psychiatry*, 54(4), 369-380. doi:<https://dx.doi.org/10.1016/j.comppsych.2012.10.005>

Lam, K. C., Ho, C. P., Wa, J. C., Chan, S. M., Yam, K. K., Yeung, O. S., . . . Balzan, R. P. (2015). Metacognitive training (MCT) for schizophrenia improves cognitive insight: a randomized controlled trial in a Chinese sample with schizophrenia spectrum disorders. *Behaviour Research & Therapy*, 64, 38-42. doi:<https://dx.doi.org/10.1016/j.brat.2014.11.008>

Lambert, M., Bock, T., Schöttle, D., Golks, D., Meister, K., Rietschel, L., . . . Schimmelmann, B. (2010). Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). *Journal of Clinical Psychiatry*, 71(10), 1313-1323. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/765/CN-00771765/frame.html> doi:10.4088/JCP.09m05113yel

Lambert, M., De, M., Pfeil, J., Naber, D., & Schreiner, A. (2010). Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. *European Psychiatry: the Journal of the Association of European Psychiatrists*, 25(4), 220-229. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/844/CN-00774844/frame.html>

Lamure, M., Toumi, M., Chabannes, J.-P., Dansette, G.-Y., Benyaya, J., & Hansen, K. (2003). Zuclopentixol versus haloperidol: an observational randomised pharmacoeconomic evaluation of patients with chronic schizophrenia exhibiting acute psychosis. *International Journal of Psychiatry in Clinical Practice*, 7(3), 177-185. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/586/CN-00474586/frame.html> doi:10.1080/13651500310000906

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Lanfredi, M., Deste, G., Ferrari, C., Barlati, S., Magni, L., Rossi, R., . . . Vita, A. (2017). Effects of cognitive remediation therapy on neurocognition and negative symptoms in schizophrenia: an Italian naturalistic study. *Cognitive Neuropsychiatry*, 22(1), 53-68. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/631/CN-01424631/frame.html> doi:10.1080/13546805.2016.1260537
- Langer, A. I., Cangas, A. J., & Gallego, J. (2010). Mindfulness-based intervention on distressing hallucination-like experiences in a nonclinical sample. *Behaviour Change*, 27(3), 176-183. doi:<http://dx.doi.org/10.1375/bech.27.3.176>
- Langer, A. I., Cangas, A. J., Salcedo, E., & Fuentes, B. (2012). Applying mindfulness therapy in a group of psychotic individuals: a controlled study. *Behavioural & Cognitive Psychotherapy*, 40(1), 105-109. doi:<https://dx.doi.org/10.1017/S1352465811000464>
- Langer, A. I., Schmidt, C., Mayol, R., Diaz, M., Lecaros, J., Krogh, E., . . . Gaspar, P. A. (2017). The effect of a mindfulness-based intervention in cognitive functions and psychological well-being applied as an early intervention in schizophrenia and high-risk mental state in a Chilean sample: study protocol for a randomized controlled trial. *Trials [Electronic Resource]*, 18(1), 233. doi:<https://dx.doi.org/10.1186/s13063-017-1967-7>
- Lapierre, Y., & Frenckell, R. (1983). AMDP psychopathology factors in chronic schizophrenia: a clinical trial of two long-acting neuroleptics. *Modern problems of pharmacopsychiatry*, 20, 193-203. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/515/CN-00239515/frame.html>
- Lasalvia, A., Bonetto, C., Lenzi, J., Rucci, P., Iozzino, L., Cellini, M., . . . Group, G. U. (2017). Predictors and moderators of treatment outcome in patients receiving multi-element psychosocial intervention for early psychosis: results from the GET UP pragmatic cluster randomised controlled trial. *British Journal of Psychiatry*, 210(5), 342-349. doi:<https://dx.doi.org/10.1192/bjp.bp.116.190058>
- Lassen, E. (2011). The effects of Acceptance and Commitment Therapy (ACT) on anxiety in people with psychosis. *Dissertation abstracts international: section b: the sciences and engineering.*, 71(11-b), 7093. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/606/CN-00850606/frame.html>
- Lasser, R., Bossie, C., Gharabawi, G., & Turner, M. (2004). Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. *European Psychiatry*, 19(4), 219-225. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/139/CN-00656139/frame.html>
- Lasser, R., Bossie, C., Zhu, Y., Gharabawi, G., Eerdekkens, M., & Davidson, M. (2004). Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. *International Journal of Geriatric Psychiatry*, 19(9), 898-905. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/203/CN-00491203/frame.html> doi:10.1002/gps.1184

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Lauriello, J. (2011). An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia (*Journal of Clinical Psychiatry* (2008) 69, 5(790-799)). *Journal of Clinical Psychiatry*, 72(8), 1157. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/187/CN-01017187/frame.html> doi:10.4088/JCP.11lr07077a
- Lauriello, J., Lambert, T., Andersen, S., Lin, D., Taylor, C., & McDonnell, D. (2008). An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. *Journal of Clinical Psychiatry*, 69(5), 790-799. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/344/CN-00648344/frame.html>
- Lauriello, J., McEvoy, J., Rodriguez, S., Bossie, C., & Lasser, R. (2005). Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. *Schizophrenia Research*, 72(2-3), 249-258. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/131/CN-00514131/frame.html> doi:10.1016/j.schres.2004.05.006
- Laurier, C., Kennedy, W., Lachaine, J., Gariepy, L., & Tessier, G. (1997). Economic evaluation of zuclopentixol acetate compared with injectable haloperidol in schizophrenic patients with acute psychosis. *Clinical therapeutics*, 19(2), 316-329. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/612/CN-00893612/frame.html> doi:10.1016/S0149-2918%2897%2980120-8
- Law, H., Carter, L., Sellers, R., Emsley, R., Byrne, R., Davies, L., . . . Morrison, A. P. (2017). A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: Rationale, study design and baseline data of the COMPARE trial. *Psychosis: Psychological, Social and Integrative Approaches*, 9(3), 193-204. doi:<http://dx.doi.org/10.1080/17522439.2017.1316302>
- Lawlor, C., Sharma, B., Khondoker, M., Peters, E., Kuipers, E., & Johns, L. (2017). Service user satisfaction with cognitive behavioural therapy for psychosis: Associations with therapy outcomes and perceptions of the therapist. *British Journal of Clinical Psychology*, 56(1), 84-102. doi:<http://dx.doi.org/10.1111/bjcp.12122>
- Le Grange, D., Lock, J., Agras, W., Bryson, S. W., & Jo, B. (2015). Randomized clinical trial of family-based treatment and cognitive-behavioral therapy for adolescent bulimia nervosa. *Journal of the American Academy of Child & Adolescent Psychiatry*, 54(11), 886-894. doi:<http://dx.doi.org/10.1016/j.jaac.2015.08.008>
- Leatherman, S., Liang, M., Krystal, J., Lew, R., Valley, D., Thwin, S., & Rosenheck, R. (2014). Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. *Journal of Nervous and Mental Disease*, 202(1), 13-17. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/819/CN-00978819/frame.html> doi:10.1097/NMD.0000000000000069

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Lecardeur, L., Stip, E., Giguere, M., Blouin, G., Rodriguez, J. P., & Champagne-Lavau, M. (2009). Effects of cognitive remediation therapies on psychotic symptoms and cognitive complaints in patients with schizophrenia and related disorders: a randomized study. *Schizophrenia Research*, 111(1-3), 153-158.
doi:<https://dx.doi.org/10.1016/j.schres.2009.03.029>
- Leclerc, C., Lesage, A. D., Ricard, N., Lecomte, T., & Cyr, M. (2000). Assessment of a new rehabilitative coping skills module for persons with schizophrenia. *American Journal of Orthopsychiatry*, 70(3), 380-388.
- Lecomte, T., Cyr, M., Lesage, A. D., Wilde, J., Leclerc, C., & Ricard, N. (1999). Efficacy of a self-esteem module in the empowerment of individuals with schizophrenia. *Journal of Nervous & Mental Disease*, 187(7), 406-413.
- Lecomte, T., Leclerc, C., Corbiere, M., Wykes, T., Wallace, C. J., & Spidel, A. (2008). Group cognitive behavior therapy or social skills training for individuals with a recent onset of psychosis? Results of a randomized controlled trial. *Journal of Nervous & Mental Disease*, 196(12), 866-875. doi:<https://dx.doi.org/10.1097/NMD.0b013e31818ee231>
- Lecomte, T., Leclerc, C., & Wykes, T. (2012). Group CBT for early psychosis--are there still benefits one year later? *International Journal of Group Psychotherapy*, 62(2), 309-321. doi:<https://dx.doi.org/10.1521/ijgp.2012.62.2.309>
- Lee, A. C., Ou, Y., & Fong, D. (2003). Depressed Skull Fractures: A Pattern of Abusive Head Injury in Three Older Children. *Child Abuse & Neglect: The International Journal*, 27(11), 1323-1329.
- Lee, B. A., & Ruger, P. H. (1997). Accommodating Faculty and Staff with Psychiatric Disabilities (pp. 33): National Association of College and University Attorneys, One Dupont Circle, N.W., Suite 620, Washington, DC 20036;.
- Lee, H., Bastani, B., Friedman, L., Ramirez, L., & Meltzer, H. (1992). Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia. *Biological Psychiatry*, 31(5), 460-470. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/951/CN-00083951/frame.html>
- Lee, R. S., Redoblado-Hodge, M. A., Naismith, S. L., Hermens, D. F., Porter, M. A., & Hickie, I. B. (2013). Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients. *Psychological Medicine*, 43(6), 1161-1173. doi:<https://dx.doi.org/10.1017/S0033291712002127>
- Lee, W. K. (2013). Effectiveness of computerized cognitive rehabilitation training on symptomatological, neuropsychological and work function in patients with schizophrenia. *Asia-Pacific psychiatry : Official Journal of the Pacific Rim College of Psychiatrists*, 5(2), 90-100. doi:<https://dx.doi.org/10.1111/appy.12070>
- Lehman, A., Dixon, L., DeForgeBr, & Kernan, E. (1995). ASSERTIVE COMMUNITY TREATMENT FOR HOMELESS PERSONS WITH SCHIZOPHRENIA AND OTHER CHRONIC MENTAL DISORDERS CONFERENCE ABSTRACT- Vth International Congress on Schizophrenia Research Wormsprings, VA, USA 6-12 April 1995. *Schizophrenia research (the vth international congress on schizophrenia research, wormsprings, VA USA. 6th-12th*

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

april, 1995.), 1, 2(128). Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/187/CN-00282187/frame.html>

Lencz, T., Robinson, D., Xu, K., Ekholm, J., Sevy, S., Gunduz-Bruce, H., . . . Malhotra, A. (2006). DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. *American Journal of Psychiatry*, 163(3), 529-531. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/549/CN-00555549/frame.html> doi:10.1176/appi.ajp.163.3.529

Lencz, T., Robinson, D. G., Xu, K., Ekholm, J., Sevy, S., Gunduz-Bruce, H., . . . Malhotra, A. K. (2006). DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. *American Journal of Psychiatry*, 163(3), 529-531.

LeonCaballero, J., Corcoles, D., Gomez-Perez, L., Sanchez, R., Jose, I. C., Herminia, M., . . . Diez-Aja, C. (2017). Mirror-image study of aripiprazole long-acting injectable for the treatment of psychiatric patients attended in community mental health team. *European neuropsychopharmacology. Conference: 30th european college of neuropsychopharmacology congress, ECNP 2017. France*, 27(Supplement 4), S751-s752. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/542/CN-01428542/frame.html>

Lesem, M., Tran-Johnson, T., Riesenber, R., Feifel, D., Allen, M., Fishman, R., . . . Cassella, J. (2011). Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. *British Journal of Psychiatry*, 198(1), 51-58. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/448/CN-00780448/frame.html> doi:10.1192/bjp.bp.110.081513

Lesem, M., Zajecka, J., Swift, R., Reeves, K., & Harrigan, E. (2001). Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. *Journal of Clinical Psychiatry*, 62(1), 12-18. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/367/CN-00328367/frame.html>

Leshner, A. F., Tom, S. R., & Kern, R. S. (2013). Errorless learning and social problem solving ability in schizophrenia: an examination of the compensatory effects of training. *Psychiatry Research*, 206(1), 1-7.
doi:<https://dx.doi.org/10.1016/j.psychres.2012.10.007>

Lester, H., Allan, T., Wilson, S., Jowett, S., & Roberts, L. (2003). A cluster randomised controlled trial of patient-held medical records for people with schizophrenia receiving shared care. *British Journal of General Practice*, 53(488), 197-203. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/362/CN-00473362/frame.html>

Lester, H., Birchwood, M., Freemantle, N., Michail, M., & Tait, L. (2009). REDIRECT: cluster randomised controlled trial of GP training in first-episode psychosis. *British Journal of General Practice*, 59(563), e183-190.
doi:<https://dx.doi.org/10.3399/bjgp09X420851>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Lester, H., Birchwood, M., Freemantle, N., Michail, M., & Tait, L. (2009). REDIRECT: cluster randomised controlled trial of GP training in first-episode psychosis. *British Journal of General Practice*, 59(563), e183-190. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/107/CN-00722107/frame.html>
doi:10.3399/bjgp09X420851

Leucht, S. (2012). Treatment of affective or negative symptoms of schizophrenia. *International journal of psychiatry in clinical practice.*, 16, 10. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/166/CN-01011166/frame.html> doi:10.3109/13651501.2012.736163

Leung, J., Kooda, K., & Fazee, E. (2015). Necrotizing deep tissue infection associated with paliperidone palmitate. *Journal of pharmacy practice. Conference: 18th annual meeting of the college of psychiatric and neurologic pharmacists, CPNP. United states*, 28(3), 372-373. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/049/CN-01362049/frame.html> doi:10.1177/0897190015582204

Lewis, S., Tarrier, N., Haddock, G., Bentall, R., Kinderman, P., Kingdon, D., . . . Dunn, G. (2002). Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. *British Journal of Psychiatry - Supplementum*, 43, s91-97.

Li, H., Rui, Q., Ning, X., Xu, H., & Gu, N. (2010). A comparative randomized, open-label, rater-blinded study of paliperidone palmitate and risperidone long-acting injectable therapy in patients with schizophrenia. *International journal of neuropsychopharmacology*, 13, 167. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/258/CN-00773258/frame.html>

Li, H., Rui, Q., Ning, X., Xu, H., & Gu, N. (2011). A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 35(4), 1002-1008. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/679/CN-00801679/frame.html>
doi:10.1016/j.pnpbp.2011.02.001

Li, M., Heidbreder, C., Fudala, P., & Nasser, A. (2014). A model-based approach to characterize risperidone release, absorption, and disposition after administration of RBP-7000 in schizophrenic patients. *Clinical pharmacology and therapeutics.*, 95, S77. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/930/CN-01058930/frame.html>
doi:10.1038/cpt.2013.249

Li, Z., Guo, Z., Wang, N., Xu, Z., Qu, Y., Wang, X., . . . Kingdon, D. (2015). Cognitive-behavioural therapy for patients with schizophrenia: A multicentre randomized controlled trial in Beijing, China. *Psychological Medicine*, 45(9), 1893-1905.
doi:<http://dx.doi.org/10.1017/S0033291714002992>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Li, Z. J., Guo, Z. H., Wang, N., Xu, Z. Y., Qu, Y., Wang, X. Q., . . . Kingdon, D. (2015). Cognitive-behavioural therapy for patients with schizophrenia: a multicentre randomized controlled trial in Beijing, China. *Psychological Medicine*, 45(9), 1893-1905. doi:<https://dx.doi.org/10.1017/S0033291714002992>
- Liem, S., & Lee, C. (2013). Effectiveness of assertive community treatment in hong kong among patients with frequent hospital admissions. *Psychiatric services (washington, D.C.)*, 64(11), 1170-1172. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/946/CN-00909946/frame.html> doi:10.1176/appi.ps.201200421
- Lincoln, T. M., Rief, W., Westermann, S., Ziegler, M., Kesting, M. L., Heibach, E., & Mehl, S. (2014). Who stays, who benefits? Predicting dropout and change in cognitive behaviour therapy for psychosis. *Psychiatry Research*, 216(2), 198-205. doi:<https://dx.doi.org/10.1016/j.psychres.2014.02.012>
- Lincoln, T. M., Ziegler, M., Mehl, S., Kesting, M. L., Lullmann, E., Westermann, S., & Rief, W. (2012). Moving from efficacy to effectiveness in cognitive behavioral therapy for psychosis: a randomized clinical practice trial. *Journal of Consulting & Clinical Psychology*, 80(4), 674-686. doi:<https://dx.doi.org/10.1037/a0028665>
- Lindenmayer, J., Adityanjee, n., Vital-Herne, M., Bark, N., Grochowski, S., & Moynihan, N. (1997). Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients. *Biological Psychiatry*, 42(1), 6-12. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/580/CN-00239580/frame.html> doi:10.1016/S0006-3223(96)00296-X
- Lindenmayer, J., Jarboe, K., Bossie, C., Zhu, Y., Mehnert, A., & Lasser, R. (2005). Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. *International Clinical Psychopharmacology*, 20(4), 213-221. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/295/CN-00522295/frame.html>
- Lindenmayer, J., & Khan, A. (2011). Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. *Schizophrenia Research*, 125(2-3), 267-277. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/733/CN-00780733/frame.html> doi:10.1016/j.schres.2010.08.021
- Lindenmayer, J., Khan, A., Eerdekens, M., Hove, I., & Kushner, S. (2007). Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. *European Neuropsychopharmacology*, 17(2), 138-144. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/911/CN-00572911/frame.html> doi:10.1016/j.euroneuro.2006.08.004
- Lindenmayer, J. P., McGurk, S. R., Mueser, K. T., Khan, A., Wance, D., Hoffman, L., . . . Xie, H. (2008). A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness. *Psychiatric Services*, 59(3), 241-247. doi:<https://dx.doi.org/10.1176/appi.ps.59.3.241>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Liparini, C. G. *Student as Active Agent: A Grounded Theory of the Postsecondary Transition Experiences for Students with Psychiatric Disabilities*. Retrieved from

<http://ez.library.latrobe.edu.au/login?url=https://search.proquest.com/docview/964191155?accountid=12001>

http://ap01.alma.exlibrisgroup.com/view/uresolver/61LATROBE_INST/openurl?ctx_enc=info:ofi/enc:UTF-8&ctx_ver=Z39.88-2004&url_ctx_fmt=info:ofi/fmt:kev:mtx:ctx&url_ver=Z39.88-2004&rft.genre=unknown&rft.atitle=&rft.jtitle=&rft.btitle=&rft.autlast=Liparini&rft.auinitm=Garczynski&rft.ausuffix=&rft.au=Liparini%2C+Christina+Garczynski&rft.date=2008&rft.volume=&rft.issue=&rft.quarter=&rft.ssn=&rft.spag_e=&rft.epage=&rft.pages=&rft.artnum=&rft.issn=&rft.eissn=&rft.isbn=9781124538495&rft.sici=&rft.coden=&rft_id=info:doi/&rft.object_id=&rft.eisbn=&rft.edition=&rft.pub=Student+as+Active+Agent%3A+A+Grounded+Theory+of+the+Postsecondary+Transition+Experiences+for+Students+with+Psychiatric+Disabilities&rft.place=&rft.series=&rft.title=&rft.bici=&rft_id=info:bibcode/&rft_id=info:hdl/&rft_id=info:lccn/&rft_id=info:oclcnnum/&rft_id=info:pmid/&rft_id=info:eric/ED527456 ERIC database.

Liu, J., Shi, Y., Tang, J., Guo, T., Li, X., Yang, Y., . . . He, L. (2005). SNPs and haplotypes in the S100B gene reveal association with schizophrenia. *Biochemical and biophysical research communications*, 328(1), 335-341. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/521/CN-00505521/frame.html>
doi:10.1016/j.bbrc.2004.12.175

Loebl, T., Angarita, G., Pachas, G., Huang, K., Lee, S., Nino, J., . . . Evins, A. (2008). A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. *Journal of Clinical Psychiatry*, 69(3), 480-486.
Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/297/CN-00630297/frame.html>

Loga, S., Curry, S., & Lader, M. (1975). Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. *British journal of clinical pharmacology*, 2(3), 197-208. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/312/CN-00704312/frame.html>

Looijmans, A., Jorg, F., Bruggeman, R., Schoevers, R., & Corpeleijn, E. (2017). Design of the Lifestyle Interventions for severely mentally ill Outpatients in the Netherlands (LION) trial; a cluster randomised controlled study of a multidimensional web tool intervention to improve cardiometabolic health in patients with severe mental illness. *BMC Psychiatry* Vol 17 2017, ArtID 107, 17.

Lopez-Luengo, B., & Vazquez, C. (2005). Effects of a neuropsychological rehabilitation programme on schizophrenic patients' subjective perception of improvement. *Neuropsychological Rehabilitation*, 15(5), 605-618.

Lopez-Navarro, E., Del Canto, C., Belber, M., Mayol, A., Fernandez-Alonso, O., Lluis, J., . . . Chadwick, P. (2015). Mindfulness improves psychological quality of life in community-based patients with severe mental health problems: A pilot

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

randomized clinical trial. *Schizophrenia Research*, 168(1-2), 530-536.

doi:<https://dx.doi.org/10.1016/j.schres.2015.08.016>

Lucena, D., Fernandes, B., Berk, M., Dodd, S., Medeiros, D., Pedrini, M., . . . Gama, C. (2009). Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. *Journal of Clinical Psychiatry*, 70(10), 1416-1423. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/158/CN-00731158/frame.html>
doi:10.4088/JCP.08m04935gry

Lullmann, E., & Lincoln, T. M. (2013). The effect of an educating versus normalizing approach on treatment motivation in patients presenting with delusions: An experimental investigation with analogue patients. *Schizophrenia Research and Treatment*, (no pagination)(261587). doi:<http://dx.doi.org/10.1155/2013/261587>

Lutgens, D., Iyer, S., Joober, R., Brown, T. G., Norman, R., Latimer, E., . . . Malla, A. (2015). A five-year randomized parallel and blinded clinical trial of an extended specialized early intervention vs. regular care in the early phase of psychotic disorders: study protocol. *BMC Psychiatry*, 15, 22. doi:<https://dx.doi.org/10.1186/s12888-015-0404-2>

Lysaker, P. H., Bond, G., Davis, L. W., Bryson, G. J., & Bell, M. D. (2005). Enhanced cognitive-behavioral therapy for vocational rehabilitation in schizophrenia: Effects on hope and work. *Journal of Rehabilitation Research & Development*, 42(5), 673-682.

Lysaker, P. H., Davis, L. W., Bryson, G. J., & Bell, M. D. (2009). Effects of cognitive behavioral therapy on work outcomes in vocational rehabilitation for participants with schizophrenia spectrum disorders. *Schizophrenia Research*, 107(2-3), 186-191. doi:<https://dx.doi.org/10.1016/j.schres.2008.10.018>

Lysaker, P. H., Kukla, M., Dubreucq, J., Gumley, A., McLeod, H., Vohs, J. L., . . . Dimaggio, G. (2015). Metacognitive deficits predict future levels of negative symptoms in schizophrenia controlling for neurocognition, affect recognition, and self-expectation of goal attainment. *Schizophrenia Research*, 168(1-2), 267-272.
doi:<https://dx.doi.org/10.1016/j.schres.2015.06.015>

Lystad, J. U., Falkum, E., Haaland, V. O., Bull, H., Evensen, S., McGurk, S. R., & Ueland, T. (2017). Cognitive remediation and occupational outcome in schizophrenia spectrum disorders: A 2year follow-up study. *Schizophrenia Research*, 185, 122-129. doi:<https://dx.doi.org/10.1016/j.schres.2016.12.020>

Ma, J., Li, Y.-C., Xu, H.-M., Zeng, H.-L., Xie, J., Lei, Y., . . . Li, J.-G. (2014). Efficacy and safety of paliperidonepalmitate injection in the treatment of schizophrenia in teenagers. *Chinese journal of new drugs*, 23(8), 972-976. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/902/CN-00995902/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Maas, J., Contreras, S., Bowden, C., & Weintraub, S. (1985). Effects of debrisoquin on CSF and plasma HVA concentrations in man. *Life sciences*, 36(22), 2163-2170. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/213/CN-00038213/frame.html>
- Macias, C., Rodican, C., Hargreaves, W., Jones, D., Barreira, P., & Wang, Q. (2006). Supported employment outcomes of a randomized controlled trial of ACT and clubhouse models. *Psychiatric services (washington, D.C.)*, 57(10), 1406-1415. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/777/CN-00572777/frame.html>
doi:10.1176/ps.2006.57.10.1406
- Mack, J. H. (1980). An Analysis of State Definitions of Severely Emotionally Disturbed (pp. 21).
- Mackenzie, A., Harvey, S., Mewton, L., & Andrews, G. (2014). Occupational impact of internet-delivered cognitive behaviour therapy for depression and anxiety: reanalysis of data from five Australian randomised controlled trials. *Medical Journal of Australia*, 201(7), 417-419.
- MacPherson, H. A., Weinstein, S. M., Henry, D. B., & West, A. E. (2016). Mediators in the randomized trial of Child- and Family-Focused Cognitive-Behavioral Therapy for pediatric bipolar disorder. *Behav Res Ther*, 85, 60-71.
doi:<http://dx.doi.org/10.1016/j.brat.2016.08.014>
- Macpherson, R., Molodynki, A., Freeth, R., Uppal, A., Steer, H., Buckle, D., & Jones, A. (2010). Supervised community treatment: Guidance for clinicians. *Advances in Psychiatric Treatment*, 16(4), 253-259.
doi:<http://dx.doi.org/10.1192/apt.bp.109.007203>
- Madigan, K., Brennan, D., Lawlor, E., Turner, N., Kinsella, A., O'Connor, J. J., . . . O'Callaghan, E. (2013). A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. *Schizophrenia Research*, 143(1), 138-142.
doi:<https://dx.doi.org/10.1016/j.schres.2012.10.018>
- Magnusson, M., Samtani, M., Plan, E., Jonsson, E., Rossenu, S., Vermeulen, A., & Russu, A. (2017). Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. *Clinical pharmacokinetics*, 56(4), 421-433. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/520/CN-01426520/frame.html> doi:10.1007/s40262-016-0459-3
- Mak, M., Samochowiec, J., Tybura, P., Bienkowski, P., Karakiewicz, B., Zaremba Pechmann, L., & Mroczek, B. (2013). The efficacy of cognitive rehabilitation with RehaCom programme in schizophrenia patients. The role of selected genetic polymorphisms in successful cognitive rehabilitation. *Annals of Agricultural & Environmental Medicine*, 20(1), 77-81.
- Malik, N., Kingdon, D., Pelton, J., Mehta, R., & Turkington, D. (2009). Effectiveness of brief cognitive-behavioral therapy for schizophrenia delivered by mental health nurses: relapse and recovery at 24 months. *Journal of Clinical Psychiatry*, 70(2), 201-207.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Malla, A., Chue, P., Jordan, G., Stip, E., Kocerginski, D., Milliken, H., . . . Roy, M. (2016). An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. *Clinical schizophrenia & related psychoses*, 9(4), 198-208. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/765/CN-01130765/frame.html> doi:10.3371/CSRP.MACH.061213
- Malla, A., Chue, P., Jordan, G., Stip, E., Kocerginski, D., Milliken, H., . . . Roy, M.-A. (2012). An open-label randomized trial comparing risperidone long acting injectable (RLAI) with oral antipsychotic medication in the treatment of early psychosis. *Early intervention in psychiatry*, 6, 100. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/793/CN-01029793/frame.html> doi:10.1111/j.1751-7893.2012.00394.x
- Maneesakorn, S., Robson, D., Gournay, K., & Gray, R. (2007). An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand. *Journal of Clinical Nursing*, 16(7), 1302-1312.
- Manoach, D., Wamsley, E., Shinn, A., Tucker, M., Ono, K., McKinley, S., . . . Stickgold, R. (2012). The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia. *Sleep*, 35, A339. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/504/CN-01059504/frame.html>
- Manoach, D., Wamsley, E., Shinn, A., Tucker, M., Ono, K., McKinley, S., . . . Stickgold, R. (2013). Can we improve cognitive function in schizophrenia by treating abnormal sleep? *Biological psychiatry*, 73(9 suppl. 1), 21s-22s. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/615/CN-01025615/frame.html>
- Manuel, J., Covell, N., Jackson, C., & Essock, S. (2011). Does assertive community treatment increase medication adherence for people with co-occurring psychotic and substance use disorders? *Journal of the American Psychiatric Nurses Association*, 17(1), 51-56. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/421/CN-00799421/frame.html> doi:10.1177/1078390310395586
- Manuel, J. I., Covell, N. H., Jackson, C. T., & Essock, S. M. (2011). Does assertive community treatment increase medication adherence for people with co-occurring psychotic and substance use disorders? *Journal of the American Psychiatric Nurses Association*, 17(1), 51-56. doi:<https://dx.doi.org/10.1177/1078390310395586>
- Marchesi, G., Santone, G., Cotani, P., Giordano, A., & Chelli, F. (1995). The therapeutic role of naltrexone in negative symptom schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 19(8), 1239-1249. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/868/CN-00131868/frame.html>
- Markowitz, M., Turkoz, I., Jing, F. D., Levitan, B., Gopal, S., Simpson, G., & Alphs, L. (2010). Post Hoc comparative effectiveness study of paliperidone palmitate vs paliperidone ER: an indirect comparison from placebo-controlled relapse prevention studies. *Neuropsychopharmacology*, 35, S209. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/135/CN-01032135/frame.html> doi:10.1038/npp.2010.217

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Markulev, C., McGorry, P. D., Nelson, B., Yuen, H. P., Schaefer, M., Yung, A. R., . . . Amminger, G. P. (2017). NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. *Early intervention in psychiatry*, 11(5), 418-428. doi:<https://dx.doi.org/10.1111/eip.12260>
- Martin, G., Costello, H., Leese, M., Slade, M., Bouras, N., Higgins, S., & Holt, G. (2005). An exploratory study of assertive community treatment for people with intellectual disability and psychiatric disorders: conceptual, clinical, and service issues. *Journal of Intellectual Disability Research*, 49(Pt 7), 516-524.
- Martin, G., Costello, H., Leese, M., Slade, M., Bouras, N., Higgins, S., & Holt, G. (2005). An exploratory study of assertive community treatment for people with intellectual disability and psychiatric disorders: conceptual, clinical, and service issues. *Journal of Intellectual Disability Research*, 49(Pt 7), 516-524. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/590/CN-00528590/frame.html> doi:10.1111/j.1365-2788.2005.00709.x
- Matsui, M., Arai, H., Yonezawa, M., Sumiyoshi, T., Suzuki, M., & Kurachi, M. (2009). The effects of cognitive rehabilitation on social knowledge in patients with schizophrenia. *Applied Neuropsychology*, 16(3), 158-164. doi:<https://dx.doi.org/10.1080/09084280903098414>
- Mauri, M., Maffini, M., Pace, C., Reggiori, A., Paletta, S., Moliterno, D., . . . Altamura, C. (2014). "long-acting" olanzapine in maintenance therapy of schizophrenia: a study with plasma levels. *International Journal of Psychiatry in Clinical Practice*, 19(2), 99-105. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/385/CN-01102385/frame.html> doi:10.3109/13651501.2014.1000928
- Mausbach, B. T., Cardenas, V., McKibbin, C. L., Jeste, D. V., & Patterson, T. L. (2008). Reducing emergency medical service use in patients with chronic psychotic disorders: results from the FAST intervention study. *Behaviour Research & Therapy*, 46(1), 145-153.
- McCreadie, R. (1995). Managing the First Episode of Schizophrenia: the Role of New Therapies CONFERENCE ABSTRACT. *8th european college of neuropsychopharmacology congress. Venice, italy. 30th september - 4th october, 1995*. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/836/CN-00282836/frame.html>
- McCrone, P., Beecham, J., & Knapp, M. (1994). Community psychiatric nurse teams: cost-effectiveness of intensive support versus generic care. *British Journal of Psychiatry*, 165(2), 218-221. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/133/CN-00106133/frame.html>
- McCrone, P., Killaspy, H., Bebbington, P., Johnson, S., Nolan, F., Pilling, S., & King, M. (2009). The REACT study: cost-effectiveness analysis of assertive community treatment in north London. *Psychiatric Services*, 60(7), 908-913. doi:<https://dx.doi.org/10.1176/appi.ps.60.7.908>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- McCrone, P., Killaspy, H., Bebbington, P., Johnson, S., Nolan, F., Pilling, S., & King, M. (2009). The REACT study: cost-effectiveness analysis of assertive community treatment in north London. *Psychiatric services (washington, D.C.)*, 60(7), 908-913. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/842/CN-00720842/frame.html> doi:10.1176/ps.2009.60.7.908
- McDonald, W., Easley, K., Byrd, E., Holtzheimer, P., Tuohy, S., Woodard, J., . . . Epstein, C. (2006). Combination rapid transcranial magnetic stimulation in treatment refractory depression. *Neuropsychiatric Disease and Treatment*, 2(1), 85-94. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/740/CN-00622740/frame.html>
- McDonnell, D., Kryzhanovskaya, L., Zhao, F., Detke, H., & Feldman, P. (2011). Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. *Human psychopharmacology*, 26(6), 422-433. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/233/CN-00972233/frame.html> doi:10.1002/hup.1225
- McDonnell, D., Landry, J., & Detke, H. (2014). Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study. *International Clinical Psychopharmacology*, 29(6), 322-331. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/486/CN-01116486/frame.html> doi:10.1097/YIC.0000000000000038
- McEvoy, J., Byerly, M., Hamer, R., Dominik, R., Swartz, M., Rosenheck, R., . . . Stroup, T. (2014). Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. *JAMA - Journal of the American Medical Association*, 311(19), 1978-1986. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/278/CN-00993278/frame.html> doi:10.1001/jama.2014.4310
- McGorry, P. D., Nelson, B., Markulev, C., Yuen, H. P., Schafer, M. R., Mossaheb, N., . . . Amminger, G. P. (2017). Effect of omega-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial. *JAMA Psychiatry*, 74(1), 19-27. doi:<https://dx.doi.org/10.1001/jamapsychiatry.2016.2902>
- McGorry, P. D., Nelson, B., Phillips, L. J., Yuen, H. P., Francey, S. M., Thamphi, A., . . . Yung, A. R. (2013). Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. *Journal of Clinical Psychiatry*, 74(4), 349-356. doi:<https://dx.doi.org/10.4088/JCP.12m07785>
- McGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., . . . Jackson, H. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. *Archives of General Psychiatry*, 59(10), 921-928.
- McGurk, S. R., Mueser, K. T., DeRosa, T. J., & Wolfe, R. (2009). Work, recovery, and comorbidity in schizophrenia: a randomized controlled trial of cognitive remediation. *Schizophrenia Bulletin*, 35(2), 319-335. doi:<https://dx.doi.org/10.1093/schbul/sbn182>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

McGurk, S. R., Mueser, K. T., Feldman, K., Wolfe, R., & Pascaris, A. (2007). Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial. *American Journal of Psychiatry*, 164(3), 437-441.

McIntyre, R., Cohen, M., Zhao, J., Alphs, L., Macek, T., & Panagides, J. (2009). A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. *Bipolar Disorders*, 11(7), 673-686. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/877/CN-00729877/frame.html>
doi:10.1111/j.1399-5618.2009.00748.x

McKenzie, K., Os, J., Samele, C., Horn, E., Tattan, T., & Murray, R. (2003). Suicide and attempted suicide among people of Caribbean origin with psychosis living in the UK. *British Journal of Psychiatry*, 183, 40-44. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/863/CN-00438863/frame.html>

McLeod, T., Morris, M., Birchwood, M., & Dovey, A. (2007). Cognitive behavioural therapy group work with voice hearers. Part 1. *British Journal of Nursing*, 16(4), 248-252.

McMurran, M., Crawford, M. J., Reilly, J. G., McCrone, P., Moran, P., Williams, H., . . . Day, F. (2011). Psycho-education with problem solving (PEPS) therapy for adults with personality disorder: a pragmatic multi-site community-based randomised clinical trial. *Trials [Electronic Resource]*, 12, 198. doi:<https://dx.doi.org/10.1186/1745-6215-12-198>

Meilijson, S. R., Kasher, A., & Elizur, A. (2004). Language Performance in Chronic Schizophrenia: A Pragmatic Approach. *Journal of Speech, Language, and Hearing Research*, 47(3), 695.

Mela, M., & Depiang, G. (2016). Clozapine's Effect on Recidivism Among Offenders with Mental Disorders. *Journal of the American Academy of Psychiatry and the Law*, 44(1), 82-90. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/741/CN-01372741/frame.html>

Melau, M., Jeppesen, P., Thorup, A., Bertelsen, M., Petersen, L., Gluud, C., . . . Nordentoft, M. (2011). The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial. *Trials [Electronic Resource]*, 12, 72. doi:<https://dx.doi.org/10.1186/1745-6215-12-72>

Meltzer, H., Lee, M., & Jayathilake, K. (2001). The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. *Neuropsychopharmacology*, 24(3), 278-290. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/975/CN-00455975/frame.html> doi:10.1016/S0893-133X(00)00201-3

Meltzer, H., Lindenmayer, J., Kwentus, J., Share, D., Johnson, R., & Jayathilake, K. (2014). A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. *Schizophrenia Research*, 154(1-3), 14-22. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/167/CN-00985167/frame.html> doi:10.1016/j.schres.2014.02.015

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Meltzer, H., Lindenmayer, J.-P., Kwentus, J., Share, D., Shebaro, R., & Jayathilake, K. (2012). A six month randomized controlled trial of long acting injectable risperidone 50 and 100 mg in treatment resistant schizophrenia.

Neuropsychopharmacology, 38, S444. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/604/CN-01008604/frame.html> doi:10.1038/npp.2012.221

Meltzer, H., Perline, R., Tricou, B., Lowy, M., & Robertson, A. (1984). Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. II. Relation to suicide, psychosis, and depressive symptoms. *Archives of General Psychiatry*, 41(4), 379-387. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/961/CN-00033961/frame.html>

Meltzer, H., Risinger, R., Nasrallah, H., Du, Y., Zummo, J., Corey, L., . . . Ehrich, E. (2015). A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. *Journal of Clinical Psychiatry*, 76(8), 1085-1090. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/548/CN-01089548/frame.html> doi:10.4088/JCP.14m09741

Meltzer, H., Share, D., & Jayathilake, K. (2015). Lurasidone is an effective treatment for treatment resistant schizophrenia. *Neuropsychopharmacology*, 40, S546. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/074/CN-01163074/frame.html> doi:10.1038/npp.2015.327

Mendella, P. D., Burton, C. Z., Tasca, G. A., Roy, P., St Louis, L., & Twamley, E. W. (2015). Compensatory cognitive training for people with first-episode schizophrenia: results from a pilot randomized controlled trial. *Schizophrenia Research*, 162(1-3), 108-111. doi:<https://dx.doi.org/10.1016/j.schres.2015.01.016>

Metzger, W., Paige, S., & Newton, J. (1993). Inefficacy of propranolol in attenuation of drug-induced parkinsonian tremor. *Movement disorders*, 8(1), 43-46. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/965/CN-00089965/frame.html> doi:10.1002/mds.870080108

Mezler, M., Geneste, H., Gault, L., & Marek, G. (2010). LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. *Current opinion in investigational drugs (london, england : 2000)*, 11(7), 833-845. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/812/CN-00760812/frame.html>

Miceli, J., Preskorn, S., Wilner, K., Folger, C., & Tensfeld, T. (1998). Characterization of the intramuscular phar-macokinetics of ziprasidone in schizophrenic patients. *9th congress of the association of european psychiatrists. Copenhagen, denmark. 20-24th september 1998*. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/299/CN-00657299/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Michalopoulou, P. G., Lewis, S. W., Drake, R. J., Reichenberg, A., Emsley, R., Kalpakidou, A. K., . . . Kapur, S. (2015).

Modafinil combined with cognitive training: pharmacological augmentation of cognitive training in schizophrenia.

European Neuropsychopharmacology, 25(8), 1178-1189. doi:<https://dx.doi.org/10.1016/j.euroneuro.2015.03.009>

Miller, D. (2015). Pharmacogenetics of relapse in schizophrenia in the proactive trial. *Schizophrenia bulletin.*, 41, S208-s209.

Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/810/CN-01077810/frame.html>

doi:10.1093/schbul/sbv010

Monroe, R. (1975). Anticonvulsants in the treatment of aggression. *Journal of Nervous and Mental Disease*, 160(2-1), 119-126.

Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/666/CN-00011666/frame.html>

Montejo, G. A., Hernandez, A., Prieto, N., Sanchez-Iglesias, S., Gallego, M., Bote, B., . . . Guerro, D. (2016). Frequency of severe iatrogenic hyperprolactinaemia with atypical long acting and oral antipsychotics: paliperidone, risperidone, olanzapine, quetiapine and aripiprazole. *European neuropsychopharmacology. Conference: 29th european college of neuropsychopharmacology congress, ECNP 2016. Austria. Conference start: 20160917. Conference end: 20160920*, 26, S568-s569. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/826/CN-01303826/frame.html>

Montero, I., Masanet, M. J., Bellver, F., & Lacruz, M. (2006). The long-term outcome of 2 family intervention strategies in schizophrenia. *Comprehensive Psychiatry*, 47(5), 362-367.

Montgomery, K. L., Kim, J. S., & Franklin, C. (2011). Acceptance and Commitment Therapy for Psychological and Physiological Illnesses: A Systematic Review for Social Workers. *Health & Social Work*, 36(3), 169-181.

Montgomery, S., Roy, D., & Montgomery, D. (1983). The prevention of recurrent suicidal acts. *British journal of clinical pharmacology*, 15 Suppl 2, 183s-188s. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/195/CN-00030195/frame.html>

Moran, K., & Priebe, S. (2016). Better quality of life in patients offered financial incentives for taking anti-psychotic medication: linked to improved adherence or more money? *Quality of Life Research*, 25(8), 1897-1902. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/620/CN-01164620/frame.html> doi:10.1007/s11136-016-1238-1

Moran, P., Borschmann, R., Flach, C., Barrett, B., Byford, S., Hogg, J., . . . Thornicroft, G. (2010). The effectiveness of joint crisis plans for people with borderline personality disorder: protocol for an exploratory randomised controlled trial. *Trials [Electronic Resource]*, 11, 18. doi:<https://dx.doi.org/10.1186/1745-6215-11-18>

Moran, P., Borschmann, R., Flach, C., Barrett, B., Byford, S., Hogg, J., . . . Thornicroft, G. (2010). The effectiveness of joint crisis plans for people with borderline personality disorder: protocol for an exploratory randomised controlled trial.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Trials [Electronic Resource], 11, 18. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/715/CN-00742715/frame.html> doi:10.1186/1745-6215-11-18

Morberg Pain, C., Chadwick, P., & Abba, N. (2008). Clients' experience of case formulation in cognitive behaviour therapy for psychosis. *British Journal of Clinical Psychology*, 47(Pt 2), 127-138.

Moritz, S., Cludius, B., Hottenrott, B., Schneider, B., Saathoff, K., Kuelz, A., & Gallinat, J. (2015). Mindfulness and relaxation treatment reduce depressive symptoms in individuals with psychosis. *European Psychiatry*, 30(6), 709-714. doi:<http://dx.doi.org/10.1016/j.eurpsy.2015.05.002>

Moritz, S., Cludius, B., Hottenrott, B., Schneider, B. C., Saathoff, K., Kuelz, A. K., & Gallinat, J. (2015). Mindfulness and relaxation treatment reduce depressive symptoms in individuals with psychosis. *European Psychiatry: the Journal of the Association of European Psychiatrists*, 30(6), 709-714. doi:<https://dx.doi.org/10.1016/j.eurpsy.2015.05.002>

Moritz, S., Kerstan, A., Veckenstedt, R., Randjbar, S., Vitzthum, F., Schmidt, C., . . . Woodward, T. S. (2011). Further evidence for the efficacy of a metacognitive group training in schizophrenia. *Behaviour Research & Therapy*, 49(3), 151-157. doi:<https://dx.doi.org/10.1016/j.brat.2010.11.010>

Moritz, S., Veckenstedt, R., Andreou, C., Bohn, F., Hottenrott, B., Leighton, L., . . . Roesch-Ely, D. (2014). Sustained and "sleeper" effects of group metacognitive training for schizophrenia: a randomized clinical trial. *JAMA Psychiatry*, 71(10), 1103-1111. doi:<https://dx.doi.org/10.1001/jamapsychiatry.2014.1038>

Moritz, S., Veckenstedt, R., Bohn, F., Hottenrott, B., Scheu, F., Randjbar, S., . . . Roesch-Ely, D. (2013). Complementary group Metacognitive Training (MCT) reduces delusional ideation in schizophrenia. *Schizophrenia Research*, 151(1-3), 61-69. doi:<https://dx.doi.org/10.1016/j.schres.2013.10.007>

Moritz, S., Veckenstedt, R., Randjbar, S., Vitzthum, F., & Woodward, T. S. (2011). Antipsychotic treatment beyond antipsychotics: metacognitive intervention for schizophrenia patients improves delusional symptoms. *Psychological Medicine*, 41(9), 1823-1832. doi:<https://dx.doi.org/10.1017/S0033291710002618>

Moritz, S., & Woodward, T. S. (2007). Metacognitive training for schizophrenia patients (MCT): A pilot study on feasibility, treatment adherence, and subjective efficacy. *German Journal of Psychiatry*, 10(3), 69-78.

Mormont, C. (1974). Rating of psychological effects induced by 'ordinary' Noveril and time released Noveril.

Psychopharmacologia 37 (4), 37(4), 365-370. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/759/CN-00712759/frame.html>

Mormont, C. (1974). Rating of psychological effects induced by 'ordinary' Noveril and time released Noveril. <ORIGINAL>

EVALUATION DES EFFETS PSYCHOLOGIQUES DU NOVERIL SIMPLE ET DU NOVERIL TR.

Psychopharmacologia (berl), 37(4), 365-370. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/806/CN-00194806/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Morrison, A., Turkington, D., Pyle, M., Spencer, H., Brabban, A., Dunn, G., . . . Hutton, P. (2014). Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. *Lancet (london, england)*, 383(9926), 1395-1403. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/930/CN-00988930/frame.html> doi:10.1016/S0140-6736(13)62246-1
- Morrison, A. P. (2007). The Use of Attention Training With Voice Hearers May Reduce Distress and Improve Quality of Life. *Cognitive and Behavioral Practice*, 14(2), 142-143. doi:<http://dx.doi.org/10.1016/j.cbpra.2006.02.004>
- Morrison, A. P., Bentall, R. P., French, P., Walford, L., Kilcommons, A., Knight, A., . . . Lewis, S. W. (2002). Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. *British Journal of Psychiatry - Supplementum*, 43, s78-84.
- Morrison, A. P., Birchwood, M., Pyle, M., Flach, C., Stewart, S. L., Byrne, R., . . . French, P. (2013). Impact of cognitive therapy on internalised stigma in people with at-risk mental states. *British Journal of Psychiatry*, 203(2), 140-145. doi:<https://dx.doi.org/10.1192/bjp.bp.112.123703>
- Morrison, A. P., Burke, E., Murphy, E., Pyle, M., Bowe, S., Varese, F., . . . Wood, L. J. (2016). Cognitive therapy for internalised stigma in people experiencing psychosis: A pilot randomised controlled trial. *Psychiatry Research*, 240, 96-102. doi:<https://dx.doi.org/10.1016/j.psychres.2016.04.024>
- Morrison, A. P., French, P., Parker, S., Roberts, M., Stevens, H., Bentall, R. P., & Lewis, S. W. (2007). Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. *Schizophrenia Bulletin*, 33(3), 682-687.
- Morrison, A. P., French, P., Stewart, S. L., Birchwood, M., Fowler, D., Gumley, A. I., . . . Dunn, G. (2012). Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. *BMJ*, 344, e2233. doi:<https://dx.doi.org/10.1136/bmj.e2233>
- Morrison, A. P., French, P., Walford, L., Lewis, S. W., Kilcommons, A., Green, J., . . . Bentall, R. P. (2004). Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. *British Journal of Psychiatry*, 185, 291-297.
- Morrison, A. P., Stewart, S. L., French, P., Bentall, R. P., Birchwood, M., Byrne, R., . . . Dunn, G. (2011). Early detection and intervention evaluation for people at high-risk of psychosis-2 (EDIE-2): trial rationale, design and baseline characteristics. *Early intervention in psychiatry*, 5(1), 24-32. doi:<https://dx.doi.org/10.1111/j.1751-7893.2010.00254.x>
- Morrison, A. P., Turkington, D., Pyle, M., Spencer, H., Brabban, A., Dunn, G., . . . Hutton, P. (2014). Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. *Lancet*, 383(9926), 1395-1403. doi:[https://dx.doi.org/10.1016/S0140-6736\(13\)62246-1](https://dx.doi.org/10.1016/S0140-6736(13)62246-1)

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Morthorst, B., Krogh, J., Erlangsen, A., Alberdi, F., & Nordentoft, M. (2012). Effect of assertive outreach after suicide attempt in the AID (assertive intervention for deliberate self harm) trial: randomised controlled trial. *BMJ (Clinical research ed.)*, 345, e4972. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/353/CN-00836353/frame.html>
- Mueller, D. R., Schmidt, S. J., & Roder, V. (2015). One-year randomized controlled trial and follow-up of integrated neurocognitive therapy for schizophrenia outpatients. *Schizophrenia Bulletin*, 41(3), 604-616.
doi:<https://dx.doi.org/10.1093/schbul/sbu223>
- Mueser, K. T., McGurk, S. R., Xie, H., Bolton, E. E., Jankowski, M., Lu, W., . . . Wolfe, R. (2018). Neuropsychological predictors of response to cognitive behavioral therapy for posttraumatic stress disorder in persons with severe mental illness. *Psychiatry Research*, 259, 110-116. doi:<http://dx.doi.org/10.1016/j.psychres.2017.10.016>
- Mueser, K. T., Rosenberg, S. D., Xie, H., Jankowski, M., Bolton, E. E., Lu, W., . . . Wolfe, R. (2008). A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. *Journal of Consulting and Clinical Psychology*, 76(2), 259-271. doi:<http://dx.doi.org/10.1037/0022-006X.76.2.259>
- Mueser, K. T., Rosenberg, S. D., Xie, H., Jankowski, M. K., Bolton, E. E., Lu, W., . . . Wolfe, R. (2008). A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. *Journal of Consulting & Clinical Psychology*, 76(2), 259-271. doi:<https://dx.doi.org/10.1037/0022-006X.76.2.259>
- Müller, M., Wetzel, H., & Benkert, O. (1998). Latent dimensions of depressive and negative symptoms in acute schizophrenia: treatment effects of high dose amisulpride vs. flupentixol CONFERENCE ABSTRACT. *11th european college of neuropsychopharmacology congress. Paris, france. 31st october - 4th november 1998*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/135/CN-00283135/frame.html>
- Müller, W., Haffelder, G., Schlotmann, A., Schaefers, A., & Teuchert-Noodt, G. (2014). Amelioration of psychiatric symptoms through exposure to music individually adapted to brain rhythm disorders - a randomised clinical trial on the basis of fundamental research. *Cognitive Neuropsychiatry*, 19(5), 399-413. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/366/CN-00992366/frame.html> doi:[10.1080/13546805.2013.879054](https://dx.doi.org/10.1080/13546805.2013.879054)
- Muller, W., Haffelder, G., Schlotmann, A., Schaefers, A. T., & Teuchert-Noodt, G. (2014). Amelioration of psychiatric symptoms through exposure to music individually adapted to brain rhythm disorders - a randomised clinical trial on the basis of fundamental research. *Cognitive Neuropsychiatry*, 19(5), 399-413.
doi:<https://dx.doi.org/10.1080/13546805.2013.879054>
- Mura, G., Specchio, L., Corfiati, L., Porro, V., & Bertolino, A. (1974). [Treatment of psychoses with a long-acting neuroleptic agent (fluphenazine decanoate). Clinico-psychopathological study of 53 patients]. Trattamento delle psicosi con un

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- neurolettico long-acting (flufenazina decanoato). Studio clinico-psicopatologico su 53 pazienti. *Acta neurologica*, 29, 446-459. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/166/CN-00322166/frame.html>
- Murrell, A. R., & Scherbarth, A. J. (2011). State of the Research and Literature Address: ACT with Children, Adolescents and Parents (Vol. 7, pp. 15-22): Joseph Cautilli, Ph.D. & The Behavior Analyst Online Organization. 535 Queen Street, Philadelphia, PA 19147-3220.
- Murrough, J., Iosifescu, D., Chang, L., Al, J. R., Green, C., Iqbal, S., . . . Mathew, S. (2012). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site, randomized, parallel-arm, midazolam-controlled, clinical trial. *Neuropsychopharmacology*, 38, S151-s152. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/612/CN-01008612/frame.html> doi:10.1038/npp.2012.219
- Naber, D., Baker, R., Eramo, A., Forray, C., Hansen, K., Sapin, C., . . . Potkin, S. (2015). Effects of aripiprazole once-monthly and paliperidone palmitate in patients with schizophrenia and concomitant substance use: a post-hoc analysis of QUALIFY, a head-to-head study. *Neuropsychopharmacology*, 40, S539-s540. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/075/CN-01163075/frame.html> doi:10.1038/npp.2015.327
- Naber, D., Hansen, K., Forray, C., Baker, R., Sapin, C., Beillat, M., . . . Potkin, S. (2016). Improvement in secondary effectiveness measures with aripiprazole once-monthly vs paliperidone palmitate in qualify, a head-to-head study. *CNS spectrums. Conference: 11th annual neuroscience education institute psychopharmacology congress, NEI 2015. United states*, 21(1), 95-96. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/007/CN-01430007/frame.html> doi:10.1017/S1092852915000905
- Naber, D., Hansen, K., Forray, C., Baker, R., Sapin, C., Beillat, M., . . . Potkin, S. (2015). Aripiprazole once-monthly and paliperidone palmitate in patients with schizophrenia stratified by age: results from QUALIFY, a head-to-head study. *European neuropsychopharmacology*, 25, S527-s528. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/193/CN-01163193/frame.html>
- Naber, D., Hansen, K., Forray, C., Baker, R., Sapin, C., Beillat, M., . . . Potkin, S. (2015). Clinical Global Impression after aripiprazole once-monthly and paliperidone palmitate: results from QUALIFY, a head-to-head study in schizophrenia. *European neuropsychopharmacology*, 25, S525-s526. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/196/CN-01163196/frame.html>
- Naber, D., Hansen, K., Forray, C., Baker, R., Sapin, C., Beillat, M., . . . Potkin, S. (2016). Clinical global impression after aripiprazole once-monthly and paliperidone palmitate: results from qualify, a head-to-head study in schizophrenia. *CNS spectrums. Conference: 11th annual neuroscience education institute psychopharmacology congress, NEI 2015. United states*, 21(1), 93-94. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/009/CN-01430009/frame.html> doi:10.1017/S1092852915000905

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Naeem, F., Johal, R., McKenna, C., Rathod, S., Ayub, M., Lecomte, T., . . . Farooq, S. (2016). Cognitive Behavior Therapy for psychosis based Guided Self-help (CBTp-GSH) delivered by frontline mental health professionals: Results of a feasibility study. *Schizophrenia Research*, 173(1-2), 69-74. doi:<https://dx.doi.org/10.1016/j.schres.2016.03.003>
- Naeem, F., Kingdon, D., & Turkington, D. (2005). Cognitive behavior therapy for schizophrenia in patients with mild to moderate substance misuse problems. *Cognitive Behaviour Therapy*, 34(4), 207-215.
- Naeem, F., Kingdon, D., & Turkington, D. (2006). Cognitive behaviour therapy for schizophrenia: relationship between anxiety symptoms and therapy. *Psychology & Psychotherapy: Theory, Research & Practice*, 79(Pt 2), 153-164.
- Naeem, F., Saeed, S., Irfan, M., Kiran, T., Mehmood, N., Gul, M., . . . Kingdon, D. (2015). Brief culturally adapted CBT for psychosis (CaCBTp): A randomized controlled trial from a low income country. *Schizophrenia Research*, 164(1-3), 143-148. doi:<https://dx.doi.org/10.1016/j.schres.2015.02.015>
- Nasrallah, H., Aquila, R., Stanford, A., Jamal, H., Weiden, P., & Risinger, R. (2017). Metabolic and endocrine profiles during 1-year treatment of outpatients with schizophrenia with aripiprazole lauroxil. *Psychopharmacology bulletin*, 47(3), 35-43. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/165/CN-01419165/frame.html>
- Nasrallah, H., Duchesne, I., Mehnert, A., & Janagap, C. (2002). Long-acting, injectable risperidone - the first long-acting, atypical antipsychotic - improves quality of life. *European neuropsychopharmacology; 15th international congress of the european college of neuropsychopharmacology, october 5-9, barcelona, spain*, 12(Suppl 3), S282. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/714/CN-00659714/frame.html>
- Nasrallah, H., Duchesne, I., Mehnert, A., Janagap, C., & Eerdekkens, M. (2004). Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. *Journal of Clinical Psychiatry*, 65(4), 531-536. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/975/CN-00469975/frame.html>
- Nasrallah, H., Gopal, S., Gassmann-Mayer, C., Quiroz, J., Lim, P., Eerdekkens, M., . . . Hough, D. (2010). A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. *Neuropsychopharmacology*, 35(10), 2072-2082. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/491/CN-00771491/frame.html> doi:10.1038/npp.2010.79
- Nasrallah, H., Newcomer, J., Risinger, R., Du, Y., Zummo, J., Bose, A., . . . Ehrlich, E. (2016). Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. *Journal of Clinical Psychiatry*, 77(11), 1519-1525. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/104/CN-01286104/frame.html> doi:10.4088/JCP.15m10467
- Nasser, A., Henderson, D., Fava, M., Fudala, P., Twumasi-Ankrah, P., Kouassi, A., & Heidbreder, C. (2016). Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. *Journal of Clinical Psychopharmacology*,

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

36(2), 130-140. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/418/CN-01141418/frame.html> doi:10.1097/JCP.0000000000000479

Nelson, E. L., Barnard, M., & Cain, S. (2003). Treating childhood depression over videoconferencing. *Telemedicine Journal & E-Health*, 9(1), 49-55.

Nemoto, T., Yamazawa, R., Kobayashi, H., Fujita, N., Chino, B., Fujii, C., . . . Mizuno, M. (2009). Cognitive training for divergent thinking in schizophrenia: a pilot study. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 33(8), 1533-1536. doi:<https://dx.doi.org/10.1016/j.pnpbp.2009.08.015>

Neuhaus, A., Goldberg, T., Hassoun, Y., Bates, J., Nassauer, K., Sevy, S., . . . Malhotra, A. (2009). Acute dopamine depletion with branched chain amino acids decreases auditory top-down event-related potentials in healthy subjects. *Schizophrenia Research*, 111(1-3), 167-173. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/597/CN-00720597/frame.html> doi:10.1016/j.schres.2009.03.023

Nienow, T. M., MacDonald, A. W., 3rd, & Lim, K. O. (2016). TDCS produces incremental gain when combined with working memory training in patients with schizophrenia: A proof of concept pilot study. *Schizophrenia Research*, 172(1-3), 218-219. doi:<https://dx.doi.org/10.1016/j.schres.2016.01.053>

Nilsson, A., Janson, H., Wold, H., Fugelli, A., Andersson, K., Hakangard, C., . . . Olsen, W. (2014). Ltx-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive staphylococcus aureus. *Antimicrobial agents and chemotherapy*, 59(1), 145-151. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/213/CN-01040213/frame.html> doi:10.1128/AAC.03513-14

Nordon, C., Bovagnet, T., Belger, M., Jimenez, J., Olivares, R., Chevrou-Severac, H., . . . Karcher, H. (2017). Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: a case study using the SOHO database. *Schizophrenia Research*, (no pagination). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/305/CN-01394305/frame.html> doi:10.1016/j.schres.2017.07.031

Nuechterlein, K. (2012). Long-acting injectable antipsychotic medication after a first episode of schizophrenia. *Early intervention in psychiatry*, 6, 7. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/042/CN-01004042/frame.html> doi:10.1111/j.1751-7893.2012.00392.x

Nuechterlein, K., Subotnik, K., Ventura, J., Gretchen-Doorly, D., Casaus, L., & Luo, J. (2013). Efficacy of depot antipsychotics beyond mere relapse prevention. *Schizophrenia bulletin*, 39, S346. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/232/CN-01007232/frame.html> doi:10.1093/schbul/sbt011

Nuechterlein, K., Subotnik, K., Ventura, J., Gretchen-Doorly, D., Casaus, L., Luo, J., . . . Kurtz, A. (2012). The impact of long-acting injectable versus oral risperidone on cognition and work functioning after an initial psychotic episode: the

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- critical role of early medication adherence. *Early intervention in psychiatry*, 6, 8. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/040/CN-01004040/frame.html> doi:10.1111/j.1751-7893.2012.00392.x
- Nuechterlein, K., Subotnik, K., Ventura, J., Gretchen-Doorly, D., Casaus, L., Luo, J., . . . DeTore, N. (2013). Long-acting injectable risperidone and medication adherence enhance cognition and work functioning after a first psychotic episode. *Schizophrenia bulletin*, 39, S347. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/231/CN-01007231/frame.html> doi:10.1093/schbul/sbt011
- Ochoa, S., Lopez-Carrilero, R., Barrigon, M. L., Pousa, E., Barajas, A., Lorente-Rovira, E., . . . Spanish Metacognition Study, G. (2017). Randomized control trial to assess the efficacy of metacognitive training compared with a psycho-educational group in people with a recent-onset psychosis. *Psychological Medicine*, 47(9), 1573-1584. doi:<https://dx.doi.org/10.1017/S0033291716003421>
- O'Connor, K., Stip, E., Pelissier, M. C., Aardema, F., Guay, S., Gaudette, G., . . . Leblanc, V. (2007). Treating delusional disorder: a comparison of cognitive-behavioural therapy and attention placebo control. *Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie*, 52(3), 182-190.
- O'Connor, K., Stip, E., Pelissier, M.-C., Aardema, F., Guay, S., Gaudette, G., . . . Leblanc, V. (2007). Treating delusional disorder: A comparison of cognitive-behavioural therapy and attention placebo control. *The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie*, 52(3), 182-190.
- O'Donoghue, B., Roche, E., Naji, A., Daly, R., Madigan, K., Cole, I., & Lyne, J. (2017). A randomized study of a smartphone application compared with booklet to improve service user's knowledge of their legal rights. *Irish Journal of Psychological Medicine*, 1-7. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/812/CN-01419812/frame.html> doi:10.1017/ipm.2017.60
- O'Donoghue, B., Roche, E., Naji, A., Daly, R., Madigan, K., Cole, I., . . . O'Donoghue, D. B. (2017). A randomized study of a smartphone application compared with booklet to improve service user's knowledge of their legal rights. *Irish Journal of Psychological Medicine*, 34(4), 287-293. doi:<http://dx.doi.org/10.1017/ipm.2017.60>
- O'Driscoll, C., Mason, O., Brady, F., Smith, B., & Steel, C. (2016). Process analysis of trauma-focused cognitive behavioural therapy for individuals with schizophrenia. *Psychology & Psychotherapy: Theory, Research & Practice*, 89(2), 117-132. doi:<https://dx.doi.org/10.1111/papt.12072>
- Oefelein, M. (2011). Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. *Drug safety*, 34(9), 733-754. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/225/CN-00894225/frame.html> doi:10.2165/11592790-00000000-00000
- Ohkuma, T., Kurihara, M., Yamashita, I., Takahashi, R., Mori, A., Yagi, G., . . . Kawakita, Y. (1988). Further analysis of the phase III comparative study of KD-136 (haloperidol decanoate: a long-acting injectable neuroleptic) and oral

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- haloperidol in the treatment of chronic schizophrenia. *Rinsho hyoka (clinical evaluation)*, 16(3), 487-497. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/306/CN-00660306/frame.html>
- Ohkuma, T., Yagi, G., Yamashita, I., Takahashi, R., Mori, A., Kudo, Y., . . . Yamaguchi, N. (1987). A phase III study of KD-136 (haloperidol decanoate: a long-acting neuroleptic) in the treatment of schizophrenia - The detailed analysis of multi-clinical double-blind comparative study of haloperidol decanoate with oral haloperidol preparation. *Rinsho hyoka (clinical evaluation)*, 15(1), 37-72. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/177/CN-00659177/frame.html>
- Olivares, J., Rodriguez-Morales, A., Diels, J., Povey, M., Jacobs, A., Zhao, Z., . . . Fernández, J. (2009). Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). *European Psychiatry*, 24(5), 287-296. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/830/CN-00719830/frame.html>
doi:10.1016/j.eurpsy.2008.12.002
- Omidi, A., Mohammadkhani, P., Mohammadi, A., & Zargar, F. (2013). Comparing mindfulness based cognitive therapy and traditional cognitive behavior therapy with treatments as usual on reduction of major depressive disorder symptoms. *Iranian Red Crescent Medical Journal*, 15(2), 142-146. doi:<http://dx.doi.org/10.5812/ircmj.8018>
- Ono, H., Fujikoshi, S., Oka, T., Sugiura, M., & Takahashi, M. (2008). A double-blind dose-response study comparing rapid acting intramuscular olanzapine and placebo in agitated schizophrenia. *European Neuropsychopharmacology*, 18, S410-s411. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/923/CN-00688923/frame.html>
- Onwumere, J., Grice, S., Garety, P., Bebbington, P., Dunn, G., Freeman, D., . . . Kuipers, E. (2014). Caregiver reports of patient-initiated violence in psychosis. *Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie*, 59(7), 376-384.
- Onwumere, J., Grice, S., Garety, P., Bebbington, P., Dunn, G., Freeman, D., . . . Kuipers, E. (2014). Caregiver reports of patient-initiated violence in psychosis. *Canadian journal of psychiatry. Revue canadienne de psychiatrie*, 59(7), 376-384. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/878/CN-01037878/frame.html>
doi:10.1177/070674371405900705
- Onwumere, J., Kuipers, E., Bebbington, P., Dunn, G., Freeman, D., Fowler, D., & Garety, P. (2009). Patient perceptions of caregiver criticism in psychosis: links with patient and caregiver functioning. *Journal of Nervous & Mental Disease*, 197(2), 85-91. doi:<https://dx.doi.org/10.1097/NMD.0b013e3181960e57>
- O'Reilly, K., Donohoe, G., O'Sullivan, D., Coyle, C., Mullaney, R., O'Connell, P., . . . Kennedy, H. G. (2016). Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder. *BMC Psychiatry*, 16, 5. doi:<https://dx.doi.org/10.1186/s12888-016-0707-y>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Ostergaard Christensen, T., Vesterager, L., Krarup, G., Olsen, B. B., Melau, M., Gluud, C., & Nordentoft, M. (2014). Cognitive remediation combined with an early intervention service in first episode psychosis. *Acta Psychiatrica Scandinavica*, 130(4), 300-310. doi:<https://dx.doi.org/10.1111/acps.12287>
- Owen, M., Sellwood, W., Kan, S., Murray, J., & Sarsam, M. (2015). Group CBT for psychosis: A longitudinal, controlled trial with inpatients. *Behav Res Ther*, 65, 76-85. doi:<http://dx.doi.org/10.1016/j.brat.2014.12.008>
- Palma-Sevillano, C., CaneTe-Crespillo, J., Farriols-Hernando, N., Cebria-Andreu, J., Michael, M., Alonso-Fernandez, I., . . . Segarra-Gutierrez, G. (2011). Randomised controlled trial of cognitive-motivational therapy program for the initial phase of schizophrenia: A 6-month assessment. *European Journal of Psychiatry*, 25(2), 68-80.
- Palumbo, D., Mucci, A., Piegari, G., D'Alise, V., Mazza, A., & Galderisi, S. (2017). SoCIAL - training cognition in schizophrenia: A pilot study. *Neuropsychiatric Disease and Treatment*, 13, 1947-1956. doi:<http://dx.doi.org/10.2147/NDT.S136732>
- Pandina, G., Bilder, R., Turkoz, I., & Alphs, L. (2013). Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. *Schizophrenia Research*, 143(2-3), 312-318. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/871/CN-00877871/frame.html> doi:10.1016/j.schres.2012.11.031
- Pandina, G., Lane, R., Gopal, S., Gassman-Mayer, C., Hough, D., & Remmerie, B. (2010). A randomized, double-blind, study of flexible doses of paliperidone palmitate and risperidone long-acting therapy in patients with schizophrenia. *Biological Psychiatry*, 67(9), 77-78. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/619/CN-00773619/frame.html>
- Pandina, G., Lane, R., Gopal, S., Gassmann-Mayer, C., Hough, D., Remmerie, B., & Simpson, G. (2011). A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 35(1), 218-226. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/724/CN-00779724/frame.html> doi:10.1016/j.pnpbp.2010.11.008
- Panizzutti, R., Hamilton, S. P., & Vinogradov, S. (2013). Genetic correlate of cognitive training response in schizophrenia. *Neuropharmacology*, 64, 264-267. doi:<https://dx.doi.org/10.1016/j.neuropharm.2012.07.048>
- Pankowski, S., Svanborg, C., Adler, M., Andersson, G., & Lindefors, N. (2014). A new CBT-treatment for bipolar disorder-results from a pilot-study and plan for further testing of the model including an internetmediated support system. *Bipolar disorders*, 16, 127-128. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/733/CN-01010733/frame.html> doi:10.1111/bdi.12189

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Parellada, E., Bioque, M., Herrera, B., & Garcia-Dorado, M. (2016). Real-world paliperidone palmitate data from acute units: the SHADOW study. *European psychiatry.*, 33, S251. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/391/CN-01160391/frame.html> doi:10.1016/j.eurpsy.2016.01.638

Parker, S., Foley, S., Walker, P., & Dark, F. (2013). Improving the social cognitive deficits of schizophrenia: A community trial of Social Cognition and Interaction Training (SCIT). *Australasian Psychiatry*, 21(4), 346-351.
doi:<http://dx.doi.org/10.1177/1039856213486305>

Patel, A., Everitt, B., Knapp, M., Reeder, C., Grant, D., Ecker, C., & Wykes, T. (2006). Schizophrenia patients with cognitive deficits: factors associated with costs. *Schizophrenia Bulletin*, 32(4), 776-785.

Patel, A., Knapp, M., Romeo, R., Reeder, C., Matthiasson, P., Everitt, B., & Wykes, T. (2010). Cognitive remediation therapy in schizophrenia: cost-effectiveness analysis. *Schizophrenia Research*, 120(1-3), 217-224.
doi:<https://dx.doi.org/10.1016/j.schres.2009.12.003>

Patil, S., Zhang, L., Martenyi, F., Lowe, S., Jackson, K., Andreev, B., . . . Schoepp, D. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. *Nature Medicine*, 13(9), 1102-1107.
Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/737/CN-00627737/frame.html>
doi:10.1038/nm1632

Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., . . . Schoepp, D. D. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.[Erratum appears in Nat Med. 2007 Oct;13(10):1264]. *Nature Medicine*, 13(9), 1102-1107.

Paulson, R. I., Clarke, G., Herinckx, H., Kinney, R., Lewis, K., & Oxman, E. (1996). First year outcomes from a randomised trial comparing consumer and non-consumer assertive community treatment teams with usual care CONFERENCE ABSTRACT. *Schizophrenia 1996: breaking down the barriers. 4th international conference, vancouver, B.C., canada. October 6-9, 1996*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/508/CN-00283508/frame.html>

Pavlickova, H., Bremner, S., & Priebe, S. (2015). The effect of financial incentives on adherence to antipsychotic depot medication: does it change over time? *Journal of Clinical Psychiatry*, 76(8), e1029-e1034. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/109/CN-01098109/frame.html>
doi:10.4088/JCP.14m09669

Pedrini, T. D., & Pedrini, B. C. (1972). Intellectualization, Obsessive Ideation, Compulsion: A Bibliography (pp. 4).

Pena, J., Ibarretxe-Bilbao, N., Sanchez, P., Iriarte, M. B., Elizagarate, E., Garay, M. A., . . . Ojeda, N. (2016). Combining social cognitive treatment, cognitive remediation, and functional skills training in schizophrenia: A randomized controlled trial. *npj Schizophrenia*, 2 (no pagination)(16037). doi:<http://dx.doi.org/10.1038/npjschz.2016.37>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Penades, R., Catalan, R., Puig, O., Masana, G., Pujol, N., Navarro, V., . . . Gasto, C. (2010). Executive function needs to be targeted to improve social functioning with Cognitive Remediation Therapy (CRT) in schizophrenia. *Psychiatry Research*, 177(1-2), 41-45. doi:<https://dx.doi.org/10.1016/j.psychres.2009.01.032>
- Penades, R., Catalan, R., Salamero, M., Boget, T., Puig, O., Guarch, J., & Gasto, C. (2006). Cognitive remediation therapy for outpatients with chronic schizophrenia: a controlled and randomized study. *Schizophrenia Research*, 87(1-3), 323-331.
- Penades, R., Pujol, N., Catalan, R., Massana, G., Rametti, G., Garcia-Rizo, C., . . . Junque, C. (2013). Brain effects of cognitive remediation therapy in schizophrenia: a structural and functional neuroimaging study.[Erratum appears in Biol Psychiatry. 2014 Mar 1;75(5):425]. *Biological Psychiatry*, 73(10), 1015-1023. doi:<https://dx.doi.org/10.1016/j.biopsych.2013.01.017>
- Penn, D. L., Meyer, P. S., Evans, E., Wirth, R. J., Cai, K., & Burchinal, M. (2009). A randomized controlled trial of group cognitive-behavioral therapy vs. enhanced supportive therapy for auditory hallucinations. *Schizophrenia Research*, 109(1-3), 52-59. doi:<https://dx.doi.org/10.1016/j.schres.2008.12.009>
- Penn, D. L., Uzenoff, S. R., Perkins, D., Mueser, K. T., Hamer, R., Waldheter, E., . . . Cook, L. (2011). A pilot investigation of the Graduated Recovery Intervention Program (GRIP) for first episode psychosis.[Erratum appears in Schizophr Res. 2012 Oct;141(1):106-7]. *Schizophrenia Research*, 125(2-3), 247-256. doi:<https://dx.doi.org/10.1016/j.schres.2010.08.006>
- Perepletchikova, F., Nathanson, D., Axelrod, S. R., Merrill, C., Walker, A., Grossman, M., . . . Walkup, J. (2017). Randomized clinical trial of dialectical behavior therapy for preadolescent children with disruptive mood dysregulation disorder: Feasibility and outcomes. *Journal of the American Academy of Child & Adolescent Psychiatry*, 56(10), 832-840. doi:<http://dx.doi.org/10.1016/j.jaac.2017.07.789>
- Peters, E., Landau, S., McCrone, P., Cooke, M., Fisher, P., Steel, C., . . . Kuipers, E. (2010). A randomised controlled trial of cognitive behaviour therapy for psychosis in a routine clinical service. *Acta Psychiatrica Scandinavica*, 122(4), 302-318. doi:<https://dx.doi.org/10.1111/j.1600-0447.2010.01572.x>
- Peters-Strickland, T., Fleischhacker, W., Sanchez, R., Jin, N., Baker, R., Johnson, B., . . . Kane, J. (2013). Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole. *European neuropsychopharmacology*, 23, S473-s474. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/766/CN-01024766/frame.html> doi:10.1016/S0924-977X%2813%2970750-8
- Peters-Strickland, T., Jin, N., Such, P., & Salzman, P. (2017). Sustained remission and symptom stability in patients with schizophrenia receiving aripiprazole once-monthly: a 52-week, open-label, maintenance study. *European neuropsychopharmacology. Conference: 30th european college of neuropsychopharmacology congress, ECNP 2017*.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

France, 27(Supplement 4), S942-s943. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/553/CN-01428553/frame.html>

Phillips, L. J., Edwards, J., McMurray, N., & Francey, S. (2012). Comparison of experiences of stress and coping between young people at risk of psychosis and a non-clinical cohort. *Behavioural & Cognitive Psychotherapy, 40*(1), 69-88.
doi:<https://dx.doi.org/10.1017/S1352465811000397>

Phillips, L. J., Nelson, B., Yuen, H. P., Francey, S. M., Simmons, M., Stanford, C., . . . McGorry, P. D. (2009). Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. *Australian & New Zealand Journal of Psychiatry, 43*(9), 818-829.
doi:<https://dx.doi.org/10.1080/00048670903107625>

Pijnenborg, G., Vos, A., Meer, L., Sportel, E., Bockting, C., Gaag, M., & Aleman, A. (2014). Reflex: a metacognitive group treatment to improve insight in psychosis. *Schizophrenia Research, 153*, S162. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/027/CN-01050027/frame.html>

Pijnenborg, G., Vos, A., Meer, L., Sportel, E., Bockting, C., Gaag, M., & Aleman, A. (2014). Reflex: results of a metacognitive group treatment to improve insight in psychosis (correct version of the abstract this replaces the previously submitted abstract on reflex). *Schizophrenia Research, 153*, S354. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/014/CN-01050014/frame.html>

Pijnenborg, G. H., Van der Gaag, M., Bockting, C. L., Van der Meer, L., & Aleman, A. (2011). REFLEX, a social-cognitive group treatment to improve insight in schizophrenia: study protocol of a multi-center RCT. *BMC Psychiatry, 11*, 161.
doi:<https://dx.doi.org/10.1186/1471-244X-11-161>

Pijnenborg, M., Meer, L., Vos, A., Bockting, C., Gaag, M., & Aleman, A. (2013). REFLEX: a metacognitive group treatment to improve insight in psychosis. *Schizophrenia bulletin, 39*, S349. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/228/CN-01007228/frame.html> doi:10.1093/schbul/sbt011

Pijnenborg, M., Vos, A., Meer, L., Bockting, C., Gaag, M., & Aleman, A. (2015). REFLEX: a metacognitive group treatment to improve insight in psychosis and to reduce self-stigma. *European archives of psychiatry and clinical neuroscience, 265*(1 suppl. 1), S72. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/558/CN-01139558/frame.html>

Pinninti, N. R., Rissmiller, D. J., & Steer, R. A. (2010). Cognitive-behavioral therapy as an adjunct to second-generation antipsychotics in the treatment of schizophrenia. *Psychiatric Services, 61*(9), 940-943.
doi:<https://dx.doi.org/10.1176/ps.2010.61.9.940>

Pino, M. C., Pettinelli, M., Clementi, D., Gianfelice, C., & Mazza, M. (2015). Improvement in cognitive and affective theory of mind with observation and imitation treatment in subjects with schizophrenia. *Clinical Neuropsychiatry, 12*(3), 64-72.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Pinto, A., La Pia, S., Mennella, R., Giorgio, D., & DeSimone, L. (1999). Cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. *Psychiatric Services, 50*(7), 901-904.
- Pitschel-Walz, G., Bauml, J., Frobese, T., Gsotschneider, A., & Jahn, T. (2009). Do individuals with schizophrenia and a borderline intellectual disability benefit from psychoeducational groups? *Journal of Intellectual Disabilities, 13*(4), 305-320. doi:<https://dx.doi.org/10.1177/1744629509353237>
- Poletti, S., Anselmetti, S., Bechi, M., Ermoli, E., Bosia, M., Smeraldi, E., & Cavallaro, R. (2010). Computer-aided neurocognitive remediation in schizophrenia: durability of rehabilitation outcomes in a follow-up study. *Neuropsychological Rehabilitation, 20*(5), 659-674. doi:<https://dx.doi.org/10.1080/09602011003683158>
- Popov, T., Jordanov, T., Rockstroh, B., Elbert, T., Merzenich, M. M., & Miller, G. A. (2011). Specific cognitive training normalizes auditory sensory gating in schizophrenia: a randomized trial. *Biological Psychiatry, 69*(5), 465-471. doi:<https://dx.doi.org/10.1016/j.biopsych.2010.09.028>
- Posner, M. I. (1987). Structures and Functions of Selective Attention (pp. 59).
- Potkin, S., Loze, J., Forray, C., Baker, R., Sapin, C., Peters-Strickland, T., . . . Naber, D. (2015). Aripiprazole once-monthly is superior to paliperidone palmitate: results from QUALIFY, a randomized, head-to-head clinical study in schizophrenia. *European neuropsychopharmacology, 25*, S529-s530. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/191/CN-01163191/frame.html>
- Potkin, S., Loze, J., Forray, C., Baker, R., Sapin, C., Peters-Strickland, T., . . . Naber, D. (2015). Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY, a head-to-head study in schizophrenia. *European neuropsychopharmacology, 25*, S526. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/195/CN-01163195/frame.html>
- Potkin, S., Loze, J.-Y., Forray, C., Baker, R., Sapin, C., Peters-Strickland, T., . . . Naber, D. (2016). Work readiness after treatment with aripiprazole once-monthly and paliperidone palmitate: results from qualify, a head-to-head study in schizophrenia. *CNS spectrums. Conference: 11th annual neuroscience education institute psychopharmacology congress, NEI 2015. United states, 21*(1), 90-91. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/013/CN-01430013/frame.html> doi:10.1017/S1092852915000905
- Potkin, S., Loze, J.-Y., Forray, C., Baker, R., Sapin, C., Peters-Strickland, T., . . . Naber, D. (2015). Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning: a post-hoc analysis of QUALIFY, a head-to-head study in schizophrenia. *Neuropsychopharmacology, 40*, S392-s393. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/093/CN-01163093/frame.html> doi:10.1038/npp.2015.326

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Potkin, S., Loze, J.-Y., Forray, C., Baker, R., Sapin, C., Peters-Strickland, T., . . . Naber, D. (2016). Reduced sexual dysfunction with aripiprazole once-monthly vs paliperidone palmitate: results from qualify, a head-to-head study in schizophrenia. *CNS spectrums. Conference: 11th annual neuroscience education institute psychopharmacology congress, NEI 2015. United states*, 21(1), 97. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/003/CN-01430003/frame.html> doi:10.1017/S1092852915000905
- Potkin, S., Loze, J.-Y., Forray, C., Baker, R., Sapin, C., Peters-Strickland, T., . . . Naber, D. (2016). Effects of aripiprazole once-monthly and paliperidone palmitate on qls domain scores: results from qualify, a randomized head-to-head clinical study. *CNS spectrums. Conference: 11th annual neuroscience education institute psychopharmacology congress, NEI 2015. United states*, 21(1), 94-95. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/008/CN-01430008/frame.html> doi:10.1017/S1092852915000905
- Potkin, S., Loze, J.-Y., Forray, C., Baker, R., Sapin, C., Peters-Strickland, T., . . . Naber, D. (2016). Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. *CNS spectrums. Conference: 11th annual neuroscience education institute psychopharmacology congress, NEI 2015. United states*, 21(1), 91-92. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/011/CN-01430011/frame.html> doi:10.1017/S1092852915000905
- Potkin, S., Nitschky, S. S., Salzman, P., Such, P., Ettrup, A., Eramo, A., . . . Naber, D. (2016). Effect sizes of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia: a post-hoc analysis of QUALIFY. *European neuropsychopharmacology. Conference: 29th european college of neuropsychopharmacology congress, ECNP 2016. Austria. Conference start: 20160917. Conference end: 20160920, 26, S564-s565*. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/842/CN-01303842/frame.html>
- Potkin, S., Raoufinia, A., Mallikaarjun, S., Bricmont, P., Peters-Strickland, T., Kasper, W., . . . McQuade, R. (2013). Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. *Current medical research and opinion*, 29(10), 1241-1251. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/842/CN-00996842/frame.html> doi:10.1185/03007995.2013.821973
- Potkin, S., Risinger, R., Du, Y., Zummo, J., Bose, A., Silverman, B., . . . Ehrlich, E. (2017). Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. *Schizophrenia research. (no pagination)*, 2017, Date of Publication: October 28. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/553/CN-01371553/frame.html> doi:10.1016/j.schres.2017.03.003

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Pot-Kolder, R. M., Geraets, C. N., Veling, W., van Beilen, M., Staring, A. B., Gijsman, H. J., . . . van der Gaag, M. (2018). Virtual-reality-based cognitive behavioural therapy versus waiting list control for paranoid ideation and social avoidance in patients with psychotic disorders: A single-blind randomised controlled trial. *The Lancet Psychiatry*, 5(3), 217-226. doi:<http://dx.doi.org/10.1016/S2215-0366%2818%2930053-1>
- Powell, S. (2003). *Special Teaching in Higher Education: Successful Strategies for Access and Inclusion*: Stylus Publishing LLC, P.O. Box 605, Herndon, VA 20172-0605 (paperback: ISBN-0-7494-3611-5, \$32.50; clothbound: ISBN-0-7494-3610-7, \$75).
- Power, P. J., Bell, R. J., Mills, R., Herrman-Doig, T., Davern, M., Henry, L., . . . McGorry, P. D. (2003). Suicide prevention in first episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. *Australian & New Zealand Journal of Psychiatry*, 37(4), 414-420.
- Praag, H., Schut, T., Dols, L., & Schilfgaarden, R. (1971). Controlled trial of penfluridol in acute psychosis. *British medical journal*, 4(5789), 710-713. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/565/CN-00006565/frame.html>
- Premoli, I., Castellanos, N., Rivolta, D., Belardinelli, P., Bajo, R., Zipser, C., . . . Ziemann, U. (2014). TMS-EEG signatures of GABAergic neurotransmission in the human cortex. *Journal of neuroscience*, 34(16), 5603-5612. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/559/CN-00988559/frame.html>
doi:10.1523/JNEUROSCI.5089-13.2014
- Priebe, S., Yeeles, K., Bremner, S., Lauber, C., Eldridge, S., Ashby, D., . . . Burns, T. (2013). Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial. *BMJ (Clinical research ed.)*, 347, f5847. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/182/CN-00909182/frame.html>
- Puig, O., Penades, R., Baeza, I., De la Serna, E., Sanchez-Gistau, V., Bernardo, M., & Castro-Fornieles, J. (2014). Cognitive remediation therapy in adolescents with early-onset schizophrenia: a randomized controlled trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, 53(8), 859-868.
doi:<https://dx.doi.org/10.1016/j.jaac.2014.05.012>
- Pyle, M., Norrie, J., Schwannauer, M., Kingdon, D., Gumley, A., Turkington, D., . . . Morrison, A. P. (2016). Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial. *BMC Psychiatry*, 16, 280. doi:<https://dx.doi.org/10.1186/s12888-016-0983-6>
- Quiroz, J., Rusch, S., Thyssen, A., Palumbo, J., & Kushner, S. (2011). Deltoid injections of risperidone long-acting injectable in patients with schizophrenia. *Innovations in clinical neuroscience*, 8(6), 20-28. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/312/CN-00894312/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Quitkin, F., Rifkin, A., Kane, J., Ramos-Lorenzi, J., & Klein, D. (1978). Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics. *Archives of General Psychiatry*, 35(7), 889-892. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/618/CN-00018618/frame.html>

Quitkin, F., Rifkin, A., & Klein, D. (1977). A one-year double-blind comparison of long-acting oral (penfluridol) versus long-acting injectable (fluphenazine decanoate) antipsychotic drugs in multiple-episode schizophrenics. *Psychopharmacology bulletin*, 13(3), 27-29. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/449/CN-00016449/frame.html>

Rakitzi, S., Georgila, P., Efthimiou, K., & Mueller, D. R. (2016). Efficacy and feasibility of the Integrated Psychological Therapy for outpatients with schizophrenia in Greece: Final results of a RCT. *Psychiatry Research*, 242, 137-143. doi:<https://dx.doi.org/10.1016/j.psychres.2016.05.039>

Ranjbar, F., Sadeghi-Bazargani, H., Khams, P., Arfaie, A., Salari, A., & Farahbakhsh, M. (2015). Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia. *Neuropsychiatric Disease and Treatment*, 11, 549-555. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/918/CN-01051918/frame.html> doi:10.2147/NDT.S69088

Rathod, S., Phiri, P., Harris, S., Underwood, C., Thagadur, M., Padmanabi, U., & Kingdon, D. (2013). Cognitive behaviour therapy for psychosis can be adapted for minority ethnic groups: a randomised controlled trial. *Schizophrenia Research*, 143(2-3), 319-326. doi:<https://dx.doi.org/10.1016/j.schres.2012.11.007>

Rattner, L. (1990). *The Borderline Personality--An Adlerian Overview*. Retrieved from <http://ez.library.latrobe.edu.au/login?url=https://search.proquest.com/docview/62965507?accountid=12001> http://ap01.alma.exlibrisgroup.com/view/uresolver/61LATROBE_INST/openurl?ctx_enc=info:ofi/enc:UTF-8&ctx_ver=Z39.88-2004&url_ctx_fmt=info:ofi/fmt:kev:mtx:ctx&url_ver=Z39.88-2004&rft.genre=unknown&rft.atitle=&rft.jtitle=&rft.btitle=The+Borderline+Personality--An+Adlerian+Overview.&rft.aulast=Rattner&rft.auinitm=&rft.ausuffix=&rft.au=Rattner%2C+Leo&rft.date=1990&rft.volume=&rft.issue=&rft.quarter=&rft.ssn=&rft.spage=&rft.epage=&rft.pages=&rft.artnum=&rft.issn=&rft.eissn=&rft.isbn=&rft.sici=&rft.coden=&rft_id=info:doi/&rft.object_id=&rft.eisbn=&rft.edition=&rft.pub=The+Borderline+Personality--An+Adlerian+Overview.&rft.place=&rft.series=&rft.stitle=&rft.bici=&rft_id=info:bibcode/&rft_id=info:hdl/&rft_id=info:lccn/&rft_id=info:oclcnum/&rft_id=info:pmid/&rft_id=info:eric/ED322449

Rauch, S., Olson, E., Buchholz, J., Rosso, I., Killgore, W., Webb, C., & Gogel, H. (2014). Internet-based cognitive behavioral therapy effects on symptom severity in major depressive disorder: preliminary results from a randomized controlled

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- trial. *Neuropsychopharmacology*, 39, S358-s359. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/913/CN-01040913/frame.html> doi:10.1038/npp.2014.281
- Rector, N. A., Seeman, M. V., & Segal, Z. V. (2003). Cognitive therapy for schizophrenia: a preliminary randomized controlled trial. *Schizophrenia Research*, 63(1-2), 1-11.
- Reeder, C., Newton, E., Frangou, S., & Wykes, T. (2004). Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program. *Schizophrenia Bulletin*, 30(1), 87-100.
- Reeder, C., Pile, V., Crawford, P., Cellia, M., Rose, D., Wykes, T., . . . Callard, F. (2016). The Feasibility and Acceptability to Service Users of CIRCuiTS, a Computerized Cognitive Remediation Therapy Programme for Schizophrenia. *Behavioural & Cognitive Psychotherapy*, 44(3), 288-305. doi:<https://dx.doi.org/10.1017/S1352465815000168>
- Reeder, C., Smedley, N., Butt, K., Bogner, D., & Wykes, T. (2006). Cognitive predictors of social functioning improvements following cognitive remediation for schizophrenia. *Schizophrenia Bulletin*, 32 Suppl 1, S123-131.
- Rees, C. S., Hasking, P., Breen, L. J., Lipp, O. V., & Mamotte, C. (2015). Group mindfulness based cognitive therapy vs group support for self-injury among young people: study protocol for a randomised controlled trial. *BMC Psychiatry*, 15, 154. doi:<https://dx.doi.org/10.1186/s12888-015-0527-5>
- Reeves, K., Swift, R., & Harrigan, E. (1998). A comparison of rapid-acting intramuscular (im) ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation. *9th congress of the association of european psychiatrists. Copenhagen, denmark. 20-24th september 1998*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/561/CN-00660561/frame.html>
- Reeves, K., Swift, R., & Harrigan, E. (1998). Intramuscular ziprasidone 10 mg and 20 mg in patients with psychosis and acute agitation. *9th congress of the association of european psychiatrists. Copenhagen, denmark. 20-24th september 1998*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/035/CN-00658035/frame.html>
- Reeves, K., Swift, R., & Harrigan, E. (1998). A randomized, double-blind comparison of rapid-acting, intramuscular ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation. *11th european college of neuropsychopharmacology congress*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/010/CN-00240010/frame.html>
- Reeves, K., Swift, R., & Harrigan, E. (1998). A randomized, double-blind comparison of rapid-acting, intramuscular ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation CONFERENCE ABSTRACT. *11th european college of neuropsychopharmacology congress. Paris, france. 31st october - 4th november 1998*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/917/CN-00283917/frame.html>
- Reeves, K., Swift, R., & Harrigan, E. (1998). Rapid-acting intramuscular ziprasidone 10 mg and 20 mg in patients with psychosis and acute agitation*. *Xsist collegium internationale neuro-psychopharmacologicum, glasgow, scotland. 12th-16th july, 1998*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/617/CN-00654617/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Reeves, K., Swift, R., & Harrigan, E. (1998). Ziprasidone Intramuscular 10 mg and 20 mg in Acute Agitation. *151st annual meeting of the american psychiatric association. Toronto, ontario, canada. 30th may-4th june 1998.*, (Nr494).

Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/749/CN-00655749/frame.html>

Reeves, K., Swift, R., & Harrigan, E. (1999). A COMPARISON OF RAPID-ACTING, INTRAMUSCULAR ZIPRASIDONE (2mg AND 20 mg) IN PATIENTS WITH PSYCHOSIS AND ACUTE AGITATION. *Schizophrenia research (abstracts on the viith international congress on schizophrenia research, santa fe new mexico USA. 17-21 april 1999.)*, 1-3(Spec). Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/567/CN-00660567/frame.html>

Reeves, K., Swift, R., & Harrigan, E. (1999). A COMPARISON OF RAPID-ACTING, INTRAMUSCULAR ZIPRASIDONE (2mg AND 20 mg) IN PATIENTS WITH PSYCHOSIS AND ACUTE AGITATION CONFERENCE ABSTRACT. *Schizophrenia research (abstracts on the viith international congress on schizophrenia research, santa fe new mexico USA. 17-21 april 1999.)*, 1-3(293). Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/912/CN-00283912/frame.html>

Reichmann, H. (2013). The patient with advanced Parkinson's disease. *Journal of neurology.*, 260, S6-s7. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/214/CN-01006214/frame.html> doi:10.1007/s00415-013-6924-0

Rein, W. (1995). Acute and Long-term Treatment of Schizophrenia: different Strategies for Positive and Negative Symptoms? CONFERENCE ABSTRACT. *8th european college of neuropsychopharmacology congress. Venice, italy. 30th september - 4th october, 1995.* Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/927/CN-00283927/frame.html>

Remmerie, B., Meulder, M., Ariyawansa, J., & Savitz, A. (2016). Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole. *Clinical pharmacology in drug development*, 5(6), 538-547. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/495/CN-01288495/frame.html> doi:10.1002/cpdd.291

Resick, P. A., Wachen, J. S., Dondanville, K. A., Pruiksma, K. E., Yarvis, J. S., Peterson, A. L., . . . Young-McCaughan, S. (2017). Effect of Group vs Individual Cognitive Processing Therapy in Active-Duty Military Seeking Treatment for Posttraumatic Stress Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*, 74(1), 28-36. doi:<https://dx.doi.org/10.1001/jamapsychiatry.2016.2729>

Ribeiro, S., Araujo, A., Medeiros, C., Chaves, K., Alves, M., Oliveira, A., & Martins, R. (2017). Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics. *European journal of clinical pharmacology*, 73(3), 351-355. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/010/CN-01328010/frame.html> doi:10.1007/s00228-016-2166-2

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Ricarte, J. J., Hernandez-Viadel, J. V., Latorre, J. M., Ros, L., & Serrano, J. P. (2014). Effects of specific positive events training on autobiographical memories in people with schizophrenia. *Cognitive Therapy and Research, 38*(4), 407-415.
doi:<http://dx.doi.org/10.1007/s10608-014-9610-3>
- Richards, D. A., Ekers, D., McMillan, D., Taylor, R. S., Byford, S., Warren, F. C., . . . Finning, K. (2016). Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-inferiority trial. *Lancet, 388*(10047), 871-880. doi:[https://dx.doi.org/10.1016/S0140-6736\(16\)31140-0](https://dx.doi.org/10.1016/S0140-6736(16)31140-0)
- Riehle, M., Jung, E., Wiesjahn, M., Mehl, S., Rief, W., & Lincoln, T. M. (2015). What's in an item? Predicting social outcomes in schizophrenia spectrum disorders from the PANSS item "Poor Rapport". *Schizophrenia Research, 168*(1-2), 593-594. doi:<http://dx.doi.org/10.1016/j.schres.2015.08.026>
- Riemann, D., Hohagen, F., Krieger, S., Gann, H., Müller, W., Olbrich, R., . . . Berger, M. (1994). Cholinergic REM induction test: muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia. *Journal of Psychiatric Research, 28*(3), 195-210. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/178/CN-00105178/frame.html>
- Rietdijk, J., Dragt, S., Klaassen, R., Ising, H., Nieman, D., Wunderink, L., . . . van der Gaag, M. (2010). A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. *Trials [Electronic Resource], 11*, 30. doi:<https://dx.doi.org/10.1186/1745-6215-11-30>
- Roberts, D. L., Combs, D. R., Willoughby, M., Mintz, J., Gibson, C., Rupp, B., & Penn, D. L. (2014). A randomized, controlled trial of Social Cognition and Interaction Training (SCIT) for outpatients with schizophrenia spectrum disorders. *British Journal of Clinical Psychology, 53*(3), 281-298. doi:<https://dx.doi.org/10.1111/bjcp.12044>
- Rodewald, K., Holt, D. V., Rentrop, M., Roesch-Ely, D., Liebrenz, M., Funke, J., . . . Kaiser, S. (2014). Predictors for improvement of problem-solving during cognitive remediation for patients with Schizophrenia. *Journal of the International Neuropsychological Society, 20*(4), 455-460. doi:<https://dx.doi.org/10.1017/S1355617714000162>
- Rodewald, K., Rentrop, M., Holt, D. V., Roesch-Ely, D., Backenstrass, M., Funke, J., . . . Kaiser, S. (2011). Planning and problem-solving training for patients with schizophrenia: a randomized controlled trial. *BMC Psychiatry, 11*, 73. doi:<https://dx.doi.org/10.1186/1471-244X-11-73>
- Rodriguez, S., Bossie, C., & Lasser, R. (2003). Long-Acting Risperidone in Hospital Inpatients With Schizophrenia. *156th annual meeting of the american psychiatric association, may 17-22, san francisco CA, Nr170*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/489/CN-00659489/frame.html>
- Rodriguez, S., Lasser, R., Turkoz, I., Mahableshwarkar, A., Gharabawi, G., Chung, H., & Simpson, G. (2005). Optimized Long-Acting Risperidone Maintenance Therapy. *158th annual meeting of the american psychiatric association; 2005 may*

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

21-26; atlanta, GA, Nr202. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/280/CN-00656280/frame.html>

Rodriguez, S., Lasser, R., Turkoz, I., Urioste, R., Burks, E., & Gharabawi, G. (2004). Long-Term Long-Acting Risperidone: qoL and Functioning in Schizophrenia. *157th annual meeting of the american psychiatric association; 2004 may 1-6; new york, NY*, Nr635. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/284/CN-00658284/frame.html>

Rohde, P., Briere, F. N., & Stice, E. (2018). Major depression prevention effects for a cognitive-behavioral adolescent indicated prevention group intervention across four trials. *Behav Res Ther*, 100, 1-6.
doi:<http://dx.doi.org/10.1016/j.brat.2017.10.013>

Rohde, P., Stice, E., Gau, J. M., & Marti, C. (2012). Reduced substance use as a secondary benefit of an indicated cognitive-behavioral adolescent depression prevention program. *Psychology of Addictive Behaviors*, 26(3), 599-608.
doi:<http://dx.doi.org/10.1037/a0028269>

Rollinson, R., Smith, B., Steel, C., Jolley, S., Onwumere, J., Garety, P. A., . . . Fowler, D. (2008). Measuring adherence in CBT for psychosis: A psychometric analysis of an adherence scale. *Behavioural and Cognitive Psychotherapy*, 36(2), 163-178. doi:<http://dx.doi.org/10.1017/S1352465807003980>

Rosenheck, R., Krystal, J., Lew, R., Barnett, P., Fiore, L., Valley, D., . . . Liang, M. (2011). Long-acting risperidone and oral antipsychotics in unstable schizophrenia. *New England journal of medicine*, 364(9), 842-851. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/698/CN-00778698/frame.html>
doi:[10.1056/NEJMoa1005987](https://doi.org/10.1056/NEJMoa1005987)

Rosenheck, R., Krystal, J., Lew, R., Barnett, P., Thwin, S., Fiore, L., . . . Liang, M. (2011). Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. *Clinical trials (london, england)*, 8(2), 196-204. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/849/CN-00801849/frame.html>
doi:[10.1177/1740774510392931](https://doi.org/10.1177/1740774510392931)

Rosenheck, R., Leslie, D., Sint, K., Lin, H., Li, Y., McEvoy, J., . . . Stroup, T. (2016). Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. *Psychiatric services (washington, D.C.)*, 67(10), 1124-1130. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/503/CN-01214503/frame.html> doi:[10.1176/appi.ps.201500447](https://doi.org/10.1176/appi.ps.201500447)

Rosenheck, R., Tekell, J., Peters, J., Cramer, J., Fontana, A., Xu, W., . . . Charney, D. (1998). Does participation in psychosocial treatment augment the benefit of clozapine? *Archives of General Psychiatry*, 55(7), 618-625. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/913/CN-00152913/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Rosenheck, R., Tekell, J., Peters, J., Cramer, J., Fontana, A., Xu, W., . . . Charney, D. (1998). Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. *Archives of General Psychiatry*, 55(7), 618-625. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/441/CN-00681441/frame.html>
- Rosenthal, R., Miner, C., & Hellerstein, D. (1997). Effects of Targeted Assertive Outreach in Patients with Schizophrenia and Substance Use Disorders CONFERENCE ABSTRACT. *150th annual meeting of the american psychiatric association. San diego, california, USA. 17-22 may, 1997*. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/115/CN-00284115/frame.html>
- Ross, K., Freeman, D., Dunn, G., & Garety, P. (2011). A randomized experimental investigation of reasoning training for people with delusions. *Schizophrenia Bulletin*, 37(2), 324-333. doi:<https://dx.doi.org/10.1093/schbul/sbn165>
- Rossenu, S., Cleton, A., Hough, D., Crauwels, H., Vandebosch, A., Berwaerts, J., . . . Francetic, I. (2015). Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. *Clinical pharmacology in drug development*, 4(4), 270-278. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/962/CN-01085962/frame.html> doi:10.1002/cpdd.144
- Rosso, I., Olson, E., Killgore, W., Fukunaga, R., Webb, C., & Rauch, S. (2015). A randomized trial of internet-based cognitive behavioral therapy for major depressive disorder. *Neuropsychopharmacology*, 40, S170-s171. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/265/CN-01163265/frame.html> doi:10.1038/npp.2015.325
- Roth, W., Horvath, T., Pfefferbaum, A., & Kopell, B. (1980). Event-related potentials in schizophrenics. *Electroencephalogr. Clin. Neurophysiol.*, 48(2), 127-139. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/903/CN-00183903/frame.html>
- Rothe, P., Heres, S., & Leucht, S. (2017). Dose equivalents for second generation long-acting injectable antipsychotics: the minimum effective dose method. *Schizophrenia Research*, (no pagination). Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/211/CN-01395211/frame.html> doi:10.1016/j.schres.2017.07.033
- Rouillon, F., Eriksson, L., Burba, B., Raboch, J., Kaprinis, G., & Schreiner, A. (2013). Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). *Acta neuropsychiatrica*, 25(5), 297-306. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/350/CN-00914350/frame.html> doi:10.1017/neu.2013.7
- Royer, A., Grosselin, A., Bellot, C., Pellet, J., Billard, S., Lang, F., . . . Massoubre, C. (2012). Is there any impact of cognitive remediation on an ecological test in schizophrenia? *Cognitive Neuropsychiatry*, 17(1), 19-35. doi:<https://dx.doi.org/10.1080/13546805.2011.564512>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Rubio, G., Martínez, I., Ponce, G., Jiménez-Arriero, M., López-Muñoz, F., & Alamo, C. (2006). Long-acting injectable risperidone compared with zuclopentixol in the treatment of schizophrenia with substance abuse comorbidity.

Canadian journal of psychiatry. Revue canadienne de psychiatrie, 51(8), 531-539. Retrieved from

<http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/626/CN-00567626/frame.html>

doi:10.1177/070674370605100808

Rudd, M., Bryan, C. J., Wertenberger, E. G., Peterson, A. L., Young-McCaughan, S., Mintz, J., . . . Bruce, T. O. (2015). Brief cognitive-behavioral therapy effects on post-treatment suicide attempts in a military sample: Results of a randomized clinical trial with 2-year follow-up. *The American Journal of Psychiatry*, 172(5), 441-449.

doi:<http://dx.doi.org/10.1176/appi.ajp.2014.14070843>

Rudd, M. D., Bryan, C. J., Wertenberger, E. G., Peterson, A. L., Young-McCaughan, S., Mintz, J., . . . Bruce, T. O. (2015). Brief cognitive-behavioral therapy effects on post-treatment suicide attempts in a military sample: results of a randomized clinical trial with 2-year follow-up. *American Journal of Psychiatry*, 172(5), 441-449.

doi:<https://dx.doi.org/10.1176/appi.ajp.2014.14070843>

Ruedrich, L. S., Swales, P. T., Ross vanes, C., Diana, L., Arkadiev, V., & Lim, K. (2008). Atypical Antipsychotic Medication Improves Aggression, but Not Self-Injurious Behaviour, in Adults with Intellectual Disabilities. *Journal of Intellectual Disability Research*, 52(2), 132-140.

Ruegg, N., Moritz, S., Berger, T., Ludtke, T., & Westermann, S. (2018). An internet-based intervention for people with psychosis (EviBaS): Study protocol for a randomized controlled trial. *BMC Psychiatry* Vol 18 2018, ArtID 102, 18.

Ruggeri, M., Bonetto, C., Lasalvia, A., De Girolamo, G., Fioritti, A., Rucci, P., . . . Soares, J. C. (2012). A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial. *Trials [Electronic Resource]*, 13, 73.

Ruggeri, M., Bonetto, C., Lasalvia, A., Fioritti, A., de Girolamo, G., Santonastaso, P., . . . Group, G. U. (2015). Feasibility and Effectiveness of a Multi-Element Psychosocial Intervention for First-Episode Psychosis: Results From the Cluster-Randomized Controlled GET UP PIANO Trial in a Catchment Area of 10 Million Inhabitants. *Schizophrenia Bulletin*, 41(5), 1192-1203. doi:<https://dx.doi.org/10.1093/schbul/sbv058>

Ruiz, J. C., Fuentes, I., Roder, V., Tomas, P., Dasi, C., & Soler, M. J. (2011). Effectiveness of the cognitive differentiation program of the integrated psychological therapy: group versus individual treatment. *Journal of Nervous & Mental Disease*, 199(12), 978-982. doi:<https://dx.doi.org/10.1097/NMD.0b013e3182392aca>

Rus-Calafell, M., Gutierrez-Maldonado, J., Ortega-Bravo, M., Ribas-Sabate, J., & Caqueo-Urizar, A. (2013). A brief cognitive-behavioural social skills training for stabilised outpatients with schizophrenia: a preliminary study. *Schizophrenia Research*, 143(2-3), 327-336. doi:<https://dx.doi.org/10.1016/j.schres.2012.11.014>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Rutter, K., Etschmaier, A., Ferlitsch, M., Maieron, A., Hametner, S., Horvatits, T., . . . Ferlitsch, A. (2016). von Willebrand factor antigen (vWF-Ag): a non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. *Digestive and liver disease*, 48(10), 1194-1199. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/327/CN-01290327/frame.html> doi:10.1016/j.dld.2016.06.033
- Sabbagh, M., Decourt, B., Liebsack, C., Sirrel, S., Walker, A., Gonzales, A., . . . Belden, C. (2013). A phase II double-blind, placebocontrolled randomized trial of an escalating dose of thalidomide in the treatment of Alzheimer's disease: baseline characteristics. *Alzheimer's and dementia.*, 9(4 suppl. 1), P285. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/645/CN-01058645/frame.html> doi:10.1016/j.jalz.2013.05.575
- Sachser, C., Keller, F., & Goldbeck, L. (2017). Complex PTSD as proposed for ICD-11: Validation of a new disorder in children and adolescents and their response to Trauma-Focused Cognitive Behavioral Therapy. *Journal of Child Psychology and Psychiatry*, 58(2), 160-168. doi:<http://dx.doi.org/10.1111/jcpp.12640>
- Salkever, D., Gibbons, B., & Ran, X. (2014). Do comprehensive, coordinated, recovery-oriented services alter the pattern of use of treatment services? Mental health treatment study impacts on SSDI beneficiaries' use of inpatient, emergency, and crisis services. *Journal of Behavioral Health Services & Research*, 41(4), 434-446. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/727/CN-01118727/frame.html> doi:10.1007/s11414-013-9388-1
- Salkever, D., Gibbons, B., & Ran, X. (2014). Do comprehensive, coordinated, recovery-oriented services alter the pattern of use of treatment services? Mental health treatment study impacts on SSDI beneficiaries' use of inpatient, emergency, and crisis services.[Erratum appears in J Behav Health Serv Res. 2014 Oct;41(4):559]. *Journal of Behavioral Health Services & Research*, 41(4), 434-446. doi:<https://dx.doi.org/10.1007/s11414-013-9388-1>
- Salyers, M., McGuire, A., Rollins, A., Bond, G., Mueser, K., & Macy, V. (2010). Integrating assertive community treatment and illness management and recovery for consumers with severe mental illness. *Community Mental Health Journal*, 46(4), 319-329. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/531/CN-00769531/frame.html> doi:10.1007/s10597-009-9284-6
- Salyers, M. P., McGuire, A. B., Rollins, A. L., Bond, G. R., Mueser, K. T., & Macy, V. R. (2010). Integrating assertive community treatment and illness management and recovery for consumers with severe mental illness. *Community Mental Health Journal*, 46(4), 319-329. doi:<https://dx.doi.org/10.1007/s10597-009-9284-6>
- Salzer, M., Brusilovskiy, E., Prvu-Bettger, J., & Kottsieper, P. (2014). Measuring community participation of adults with psychiatric disabilities: reliability of two modes of data collection. *Rehabilitation Psychology*, 59(2), 211-219. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/338/CN-01051338/frame.html> doi:10.1037/a0036002

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Salzer, M. S., Brusilovskiy, E., Prvu-Bettger, J., & Kottsieper, P. (2014). Measuring community participation of adults with psychiatric disabilities: reliability of two modes of data collection. *Rehabilitation Psychology*, 59(2), 211-219.
doi:<https://dx.doi.org/10.1037/a0036002>
- Salzman, P., Nitschky, S. S., Eramo, A., Hansen, K., Ettrup, A., & Such, P. (2016). Effects of aripiprazole once-monthly and paliperidone palmitate in patients with schizophrenia stratified by disease severity: a post-hoc analysis of QUALIFY. *European neuropsychopharmacology. Conference: 29th european college of neuropsychopharmacology congress, ECNP 2016. Austria. Conference start: 20160917. Conference end: 20160920, 26, S555-s556*. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/752/CN-01303752/frame.html>
- Salzman, P., Potkin, S., Loze, J.-Y., Forray, C., Baker, R., Sapin, C., . . . Naber, D. (2017). Effects of aripiprazole once-monthly and paliperidone palmitate on work readiness in patients from the QUALIFY study stratified by age. *CNS spectrums. Conference: 2016 neuroscience education institute psychopharmacology congress, NEI 2016. United states*, 22(1), 93-94. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/996/CN-01429996/frame.html>
doi:10.1017/S1092852916000900
- Samalin, L., Charpeaud, T., Blanc, O., Heres, S., & Llorca, P. (2013). Clinicians' attitudes toward the use of long-acting injectable antipsychotics. *Journal of Nervous and Mental Disease*, 201(7), 553-559. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/275/CN-00963275/frame.html>
doi:10.1097/NMD.0b013e31829829c4
- Samarasekera, N., Kingdon, D., Siddle, R., O'Carroll, M., Scott, J. L., Sensky, T., . . . Turkington, D. (2007). Befriending patients with medication-resistant schizophrenia: can psychotic symptoms predict treatment response? *Psychology & Psychotherapy: Theory, Research & Practice*, 80(Pt 1), 97-106.
- Sanchez, P., Pena, J., Bengoetxea, E., Ojeda, N., Elizagarate, E., Ezcurra, J., & Gutierrez, M. (2014). Improvements in negative symptoms and functional outcome after a new generation cognitive remediation program: a randomized controlled trial. *Schizophrenia Bulletin*, 40(3), 707-715. doi:<https://dx.doi.org/10.1093/schbul/sbt057>
- Sander, A., Maestas, K., Arciniegas, D., Clark, A., & Sherer, M. (2014). Feasibility of acceptance and commitment therapy for treating emotional distress in persons with traumatic brain injury. *Brain injury*, 28(5-6), 698. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/592/CN-01010592/frame.html>
doi:10.3109/02699052.2014.892379
- Sapin, C., Gimeno, D. L. F. V., Blancher, P., & Beillat, M. (2015). Cost effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate in Spain. *Value in health*, 18(7), A410. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/140/CN-01164140/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Sartory, G., Zorn, C., Groetzinger, G., & Windgassen, K. (2005). Computerized cognitive remediation improves verbal learning and processing speed in schizophrenia. *Schizophrenia Research*, 75(2-3), 219-223.
- Savitz, A., Xu, H., Gopal, S., Nuamah, I., Hough, D., & Hargarter, L. (2016). Symptomatic and functional remission in European patients with schizophrenia after paliperidone palmitate treatment (1-month and 3-month formulations). *European neuropsychopharmacology. Conference: 29th european college of neuropsychopharmacology congress, ECNP 2016. Austria. Conference start: 20160917. Conference end: 20160920, 26, S546-s547*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/790/CN-01303790/frame.html>
- Savitz, A., Xu, H., Gopal, S., Nuamah, I., Ravenstijn, P., Hough, D., . . . Fleischhacker, W. (2016). Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia. *European neuropsychopharmacology. Conference: 29th european college of neuropsychopharmacology congress, ECNP 2016. Austria. Conference start: 20160917. Conference end: 20160920, 26, S548-s549*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/780/CN-01303780/frame.html>
- Saxena, B. (1996). The value of depot neuroleptic injections in the treatment of chronic schizophrenia CONFERENCE ABSTRACT. *Schizophrenia 1996: breaking down the barriers. 4th international conference, vancouver, B.C., canada. October 6-9, 1996*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/342/CN-00284342/frame.html>
- Schachar, R., Ickowicz, A., Crosbie, J., Donnelly, G. A., Reiz, J. L., Miceli, P. C., . . . Darke, A. C. (2008). Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder. *Journal of Child and Adolescent Psychopharmacology*, 18(1), 11-24.
doi:<http://dx.doi.org/10.1089/cap.2007.0039>
- Schaffhauser, J.-Y., Noel, N., Staner, C., Viola, A., Saoud, J., Davidson, M., . . . Luthringer, R. (2016). MIN-101 improves sleep in patients suffering from schizophrenia: a randomized, placebocontrolled, double blind study. *Neuropsychopharmacology. Conference: 55th annual meeting of the american college of neuropsychopharmacology, ACNP 2016. United states. Conference start: 20161204. Conference end: 20161208, 41, S582*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/339/CN-01296339/frame.html>
doi:[10.1038/npp.2016.242](https://doi.org/10.1038/npp.2016.242)
- Schaub, A., Mueser, K. T., von Werder, T., Engel, R., Moller, H. J., & Falkai, P. (2016). A Randomized Controlled Trial of Group Coping-Oriented Therapy vs Supportive Therapy in Schizophrenia: Results of a 2-Year Follow-up. *Schizophrenia Bulletin*, 42 Suppl 1, S71-80. doi:<https://doi.org/10.1093/schbul/sbw032>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Schlosberg, A., & Shadmi, W. (1978). A comparative controlled study of two long-acting phenothiazines: pipotiazine palmitate and fluphenazine decanoate. *Curr ther res, clin exp*, 23(5ii), 642-654. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/829/CN-00198829/frame.html>
- Schneider, B. C., Brune, M., Bohn, F., Veckenstedt, R., Kolbeck, K., Krieger, E., . . . Moritz, S. (2016). Investigating the efficacy of an individualized metacognitive therapy program (MCT+) for psychosis: study protocol of a multi-center randomized controlled trial. *BMC Psychiatry*, 16, 51. doi:<https://dx.doi.org/10.1186/s12888-016-0756-2>
- Schneider, S., Kirby, E., & Itil, T. (1981). Clinical blood chemistry values and long acting phenothiazines. *Pharmacopsychiatry*, 14(3), 107-114. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/547/CN-00190547/frame.html> doi:[10.1055/s-2007-1019579](https://doi.org/10.1055/s-2007-1019579)
- Schooler, N. (2015). Risperidone long-acting injection vs. oral risperidone: analysis of relapse and rehospitalization controlling for switching in a pragmatic trial. *Schizophrenia bulletin.*, 41, S333. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/775/CN-01087775/frame.html> doi:[10.1093/schbul/sbv010](https://doi.org/10.1093/schbul/sbv010)
- Schooler, N., Buckley, P., Mintz, J., Goff, D., Kopelowicz, A., Lauriello, J., . . . Kane, J. (2011). PROACTIVE: initial results of an RCT comparing long-acting injectable risperidone to 2nd generation oral antipsychotics. *Neuropsychopharmacology.*, 36, S104-s105. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/487/CN-01020487/frame.html> doi:[10.1038/npp.2011.291](https://doi.org/10.1038/npp.2011.291)
- Schooler, N., Gopinath, S., Weedon, J., Buckley, P., Goff, D., Kopelowicz, A., . . . Kane, J. (2014). Risperidone long-acting injection vs. Oral risperidone: a secondary analysis of relapse and rehospitalization controlling for switching in a pragmatic trial. *Neuropsychopharmacology.*, 39, S354-s355. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/351/CN-01066351/frame.html> doi:[10.1038/npp.2014.281](https://doi.org/10.1038/npp.2014.281)
- Schooler, N., Levine, J., Severe, J., Brauzer, B., DiMascio, A., Klerman, G., & Tuason, V. (1980). Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. *Archives of General Psychiatry*, 37(1), 16-24. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/957/CN-00021957/frame.html>
- Schreiner, A., Adamsoo, K., Altamura, A., Franco, M., Gorwood, P., Neznanov, N., . . . Hargarter, L. (2015). Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. *Schizophrenia Research*, 169(1-3), 393-399. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/692/CN-01127692/frame.html> doi:[10.1016/j.schres.2015.08.015](https://doi.org/10.1016/j.schres.2015.08.015)
- Schreiner, A., Bergmans, P., Cherubin, P., & Hargarter, L. (2017). Clinical and functional response to paliperidone palmitate in early schizophrenia - A retrospective observational study in newly diagnosed patients treated over a 12-month period. *Australian and new zealand journal of psychiatry. Conference: royal australian and new zealand college of psychiatrists, RANZCP annual congress 2017. Australia*, 51(1 Supplement 1), 151. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/775/CN-01087775/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

<http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/711/CN-01375711/frame.html>

doi:10.1177/0004867417702054

Schreiner, A., Bergmans, P., Cherubin, P., & Hargarter, L. (2017). Early schizophrenia patients treated with once-monthly paliperidone palmitate over a 12-month period - A retrospective observational study. *Australian and new zealand journal of psychiatry. Conference: royal australian and new zealand college of psychiatrists, RANZCP annual congress 2017. Australia*, 51(1 Supplement 1), 150-151. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/713/CN-01375713/frame.html> doi:10.1177/0004867417702054

Schreiner, A., Bergmans, P., Cherubin, P., & Hargarter, L. (2017). The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole. *Therapeutic advances in psychopharmacology*, 7(2), 59-65. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/523/CN-01339523/frame.html> doi:10.1177/2045125316673012

Schreiner, A., Caspi, A., Bergmans, P., Cherubin, P., Keim, S., Lara, E., . . . Hargarter, L. (2016). Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: a prospective, open-label, interventional study. *Psychopharmacology*, 1-11. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/641/CN-01248641/frame.html> doi:10.1007/s00213-016-4445-0

Schreiner, A., Caspi, A., Bergmans, P., Cherubin, P., Keim, S., Lara, E., . . . Hargarter, L. (2017). Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: a prospective, open-label, interventional study. *Psychopharmacology*, 234(1), 3-13. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/786/CN-01332786/frame.html> doi:10.1007/s00213-016-4445-0

Schuster, R. M., Cather, C., Pachas, G. N., Zhang, H., Cieslak, K. M., Hoeppner, S. S., . . . Eden Evins, A. (2017). Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy. *Addictive Behaviors*, 71, 89-95.
doi:<http://dx.doi.org/10.1016/j.addbeh.2017.02.028>

Scogin, F., Morthland, M., Kaufman, A., Burgio, L., Chaplin, W., & Kong, G. (2007). Improving quality of life in diverse rural older adults: a randomized trial of a psychological treatment. *Psychology & Aging*, 22(4), 657-665.
doi:<https://dx.doi.org/10.1037/0882-7974.22.4.657>

Segarra, R., Ojeda, N., Garcia, J., Pena, J., Bravo, E., & Eguiluz, J. (2010). Risperidone injectable long-acting treatment vs other oral antipsychotics in first episode psychosis: one year longitudinal study. *Schizophrenia Research*, 117(2-3), 495.
Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/131/CN-00776131/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Sellbom, M., Bagby, M. R., Kushner, S., Quilty, L. C., & Ayearst, L. E. (2012). Diagnostic Construct Validity of MMPI-2 Restructured Form (MMPI-2-RF) Scale Scores. *Assessment, 19*(2), 176-186.
- Sellwood, W., Barrowclough, C., Tarrier, N., Quinn, J., Mainwaring, J., & Lewis, S. (2001). Needs-based cognitive-behavioural family intervention for carers of patients suffering from schizophrenia: 12-month follow-up. *Acta Psychiatrica Scandinavica, 104*(5), 346-355.
- Sellwood, W., Wittkowski, A., Tarrier, N., & Barrowclough, C. (2007). Needs-based cognitive-behavioural family intervention for patients suffering from schizophrenia: 5-year follow-up of a randomized controlled effectiveness trial. *Acta Psychiatrica Scandinavica, 116*(6), 447-452.
- Sensky, T., Turkington, D., Kingdon, D., Scott, J. L., Scott, J., Siddle, R., . . . Barnes, T. R. (2000). A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. *Archives of General Psychiatry, 57*(2), 165-172.
- Shafrin, J., May, S., Shrestha, A., Ruetsch, C., Gerlanc, N., Forma, F., . . . Lindenmayer, J.-P. (2017). Access to credible information on schizophrenia patients' medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers. *Patient preference and adherence, 11*, 1071-1081. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/251/CN-01396251/frame.html>
doi:10.2147/PPA.S135957
- Shafti, S., Jafarabad, M., & Azizi, R. (2015). Tackling negative symptoms in male patients with schizophrenia using a norepinephrine reuptake inhibitor. *Klinik psikofarmakoloji bulteni, 25*(4), 326-332. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/772/CN-01128772/frame.html>
doi:10.5455/bcp.20150511053723
- Sharip, S., Michie, P., Schall, U., Drysdale, K., Case, V., Sankaranarayanan, A., . . . Das, S. (2013). Generalization of cognitive training in an Australian sample of schizophrenia patients. *Comprehensive Psychiatry, 54*(7), 865-872.
doi:<https://dx.doi.org/10.1016/j.comppsych.2013.03.015>
- Sharma, T., Hughes, C., Aasen, I., & Kumari, V. (2005). An investigation of cognitive effects of rivastigmine in schizophrenia. *158th annual meeting of the american psychiatric association; 2005 may 21-26; atlanta, GA, No. 87*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/333/CN-00543333/frame.html>
- Sharma, T., Reed, C., Aasen, I., & Kumari, V. (2006). Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. *Schizophrenia Research, 85*(1-3), 73-83.
- Sharma, T., Reed, C., Aasen, I., & Kumari, V. (2006). Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. *Schizophrenia Research,*

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

85(1-3), 73-83. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/874/CN-00570874/frame.html> doi:10.1016/j.schres.2006.03.037

Shawyer, F., Farhall, J., Mackinnon, A., Trauer, T., Sims, E., Ratcliff, K., . . . Copolov, D. (2012). A randomised controlled trial of acceptance-based cognitive behavioural therapy for command hallucinations in psychotic disorders. *Behaviour Research & Therapy*, 50(2), 110-121. doi:<https://dx.doi.org/10.1016/j.brat.2011.11.007>

Shawyer, F., Farhall, J., Mackinnon, A., Trauer, T., Sims, E., Ratcliff, K., . . . Copolov, D. (2012). A randomised controlled trial of acceptance-based cognitive behavioural therapy for command hallucinations in psychotic disorders. *Behav Res Ther*, 50(2), 110-121. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/145/CN-00971145/frame.html> doi:10.1016/j.brat.2011.11.007

Shawyer, F., Farhall, J., Thomas, N., Hayes, S., Gallop, R., Copolov, D., & Castle, D. (2017). Acceptance and commitment therapy for psychosis: randomised controlled trial. *British Journal of Psychiatry*, 210(2), 140-148. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/671/CN-01308671/frame.html> doi:10.1192/bjp.bp.116.182865

Shawyer, F., Farhall, J., Thomas, N., Hayes, S. C., Gallop, R., Copolov, D., & Castle, D. J. (2017). Acceptance and commitment therapy for psychosis: randomised controlled trial. *British Journal of Psychiatry*, 210(2), 140-148. doi:<https://dx.doi.org/10.1192/bjp.bp.116.182865>

She, S., Deng, Y., Chen, Y., Wu, C., Yi, W., Lu, X., . . . Zheng, Y. (2017). Two-stage integrated care versus antipsychotic medication alone on outcomes of schizophrenia: One-year randomized controlled trial and follow-up. *Psychiatry Research*, 254, 164-172. doi:<https://dx.doi.org/10.1016/j.psychres.2017.04.054>

Shiozawa, P., Gomes, J. S., Ducos, D. V., Akiba, H. T., Dias, A. M., Trevizol, A. P., . . . Cordeiro, Q. (2016). Effect of transcranial direct current stimulation (tDCS) over the prefrontal cortex combined with cognitive training for treating schizophrenia: a sham-controlled randomized clinical trial. *Trends in Psychiatry & Psychotherapy*, 38(3), 175-177. doi:<https://dx.doi.org/10.1590/2237-6089-2015-0043>

Shomaker, L. B., Kelly, N. R., Pickworth, C. K., Cassidy, O. L., Radin, R. M., Shank, L. M., . . . Yanovski, J. A. (2016). A randomized controlled trial to prevent depression and ameliorate insulin resistance in adolescent girls at risk for type 2 diabetes. *Annals of Behavioral Medicine*, 50(5), 762-774. doi:<http://dx.doi.org/10.1007/s12160-016-9801-0>

Si, T., Su, Y., Liu, Y., Zhang, H., Li, H., Rui, Q., & Shu, L. (2014). Pharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjects. *Human psychopharmacology*, 29(2), 203-210. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/474/CN-00981474/frame.html> doi:10.1002/hup.2388

Sibinga, E., Webb, L., & Ellen, J. (2017). Mindfulness instruction improves anger regulation in US urban male youth. *BMC complementary and alternative medicine. Conference: world congress integrative medicine and health 2017. Germany*,

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

17(Supplement 1) (no pagination). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/570/CN-01442570/frame.html> doi:10.1186/s12906-017-1783-3

Siegel, E. Y., Haller, M., Cui, R., Trim, R. S., Tate, S. R., & Norman, S. B. (2017). Examining changes in negative mood regulation expectancies, posttraumatic stress disorder, depression, and substance use following integrated cognitive-behavioral therapy. *Substance Abuse*, 38(4), 468-472. doi:<http://dx.doi.org/10.1080/08897077.2017.1342736>

Sigrunarson, V., Grawe, R. W., & Morken, G. (2013). Integrated treatment vs. treatment-as-usual for recent onset schizophrenia; 12 year follow-up on a randomized controlled trial. *BMC Psychiatry*, 13, 200. doi:<https://dx.doi.org/10.1186/1471-244X-13-200>

Silber, E., Arnstein, R. L., Backus, V., Eddy, H. P., Liptzin, M. B., Notman, M. T., . . . Wenger, R. E. (1999). *Helping Students Adapt to Graduate School: Making the Grade*: Haworth Press, , 10 Alice Street, Binghamton, NY 13904-1580 (hardbound: ISBN-0-7890-0960-9, \$34.95; paperbound: ISBN-0-7980-0978-1, \$19.95).

Silberberg, G., Ben-Shachar, D., & Navon, R. (2010). Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder. *American journal of medical genetics, part B: neuropsychiatric genetics*, 153(7), 1318-1328. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/880/CN-00914880/frame.html> doi:10.1002/ajmg.b.31112

Silberstein, R., Mandell, W., Dalack, J., & Cooper, A. (1968). Avoiding institutionalization of psychotic children. *Archives of General Psychiatry*, 19(1), 17-21. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/104/CN-00002104/frame.html>

Silver, H., & Shmugliakov, N. (1998). Adding fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia. Evidence for a specific serotonergic mechanism. *Xxist collegium internationale neuro-psychopharmacologicum, glasgow, scotland. 12th-16th july, 1998*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/217/CN-00658217/frame.html>

Silver, H., & Shmugliakov, N. (1998). Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. *Journal of Clinical Psychopharmacology*, 18(3), 208-211. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/303/CN-00684303/frame.html>

Silverstein, S. M., Hatashita-Wong, M., Solak, B. A., Uhlhaas, P., Landa, Y., Wilkniss, S. M., . . . Smith, T. E. (2005). Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients. *Psychological Medicine*, 35(6), 829-837.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Silverstein, S. M., Spaulding, W. D., Menditto, A. A., Savitz, A., Liberman, R. P., Berten, S., & Starobin, H. (2009). Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia. *Schizophrenia Bulletin*, 35(1), 222-232. doi:<https://dx.doi.org/10.1093/schbul/sbm150>
- Simon, P., Fermanian, J., Ginestet, D., Goujet, M., & Péron-Magnan, P. (1978). Standard and long-acting depot neuroleptics in chronic schizophrenics: an 18-month open multicentric study. *Archives of General Psychiatry*, 35(7), 893-897. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/619/CN-00018619/frame.html>
- Simpson, G., Mahmoud, R., Lasser, R., Kujawa, M., Bossie, C., Turkoz, I., . . . Gharabawi, G. (2006). A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. *Journal of Clinical Psychiatry*, 67(8), 1194-1203. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/965/CN-00567965/frame.html>
- Singh, D. K. (2011). *College Students with Psychiatric Disabilities*. Retrieved from <http://ez.library.laureate.edu.au/login?url=https://search.proquest.com/docview/964176642?accountid=12001>
- Singh, M., & Kay, S. (1975). A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztrapine in schizophrenia. Theoretical implications for potency differences among neuroleptics. *Psychopharmacologia*, 43(2), 103-113. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/126/CN-00706126/frame.html>
- Singh, M., & Kay, S. (1975). A longitudinal therapeutic comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Nontherapeutic interactions with trihexyphenidyl. Theoretical implications for potency differences. *Psychopharmacologia*, 43(2), 115-121. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/084/CN-00707084/frame.html>
- Skarphedinsson, G., De Nadai, A. S., Storch, E. A., Lewin, A. B., & Ivarsson, T. (2017). Defining cognitive-behavior therapy response and remission in pediatric OCD: A signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale. *European Child & Adolescent Psychiatry*, 26(1), 47-55. doi:<http://dx.doi.org/10.1007/s00787-016-0863-0>
- Sliwa, J., Fu, D., Bossie, C., Turkoz, I., & Alphs, L. (2014). Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. *BMC Psychiatry*, 14, 52. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/296/CN-01118296/frame.html> doi:10.1186/1471-244X-14-52
- Sliwa, J., Fu, D.-J., Bossie, C., Turkoz, I., & Alphs, L. (2014). Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. *BMC Psychiatry*, 14(1). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/296/CN-01118296/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

<http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/496/CN-00986496/frame.html> doi:10.1186/1471-244X-

14-52

Smeraldi, E., Cavallaro, R., Folnegovic-Smalc, V., Bidzan, L., Ceylan, M., & Schreiner, A. (2013). Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). *Therapeutic advances in psychopharmacology*, 3(4), 191-199. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/648/CN-00979648/frame.html> doi:10.1177/2045125313479127

Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D., Perez, J., & Catalano, M. (1998). Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. *Molecular Psychiatry*, 3(6), 508-511. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/063/CN-00158063/frame.html>

Smesny, S., Milleit, B., Hippler, U., Milleit, C., Schäfer, M., Klier, C., . . . Amminger, G. (2014). Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. *Molecular Psychiatry*, 19(3), 317-324. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/123/CN-00982123/frame.html> doi:10.1038/mp.2013.7

Smesny, S., Milleit, B., Hippler, U. C., Milleit, C., Schafer, M. R., Klier, C. M., . . . Amminger, G. P. (2014). Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. *Molecular Psychiatry*, 19(3), 317-324. doi:<https://dx.doi.org/10.1038/mp.2013.7>

Smith, R., Singh, A., Infante, M., Khandat, A., & Kloos, A. (2002). Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. *Neuropsychopharmacology*, 27(3), 479-497. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/970/CN-00409970/frame.html> doi:10.1016/S0893-133X(02)00324-X

Smith, R. C., Singh, A., Infante, M., Khandat, A., & Kloos, A. (2002). Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. *Neuropsychopharmacology*, 27(3), 479-497.

Smith, T. E., Hull, J. W., Romanelli, S., Fertuck, E., & Weiss, K. A. (1999). Symptoms and neurocognition as rate limiters in skills training for psychotic patients. *American Journal of Psychiatry*, 156(11), 1817-1818.

Smucny, J., Wylie, K., Kronberg, E., Legget, K., & Tregellas, J. (2017). Nicotinic modulation of salience network connectivity and centrality in schizophrenia. *Journal of Psychiatric Research*, 89, 85-96. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/872/CN-01329872/frame.html> doi:10.1016/j.jpsychires.2017.01.018

Smucny, J., Wylie, K. P., Kronberg, E., Legget, K. T., & Tregellas, J. R. (2017). Nicotinic modulation of salience network connectivity and centrality in schizophrenia. *Journal of Psychiatric Research*, 89, 85-96. doi:<https://dx.doi.org/10.1016/j.jpsychires.2017.01.018>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Sockalingam, S., Shammi, C., & Remington, G. (2009). Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study. *Journal of Clinical Psychiatry*, 70(8), 1114-1119. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/641/CN-00722641/frame.html> doi:10.4088/JCP.08m04495
- Somers, J., Patterson, M., Moniruzzaman, A., Currie, L., Rezansoff, S., Palepu, A., & Fryer, K. (2013). Vancouver At Home: pragmatic randomized trials investigating Housing First for homeless and mentally ill adults. *Trials [Electronic Resource]*, 14(1). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/065/CN-00915065/frame.html> doi:10.1186/1745-6215-14-365
- Souma, A., Rickerson, N., & Burgstahler, S. (2002). Academic Accommodations for Students with Psychiatric Disabilities (pp. 6): DO-IT, University of Washington, Box 355670, Seattle, WA 98195-5670. Tel: 206-685-DOIT; Tel: 888-972-DOIT (Toll Free); Fax: 206-221-4171; e-mail: doit@u.washington.edu; Web site: <http://www.washington.edu/doit>. For full text: <http://www.washington.edu/doit>.
- Spidel, A., Lecomte, T., Kealy, D., & Daigneault, I. (2017). Acceptance and commitment therapy for psychosis and trauma: improvement in psychiatric symptoms, emotion regulation, and treatment compliance following a brief group intervention. *Psychology and psychotherapy*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/312/CN-01415312/frame.html> doi:10.1111/papt.12159
- Sprich, S. E., Burbridge, J., Lerner, J. A., & Safren, S. A. (2015). Cognitive-behavioral therapy for ADHD in adolescents: Clinical considerations and a case series. *Cognitive and Behavioral Practice*, 22(2), 116-126. doi:<http://dx.doi.org/10.1016/j.cbpra.2015.01.001>
- Sprich, S. E., Safren, S. A., Finkelstein, D., Remmert, J. E., & Hammerness, P. (2016). A randomized controlled trial of cognitive behavioral therapy for ADHD in medication-treated adolescents. *Journal of Child Psychology and Psychiatry*, 57(11), 1218-1226. doi:<http://dx.doi.org/10.1111/jcpp.12549>
- Stain, H. J., Bucci, S., Baker, A. L., Carr, V., Emsley, R., Halpin, S., . . . Startup, M. (2016). A randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening for young people at ultra high risk of developing psychosis: The detection and evaluation of psychological therapy (DEPTh) trial. *Schizophrenia Research*, 176(2-3), 212-219. doi:<https://dx.doi.org/10.1016/j.schres.2016.08.008>
- Startup, M., Jackson, M. C., & Bendix, S. (2004). North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: outcomes at 6 and 12 months. *Psychological Medicine*, 34(3), 413-422.
- Startup, M., Jackson, M. C., Evans, K. E., & Bendix, S. (2005). North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: two-year follow-up and economic evaluation. *Psychological Medicine*, 35(9), 1307-1316.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Steel, C., Hardy, A., Smith, B., Wykes, T., Rose, S., Enright, S., . . . Mueser, K. (2017). Cognitive-behaviour therapy for post-traumatic stress in schizophrenia. A randomized controlled trial. *Psychological Medicine*, 47(1), 43-51.

doi:<http://dx.doi.org/10.1017/S0033291716002117>

Steel, C., Hardy, A., Smith, B., Wykes, T., Rose, S., Enright, S., . . . Mueser, K. T. (2017). Cognitive-behaviour therapy for post-traumatic stress in schizophrenia. A randomized controlled trial. *Psychological Medicine*, 47(1), 43-51.

doi:<https://dx.doi.org/10.1017/S0033291716002117>

Steel, C., van der Gaag, M., Korrelboom, K., Simon, J., Phiri, P., Baksh, M. F., . . . Kingdon, D. (2015). A randomised controlled trial of positive memory training for the treatment of depression within schizophrenia. *BMC Psychiatry*, 15, 85.

doi:<https://dx.doi.org/10.1186/s12888-015-0453-6>

Stevens, H., Agerbo, E., Dean, K., Mortensen, P. B., & Nordentoft, M. (2013). Reduction of crime in first-onset psychosis: a secondary analysis of the OPUS randomized trial. *Journal of Clinical Psychiatry*, 74(5), e439-444.

doi:<https://dx.doi.org/10.4088/JCP.12m08156>

Stice, E., Rohde, P., Gau, J. M., & Wade, E. (2010). Efficacy trial of a brief cognitive-behavioral depression prevention program for high-risk adolescents: Effects at 1- and 2-year follow-up. *Journal of Consulting and Clinical Psychology*, 78(6), 856-867. doi:<http://dx.doi.org/10.1037/a0020544>

Storch, E. A., Wilhelm, S., Sprich, S., Henin, A., Micco, J., Small, B. J., . . . Geller, D. A. (2016). Efficacy of augmentation of cognitive behavior therapy with weight-adjusted D-cycloserine vs placebo in pediatric obsessive-compulsive disorder: A randomized clinical trial. *JAMA Psychiatry*, 73(8), 779-788. doi:<http://dx.doi.org/10.1001/jamapsychiatry.2016.1128>

Stroup, T. (2014). What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia? *Journal of Clinical Psychiatry*, 75(11), 1261-1262. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/720/CN-01086720/frame.html> doi:10.4088/JCP.14com09518

Stroup, T., Lieberman, J., McEvoy, J., Davis, S., Swartz, M., Keefe, R., . . . Hsiao, J. (2009). Results of phase 3 of the CATIE schizophrenia trial. *Schizophrenia Research*, 107(1), 1-12. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/082/CN-00683082/frame.html> doi:10.1016/j.schres.2008.10.011

Strzelecki, D., Podgórski, M., Ka?u?y?ska, O., Stefa?czyk, L., Kotlicka-Antczak, M., Gmitrowicz, A., & Grzelak, P. (2015). Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex. *International journal of molecular sciences*, 16(10), 24475-24489. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/279/CN-01096279/frame.html> doi:10.3390/ijms161024475

Subotnik, K., Casaus, L., Ventura, J., Luo, J., Hellemann, G., Gretchen-Doorly, D., . . . Nuechterlein, K. (2015). Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Schizophrenia. A Randomized Clinical Trial. *JAMA Psychiatry*, 72(8), 822-829. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/744/CN-01086744/frame.html> doi:10.1001/jamapsychiatry.2015.0270
- Subotnik, K., Ventura, J., Gretchen-Doorly, D., Casaus, L., Luo, J., Turner, L., . . . Nuechterlein, K. (2013). Clinical advantages of long-acting injectable risperidone after an initial episode of schizophrenia. *Schizophrenia bulletin.*, 39, S353-s354. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/226/CN-01007226/frame.html> doi:10.1093/schbul/sbt011
- Subotnik, K., Ventura, J., Gretchen-Doorly, D., Hellemann, G., Casaus, L., Luo, J., . . . Nuechterlein, K. (2012). Effectiveness of long-acting injectable risperidone after an initial psychotic episode: relapse prevention and symptom reduction. *Early intervention in psychiatry*, 6, 7. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/041/CN-01004041/frame.html> doi:10.1111/j.1751-7893.2012.00392.x
- Subotnik, K. L., Casaus, L. R., Ventura, J., Luo, J. S., Hellemann, G. S., Gretchen-Doorly, D., . . . Nuechterlein, K. H. (2015). Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. *JAMA Psychiatry*, 72(8), 822-829. doi:<https://dx.doi.org/10.1001/jamapsychiatry.2015.0270>
- Subramaniam, K., Luks, T. L., Fisher, M., Simpson, G. V., Nagarajan, S., & Vinogradov, S. (2012). Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia. *Neuron*, 73(4), 842-853. doi:<https://dx.doi.org/10.1016/j.neuron.2011.12.024>
- Subramaniam, K., Luks, T. L., Garrett, C., Chung, C., Fisher, M., Nagarajan, S., & Vinogradov, S. (2014). Intensive cognitive training in schizophrenia enhances working memory and associated prefrontal cortical efficiency in a manner that drives long-term functional gains. *Neuroimage*, 99, 281-292. doi:<https://dx.doi.org/10.1016/j.neuroimage.2014.05.057>
- Sungur, M., Soygur, H., Guner, P., Ustun, B., Cetin, I., & Falloon, I. R. (2011). Identifying an optimal treatment for schizophrenia: a 2-year randomized controlled trial comparing integrated care to a high-quality routine treatment. *International Journal of Psychiatry in Clinical Practice*, 15(2), 118-127. doi:<https://dx.doi.org/10.3109/13651501.2011.554987>
- Sungur, M. Z., Guner, P., Ustun, B., Cetin, I., & Soygur, H. (2003). Optimal treatment project for schizophrenia: results from a randomized, controlled, longitudinal study. *Seishin Shinkeigaku Zasshi - Psychiatria et Neurologia Japonica*, 105(9), 1175-1180.
- Surguladze, S., Chu, E., Marshall, N., Evans, A., Anilkumar, A., Timehin, C., . . . David, A. (2011). Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication. *Journal of psychopharmacology (oxford, england)*, 25(6), 722-733. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/493/CN-00813493/frame.html> doi:10.1177/0269881110363316

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Suzuki, H., & Gen, K. (2012). The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. *Human psychopharmacology*, 27(5), 470-475.

Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/798/CN-00878798/frame.html>

doi:10.1002/hup.2249

Suzuki, H., & Gen, K. (2012). The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. *Therapeutic advances in psychopharmacology*, 2(1), 23-29.

Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/572/CN-00917572/frame.html>

doi:10.1177/2045125311430536

Suzuki, H., & Gen, K. (2013). A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia. *Neuropsychiatric Disease and Treatment*, 9, 1281-1287. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/409/CN-00910409/frame.html>

doi:10.2147/NDT.S50754

Suzuki, H., Inoue, Y., & Gen, K. (2012). A study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia. *Therapeutic advances in psychopharmacology*, 2(6), 227-234. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/046/CN-00917046/frame.html>

doi:10.1177/2045125312457585

Swartz, M., Swanson, J., Hiday, V., Borum, R., Wagner, R., & Burns, B. (1998). Taking the wrong drugs: the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. *Social Psychiatry and Psychiatric Epidemiology*, 33 Suppl 1, S75-80. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/104/CN-00158104/frame.html>

Swift, R., Harrigan, E., & Kammen, D. (1998). A comparison of intramuscular (im) ziprasidone with im haloperidol. *9th congress of the association of european psychiatrists. Copenhagen, denmark. 20-24th september 1998*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/039/CN-00660039/frame.html>

Swift, R., Harrigan, E., & Kammen, D. (1998). A Comparison of Intramuscular Ziprasidone with Intramuscular Haloperidol. *151st annual meeting of the american psychiatric association. Toronto, ontario, canada. 30th may-4th june 1998*, (Nr465). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/061/CN-00660061/frame.html>

Swift, R., Harrigan, E., Kammen, D., & Casey, D. (1998). A comparison of fixed-dose, intramuscular (IM) ziprasidone with flexible-dose, IM haloperidol. *11th european college of neuropsychopharmacology congress*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/262/CN-00240262/frame.html>

Swift, R., Harrigan, E., Kammen, D., & Casey, D. (1998). A comparison of fixed-dose, intramuscular (IM) ziprasidone with flexible-dose, IM haloperidol CONFERENCE ABSTRACT. *11th european college of neuropsychopharmacology*

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

congress. Paris, france. 31st october - 4th november 1998. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/924/CN-00284924/frame.html>

Symonds, C. S., Taylor, S., Tippins, V., & Turkington, D. (2006). Violent Self-Harm in Schizophrenia. *Suicide and Life-Threatening Behavior*, 36(1), 44-49.

Sytema, S., Jorg, F., Nieboer, R., & Wunderink, L. (2014). Adding evidence-based interventions to assertive community treatment: a feasibility study. *Psychiatric Services*, 65(5), 689-692.

Sytema, S., Jörg, F., Nieboer, R., & Wunderink, L. (2014). Adding evidence-based interventions to assertive community treatment: a feasibility study. *Psychiatric services (washington, D.C.)*, 65(5), 689-692. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/461/CN-00996461/frame.html>
doi:10.1176/appi.ps.201300143

Szigethy, E., Kenney, E., Carpenter, J., Hardy, D. M., Fairclough, D., Bousvaros, A., . . . DeMaso, D. R. (2007). Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. *Journal of the American Academy of Child & Adolescent Psychiatry*, 46(10), 1290-1298.

Takahashi, T., Wood, S. J., Yung, A. R., Soulsby, B., McGorry, P. D., Suzuki, M., . . . Pantelis, C. (2009). Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. *Archives of General Psychiatry*, 66(4), 366-376. doi:<https://dx.doi.org/10.1001/archgenpsychiatry.2009.12>

Takekita, Y., Kato, M., Sakai, S., Sunada, N., Koshikawa, Y., Serretti, A., & Kinoshita, T. (2014). Does medication history profile affect treatment response of antagonist and partial agonist at the D2 receptors in schizophrenia? *European neuropsychopharmacology*, 24, S537-s538. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/723/CN-01054723/frame.html>

Takekita, Y., Koshikawa, Y., Fabbri, C., Sakai, S., Sunada, N., Onohara, A., . . . Kinoshita, T. (2016). Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. *BMC Psychiatry*, 16(1) (no pagination). Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/975/CN-01159975/frame.html> doi:10.1186/s12888-016-0883-9

Tamminga, C., & Lahti, A. (1996). The Development of (-)-3PPP as an Antipsychotic Drug CONFERENCE ABSTRACT. *Xxth collegium internationale neuro-psychopharmacologicum. Melbourne, australia. 23rd-27th june, 1996*. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/959/CN-00284959/frame.html>

Tan, B. L., & King, R. (2013). The effects of cognitive remediation on functional outcomes among people with schizophrenia: a randomised controlled study. *Australian & New Zealand Journal of Psychiatry*, 47(11), 1068-1080.
doi:<https://dx.doi.org/10.1177/0004867413493521>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Tanghe, A., & Vereecken, J. (1972). Fluspirilene, an injectable, and penfluridol, an oral long-acting, neuroleptic. A comparative double-blind trial in residual schizophrenia. *Acta Psychiatrica Scandinavica*, 48(4), 315-331. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/048/CN-00008048/frame.html>
- Targum, S., Risinger, R., Du, Y., Pendergrass, J., Jamal, H., & Silverman, B. (2016). Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. *Schizophrenia research. (no pagination)*, 2016, Date of Publication: July 23. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/898/CN-01267898/frame.html> doi:10.1016/j.schres.2016.09.034
- Targum, S., Risinger, R., Du, Y., Pendergrass, J., Jamal, H., & Silverman, B. (2017). Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. *Schizophrenia Research*, 179, 64-69. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/513/CN-01214513/frame.html> doi:10.1016/j.schres.2016.09.034
- Tarrier, N., Kelly, J., Maqsood, S., Snelson, N., Maxwell, J., Law, H., . . . Gooding, P. (2014). The cognitive behavioural prevention of suicide in psychosis: a clinical trial. *Schizophrenia Research*, 156(2-3), 204-210. doi:<https://dx.doi.org/10.1016/j.schres.2014.04.029>
- Tarrier, N., Kinney, C., McCarthy, E., Humphreys, L., Wittkowski, A., & Morris, J. (2000). Two-year follow-up of cognitive-behavioral therapy and supportive counseling in the treatment of persistent symptoms in chronic schizophrenia. *Journal of Consulting & Clinical Psychology*, 68(5), 917-922.
- Tarrier, N., Lewis, S., Haddock, G., Bentall, R., Drake, R., Kinderman, P., . . . Dunn, G. (2004). Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial. *British Journal of Psychiatry*, 184, 231-239.
- Tas, C., Danaci, A. E., Cubukcuoglu, Z., & Brune, M. (2012). Impact of family involvement on social cognition training in clinically stable outpatients with schizophrenia -- a randomized pilot study. *Psychiatry Research*, 195(1-2), 32-38. doi:<https://dx.doi.org/10.1016/j.psychres.2011.07.031>
- Taylor, H. E., Parker, S., Mansell, W., & Morrison, A. P. (2013). Effects of appraisals of anomalous experience on distress in people at risk of psychosis. *Behavioural & Cognitive Psychotherapy*, 41(1), 24-33. doi:<https://dx.doi.org/10.1017/S1352465812000227>
- Taylor, H. E., Stewart, S. L., Dunn, G., Parker, S., Fowler, D., & Morrison, A. P. (2014). Core schemas across the continuum of psychosis: a comparison of clinical and non-clinical groups. *Behavioural & Cognitive Psychotherapy*, 42(6), 718-730. doi:<https://dx.doi.org/10.1017/S1352465813000593>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

Taylor, R., Cella, M., Csipke, E., Heriot-Maitland, C., Gibbs, C., & Wykes, T. (2016). Tackling Social Cognition in Schizophrenia: A Randomized Feasibility Trial. *Behavioural & Cognitive Psychotherapy*, 44(3), 306-317.
doi:<https://dx.doi.org/10.1017/S1352465815000284>

Tempier, R., Balbuena, L., Garety, P., & Craig, T. (2012). Does assertive community outreach improve social support? Results from the Lambeth Study of early-episode psychosis. *Psychiatric services (Washington, D.C.)*, 63(3), 216-222. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/340/CN-00970340/frame.html>
doi:10.1176/appi.ps.20110013

Tempier, R., Balbuena, L., Garety, P., & Craig, T. J. (2012). Does assertive community outreach improve social support? Results from the Lambeth Study of early-episode psychosis. *Psychiatric Services*, 63(3), 216-222.
doi:<https://dx.doi.org/10.1176/appi.ps.20110013>

Thomas, N., Shawyer, F., Castle, D., Copolov, D., Hayes, S., & Farhall, J. (2014). A randomised controlled trial of acceptance and commitment therapy (ACT) for psychosis: study protocol. *BMC Psychiatry*, 14(1). Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/207/CN-00999207/frame.html> doi:10.1186/1471-244X-14-198

Thomas, N., Shawyer, F., Castle, D. J., Copolov, D., Hayes, S. C., & Farhall, J. (2014). A randomised controlled trial of acceptance and commitment therapy (ACT) for psychosis: study protocol. *BMC Psychiatry*, 14, 198.
doi:<https://dx.doi.org/10.1186/1471-244X-14-198>

Thompson, V. L., Akbar, M. D., & Bazile, A. (2002). *African American's Perceptions of Psychotherapy and Psychotherapists*. Retrieved from

<http://ez.library.latrobe.edu.au/login?url=https://search.proquest.com/docview/62222559?accountid=12001>

Thornicroft, G., Farrelly, S., Birchwood, M., Marshall, M., Szumukler, G., Waheed, W., . . . Sutherby, K. (2010). CRIMSON [CRisis plan IMpact: Subjective and Objective coercion and eNgagement] protocol: a randomised controlled trial of joint crisis plans to reduce compulsory treatment of people with psychosis. *Trials [Electronic Resource]*, 11, 102.
doi:<https://dx.doi.org/10.1186/1745-6215-11-102>

Thornicroft, G., Farrelly, S., Birchwood, M., Marshall, M., Szumukler, G., Waheed, W., . . . Sutherby, K. (2010). CRIMSON protocol: a randomised controlled trial of joint crisis plans to reduce compulsory treatment of people with psychosis. *Trials [Electronic Resource]*, 11, 102. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/772/CN-00770772/frame.html> doi:10.1186/1745-6215-11-102

Thorup, A., Petersen, L., Jeppesen, P., Ohlenschlaeger, J., Christensen, T., Krarup, G., . . . Nordentoft, M. (2006). Social network among young adults with first-episode schizophrenia spectrum disorders: results from the Danish OPUS trial. *Social Psychiatry & Psychiatric Epidemiology*, 41(10), 761-770.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Thorup, A., Petersen, L., Jeppesen, P., Øhlenschlaeger, J., Christensen, T., Krarup, G., . . . Nordentoft, M. (2006). Social network among young adults with first-episode schizophrenia spectrum disorders: results from the Danish OPUS trial. *Social Psychiatry and Psychiatric Epidemiology*, 41(10), 761-770. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/597/CN-00571597/frame.html> doi:10.1007/s00127-006-0098-3
- Tiffany, P. G., & Dey, K. (1983). *Control and the Aged: Environmental or Personality Factors*. Retrieved from <http://ez.library.latrobe.edu.au/login?url=https://search.proquest.com/docview/63408723?accountid=12001>
- http://ap01.alma.exlibrisgroup.com/view/uresolver/61LATROBE_INST/openurl?ctx_enc=info:ofi/enc:UTF-8&ctx_ver=Z39.88-2004&url_ctx_fmt=info:ofi/fmt:kev:mtx:ctx&url_ver=Z39.88-2004&rft.genre=unknown&rft.atitle=&rft.jtitle=&rft.btitle=Control+and+the+Aged%3A+Environmental+or+Personality+Factors.&rft.aulast=Tiffany&rft.auinitm=G.&rft.ausuffix=&rft.au=Tiffany%2C+Phyllis+G.%3BDey%2C+Kay&rft.date=1983&rft.volume=&rft.issue=&rft.quarter=&rft.ssn=&rft.spage=&rft.epage=&rft.pages=&rft.artnum=&rft.issn=&rft.eissn=&rft.isbn=&rft.sici=&rft.coden=&rft_id=info:doi/&rft.object_id=&rft.eisbn=&rft.edition=&rft.pub=Control+and+the+Aged%3A+Environmental+or+Personality+Factors.&rft.place=&rft.series=&rft.stitle=&rft.bici=&rft_id=info:bibcode/&rft_id=info:hdl/&rft_id=info:lccn/&rft_id=info:oclcnnum/&rft_id=info:pmid/&rft_id=info:eric/ED236482
- Tognin, S., Viding, E., McCrory, E. J., Taylor, L., O'Donovan, M. C., McGuire, P., & Mechelli, A. (2011). Effects of DTNBPI Genotype on Brain Development in Children. *Journal of Child Psychology and Psychiatry*, 52(12), 1287-1294.
- Tolksdorf, W., Kruschinski, H., Pfeiffer, J., & Simon, H. (1988). Methohexital/alfentanil-thiopental/alfentanil for total intravenous anesthesia for direct laryngoscopy with 100% O₂ jet ventilation. *Anesthesie, intensivtherapie, notfallmedizin*, 23(4), 191-194. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/177/CN-00056177/frame.html>
- Torp, N. C., & Skarphedinsson, G. (2017). Early responders and remitters to exposure-based CBT for pediatric OCD. *Journal of Obsessive-Compulsive and Related Disorders*, 12, 71-77. doi:<http://dx.doi.org/10.1016/j.jocrd.2016.12.007>
- Tran, A., & Ishino, R. (2016). Identifying optimal patient characteristics for initiating a long-acting injectable antipsychotic. *Journal of pharmacy practice. Conference: 19th annual meeting of the college of psychiatric and neurologic pharmacists, CPNP. United states*, 29(3), 308-309. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/021/CN-01362021/frame.html> doi:10.1177/0897190016645328
- Trillenberg, P., Sprenger, A., Talamo, S., Herold, K., Helmchen, C., Verleger, R., & Lencer, R. (2017). Visual and non-visual motion information processing during pursuit eye tracking in schizophrenia and bipolar disorder. *European Archives of Psychiatry and Clinical Neuroscience*, 267(3), 225-235. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/032/CN-01366032/frame.html> doi:10.1007/s00406-016-0671-z

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Trower, P., Birchwood, M., Meaden, A., Byrne, S., Nelson, A., & Ross, K. (2004). Cognitive therapy for command hallucinations: randomised controlled trial. *British Journal of Psychiatry*, 184, 312-320.
- Turkington, D., & Kingdon, D. (2000). Cognitive-behavioural techniques for general psychiatrists in the management of patients with psychoses. *British Journal of Psychiatry*, 177, 101-106.
- Turkington, D., Kingdon, D., Rathod, S., Hammond, K., Pelton, J., & Mehta, R. (2006). Outcomes of an effectiveness trial of cognitive-behavioural intervention by mental health nurses in schizophrenia. *British Journal of Psychiatry*, 189, 36-40.
- Turkington, D., Kingdon, D., Turner, T., & Insight into Schizophrenia Research, G. (2002). Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. *British Journal of Psychiatry*, 180, 523-527.
- Turkington, D., Sensky, T., Scott, J., Barnes, T. R., Nur, U., Siddle, R., . . . Kingdon, D. (2008). A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. *Schizophrenia Research*, 98(1-3), 1-7.
- Turkoz, I., Lasser, R., Rodriguez, S., Locklear, J., Mahableshwarkar, A., Gharabawi, G., . . . Feifel, D. (2005). Functioning and Quality of Life During Long-Acting Risperidone Maintenance Treatment. *158th annual meeting of the american psychiatric association; 2005 may 21-26; atlanta, GA*, Nr205. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/141/CN-00660141/frame.html>
- Turncliff, R., Hard, M., Du, Y., Risinger, R., & Ehrlich, E. (2014). Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. *Schizophrenia Research*, 159(2-3), 404-410. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/854/CN-01046854/frame.html> doi:10.1016/j.schres.2014.09.021
- Twamley, E. W., Burton, C. Z., & Vella, L. (2011). Compensatory cognitive training for psychosis: who benefits? Who stays in treatment? *Schizophrenia Bulletin*, 37 Suppl 2, S55-62. doi:<https://dx.doi.org/10.1093/schbul/sbr059>
- Twamley, E. W., Savla, G. N., Zurhellen, C. H., Heaton, R. K., & Jeste, D. V. (2008). Development and pilot testing of a novel compensatory cognitive training intervention for people with psychosis. *American Journal of Psychiatric Rehabilitation*, 11(2), 144-163. doi:<http://dx.doi.org/10.1080/15487760801963678>
- Twamley, E. W., Vella, L., Burton, C. Z., Heaton, R. K., & Jeste, D. V. (2012). Compensatory cognitive training for psychosis: effects in a randomized controlled trial. *Journal of Clinical Psychiatry*, 73(9), 1212-1219. doi:<https://dx.doi.org/10.4088/JCP.12m07686>
- Tyminski, R. (2012). Lost for Words: Difficulty Expressing Feelings in Work with Three Adolescent Boys. *Journal of Child Psychotherapy*, 38(1), 32-48.
- Tyler, P., & Weaver, T. (2004). Desperately seeking solutions: The search for appropriate treatment for comorbid substance misuse and psychosis. *Psychiatric Bulletin*, 28(1), 1-2. doi:<http://dx.doi.org/10.1192/pb.28.1.1>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Uchida, H., Mamo, D., Kapur, S., Labelle, A., Shammi, C., Mannaert, E., . . . Remington, G. (2008). Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. *Journal of Clinical Psychiatry*, 69(8), 1281-1286. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/866/CN-00649866/frame.html>
- Ueland, T., & Rund, B. R. (2004). A controlled randomized treatment study: the effects of a cognitive remediation program on adolescents with early onset psychosis. *Acta Psychiatrica Scandinavica*, 109(1), 70-74.
- Uher, R., Cumby, J., MacKenzie, L. E., Morash-Conway, J., Glover, J. M., Aylott, A., . . . Alda, M. (2014). A familial risk enriched cohort as a platform for testing early interventions to prevent severe mental illness. *BMC Psychiatry*, 14, 344. doi:<https://dx.doi.org/10.1186/s12888-014-0344-2>
- Ulrich, S., Neuhofer, S., Braun, V., & Meyer, F. (1999). Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. *International Clinical Psychopharmacology*, 14(4), 219-228. doi:<http://dx.doi.org/10.1097/00004850-199907000-00003>
- Umbrecht, D., Alberati, D., Martin-Facklam, M., Borroni, E., Youssef, E., Ostland, M., . . . Santarelli, L. (2014). Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. *JAMA Psychiatry*, 71(6), 637-646. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/216/CN-00996216/frame.html> doi:[10.1001/jamapsychiatry.2014.163](https://doi.org/10.1001/jamapsychiatry.2014.163)
- Urioste, R., Bossie, C., Zhu, Y., Ciliberto, N., Trinh, B., & Lasser, R. (2004). Clinical Improvement With Long-Acting Risperidone: no Impact of Race. *157th annual meeting of the american psychiatric association; 2004 may 1-6; new york, NY*, Nr629. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/569/CN-00658569/frame.html>
- Urioste, R., Lasser, R., Gharabawi, G., Jarboe, K., Litrell, K., Miller, A., . . . Crumbley, E. (2005). Patient Acceptance and Long-Acting Risperidone: start Program, Gain Approach. *158th annual meeting of the american psychiatric association; 2005 may 21-26; atlanta, GA*, Nr206. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/683/CN-00655683/frame.html>
- Usall, J., Huerta-Ramos, E., Iniesta, R., Cobo, J., Araya, S., Roca, M., . . . Ochoa, S. (2011). Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. *The Journal of Clinical Psychiatry*, 72(11), 1552-1557. doi:<http://dx.doi.org/10.4088/JCP.10m06610>
- Usall, J., Huerta-Ramos, E., Iniesta, R., Cobo, J., Araya, S., Roca, M., . . . Ochoa, S. (2011). Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. *Journal of Clinical Psychiatry*, 72(11), 1552-1557. doi:<https://dx.doi.org/10.4088/JCP.10m06610>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Usall, J., Huerta-Ramos, E., Iniesta, R., Cobo, J., Araya, S., Roca, M., . . . Ochoa, S. (2011). Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. *Journal of Clinical Psychiatry*, 72(11), 1552-1557. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/997/CN-00805997/frame.html> doi:10.4088/JCP.10m06610
- Usall, J., Huerta-Ramos, E., Labad, J., Cobo, J., Núñez, C., Creus, M., . . . Roca, M. (2016). Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: a 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial. *Schizophrenia Bulletin*, 42(2), 309-317. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/738/CN-01159738/frame.html> doi:10.1093/schbul/sbv149
- Usall, J., Huerta-Ramos, E., Labad, J., Cobo, J., Nunez, C., Creus, M., . . . Roca, M. (2016). Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: A 24-week double-blind, randomized, parallel, placebo-controlled trial. *Schizophrenia Bulletin*, 42(2), 309-317. doi:<http://dx.doi.org/10.1093/schbul/sbv149>
- Usall, J., Huerta-Ramos, E., Labad, J., Cobo, J., Nunez, C., Creus, M., . . . Group, R. (2016). Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial. *Schizophrenia Bulletin*, 42(2), 309-317. doi:<https://dx.doi.org/10.1093/schbul/sbv149>
- Valencia, M., Fresan, A., Juarez, F., Escamilla, R., & Saracco, R. (2013). The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia. *Journal of Psychiatric Research*, 47(12), 1886-1892. doi:<https://dx.doi.org/10.1016/j.jpsychires.2013.09.006>
- Valencia, M., Rascon, M. L., Juarez, F., & Murow, E. (2007). A psychosocial skills training approach in Mexican out-patients with schizophrenia. *Psychological Medicine*, 37(10), 1393-1402.
- Valmaggia, L. R., van der Gaag, M., Tarrier, N., Pijnenborg, M., & Slooff, C. J. (2005). Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial. *British Journal of Psychiatry*, 186, 324-330.
- van der Gaag, M., Nieman, D. H., Rietdijk, J., Dragt, S., Ising, H. K., Klaassen, R. M., . . . Linszen, D. H. (2012). Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. *Schizophrenia Bulletin*, 38(6), 1180-1188. doi:<https://dx.doi.org/10.1093/schbul/sbs105>
- van der Gaag, M., Stant, A. D., Wolters, K. J., Buskens, E., & Wiersma, D. (2011). Cognitive-behavioural therapy for persistent and recurrent psychosis in people with schizophrenia-spectrum disorder: cost-effectiveness analysis. *British Journal of Psychiatry*, 198(1), 59-65, sup 51. doi:<https://dx.doi.org/10.1192/bjp.bp.109.071522>
- van der Gaag, M., van Oosterhout, B., Daalman, K., Sommer, I. E., & Korrelboom, K. (2012). Initial evaluation of the effects of competitive memory training (COMET) on depression in schizophrenia-spectrum patients with persistent auditory

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

verbal hallucinations: a randomized controlled trial. *British Journal of Clinical Psychology*, 51(2), 158-171.

doi:<https://dx.doi.org/10.1111/j.2044-8260.2011.02025.x>

Van Donkersgoed, R. J., De Jong, S., Van der Gaag, M., Aleman, A., Lysaker, P. H., Wunderink, L., & Pijnenborg, G. H. (2014).

A manual-based individual therapy to improve metacognition in schizophrenia: protocol of a multi-center RCT. *BMC Psychiatry*, 14, 27. doi:<https://dx.doi.org/10.1186/1471-244X-14-27>

Vanover, K., Glass, S., O'Gorman, C., Saillard, J., Weingart, M., Correll, C., . . . Davis, R. (2016). Advancing the clinical

development of ITI-007-update on efficacy for the treatment of schizophrenia. *Neuropsychopharmacology*.

Conference: 55th annual meeting of the american college of neuropsychopharmacology, ACNP 2016. United states.

Conference start: 20161204. Conference end: 20161208, 41, S232-s233. Retrieved from http://cochanelibrary-

wiley.com/o/cochrane/clcentral/articles/337/CN-01296337/frame.html doi:10.1038/npp.2016.240

Vanover, K., Mates, S., Saillard, J., Glass, S., & Davis, R. (2018). Unique pharmacology and clinical evidence supporting the

antidepressant therapeutic potential of lumateperone; a novel agent in phase 3 development for bipolar depression.

Bipolar disorders. Conference: 20th annual conference of the international society for bipolar disorders. Mexico,

20(Supplement 1), 141. Retrieved from http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/360/CN-

01468360/frame.html doi:10.1111/bdi.12619

Vanover, K., O'Gorman, C., Correll, C., Glass, S., Mates, S., Saillard, J., . . . Davis, R. (2017). Lumateperone (ITI-007): a novel

investigational agent with broad therapeutic potential across multiple neuropsychiatric disorders. *European*

neuropsychopharmacology. Conference: 30th european college of neuropsychopharmacology congress, ECNP 2017. France,

27(Supplement 4), S660-s661. Retrieved from http://cochanelibrary-

wiley.com/o/cochrane/clcentral/articles/525/CN-01428525/frame.html

Vasavan, N. N., Suranyi-Cadotte, B., & Schwartz, G. (1986). A clinical trial comparing intramuscular haloperidol decanoate and

oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. *Journal of Clinical*

Psychopharmacology, 6(1 suppl.), 30s-37s. Retrieved from http://cochanelibrary-

wiley.com/o/cochrane/clcentral/articles/812/CN-00440812/frame.html

Vauth, R., Corrigan, P. W., Clauss, M., Dietl, M., Dreher-Rudolph, M., Stieglitz, R. D., & Vater, R. (2005). Cognitive strategies

versus self-management skills as adjunct to vocational rehabilitation. *Schizophrenia Bulletin*, 31(1), 55-66.

Velligan, D. I., Bow-Thomas, C. C., Huntzinger, C., Ritch, J., Ledbetter, N., Prihoda, T. J., & Miller, A. L. (2000). Randomized

controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia.

American Journal of Psychiatry, 157(8), 1317-1323.

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Velligan, D. I., Diamond, P., Mueller, J., Li, X., Maples, N., Wang, M., & Miller, A. L. (2009). The short-term impact of generic versus individualized environmental supports on functional outcomes and target behaviors in schizophrenia. *Psychiatry Research*, 168(2), 94-101. doi:<https://dx.doi.org/10.1016/j.psychres.2008.03.016>
- Velligan, D. I., Diamond, P. M., Maples, N. J., Mintz, J., Li, X., Glahn, D. C., & Miller, A. L. (2008). Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. *Schizophrenia Research*, 102(1-3), 312-319. doi:<https://dx.doi.org/10.1016/j.schres.2008.02.005>
- Velligan, D. I., Mueller, J., Wang, M., Dicocco, M., Diamond, P. M., Maples, N. J., & Davis, B. (2006). Use of environmental supports among patients with schizophrenia. *Psychiatric Services*, 57(2), 219-224.
- Velligan, D. I., Prihoda, T. J., Ritch, J. L., Maples, N., Bow-Thomas, C. C., & Dassori, A. (2002). A randomized single-blind pilot study of compensatory strategies in schizophrenia outpatients. *Schizophrenia Bulletin*, 28(2), 283-292.
- Velligan, D. I., Tai, S., Roberts, D. L., Maples-Aguilar, N., Brown, M., Mintz, J., & Turkington, D. (2015). A randomized controlled trial comparing cognitive behavior therapy, cognitive adaptation training, their combination and treatment as usual in chronic schizophrenia. *Schizophrenia Bulletin*, 41(3), 597-603. doi:<https://dx.doi.org/10.1093/schbul/sbu127>
- Vereecken, J., & Tanghe, A. (1972). Fluspirilene and pipothiazine undecylenate, two long-acting injectable neuroleptics. A double-blind controlled trial in residual schizophrenia. *Psychiatria, neurologia, neurochirurgia*, 75(2), 117-127.
- Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/171/CN-00007171/frame.html>
- Verster, G., Joubert, G., Stevens, M., & Merwe, H. (1998). Generic substitution--comparing the clinical efficacy of a generic substitute for fluphenazine decanoate with the original product. *South African medical journal*, 88(3), 260-262.
- Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/546/CN-00686546/frame.html>
- Vesterager, L., Christensen, T. O., Olsen, B. B., Krarup, G., Forchhammer, H. B., Melau, M., . . . Nordentoft, M. (2011). Cognitive training plus a comprehensive psychosocial programme (OPUS) versus the comprehensive psychosocial programme alone for patients with first-episode schizophrenia (the NEUROCOM trial): a study protocol for a centrally randomised, observer-blinded multi-centre clinical trial. *Trials [Electronic Resource]*, 12, 35.
- doi:<https://dx.doi.org/10.1186/1745-6215-12-35>
- Vetlugina, T., Lobacheva, O., Sergeeva, S., Nikitina, V., Nevidimova, T., & Semke, A. (2016). Adjunctive use of interferon ? inducer for treatment of patients with schizophrenia. *Acta neuropsychiatrica*, 28(3), 149-156. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/628/CN-01164628/frame.html> doi:10.1017/neu.2015.60
- Vianin, P., Urben, S., Magistretti, P., Marquet, P., Fornari, E., & Jaugey, L. (2014). Increased activation in Broca's area after cognitive remediation in schizophrenia. *Psychiatry Research*, 221(3), 204-209.
- doi:<https://dx.doi.org/10.1016/j.psychresns.2014.01.004>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Vilardaga, R., Estevez, A., Levin, M. E., & Hayes, S. C. (2012). Deictic Relational Responding, Empathy, and Experiential Avoidance as Predictors of Social Anhedonia: Further Contributions from Relational Frame Theory. *Psychological Record*, 62(3), 409-432.
- Vinar, O., Taussigova, D., Bastecky, J., & Boletouky, Z. (1970). Long acting peroral fluphenazine and its dosage in psychoses. *Activitas nervosa superior*, 12(3), 248-249. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/385/CN-00240385/frame.html>
- Vinogradov, S., Fisher, M., Holland, C., Shelly, W., Wolkowitz, O., & Mellon, S. H. (2009). Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? *Biological Psychiatry*, 66(6), 549-553. doi:<https://dx.doi.org/10.1016/j.biopsych.2009.02.017>
- Vinogradov, S., Fisher, M., Warm, H., Holland, C., Kirshner, M. A., & Pollock, B. G. (2009). The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. *American Journal of Psychiatry*, 166(9), 1055-1062. doi:<https://dx.doi.org/10.1176/appi.ajp.2009.09010017>
- Vishne, T., Aronov, S., Amiaz, R., Etchin, A., & Grunhaus, L. (2005). Remifentanil supplementation of propofol during electroconvulsive therapy: effect on seizure duration and cardiovascular stability. *Journal of ECT*, 21(4), 235-238. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/496/CN-00575496/frame.html> doi:[10.1097/01.yct.0000180040.06338.ac](https://doi.org/10.1097/01.yct.0000180040.06338.ac)
- Vita, A., De Peri, L., Barlati, S., Cacciani, P., Cisima, M., Deste, G., . . . Sacchetti, E. (2011). Psychopathologic, neuropsychological and functional outcome measures during cognitive rehabilitation in schizophrenia: a prospective controlled study in a real-world setting. *European Psychiatry: the Journal of the Association of European Psychiatrists*, 26(5), 276-283. doi:<https://dx.doi.org/10.1016/j.eurpsy.2010.03.008>
- Volz, H., Möller, H., Gerebtzoff, A., & Bischoff, S. (2002). Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience*, 252(2), 76-80. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/689/CN-00397689/frame.html> doi:[10.1007/s00406-002-0364-7](https://doi.org/10.1007/s00406-002-0364-7)
- Volz, H. P., Moller, H. J., Gerebtzoff, A., & Bischoff, S. (2002). Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia. *European Archives of Psychiatry & Clinical Neuroscience*, 252(2), 76-80.
- Wagner, B., Nagl, M., Dolemeyer, R., Klinitzke, G., Steinig, J., Hilbert, A., & Kersting, A. (2016). Randomized controlled trial of an internet-based cognitive-behavioral treatment program for binge-eating disorder. *Behavior Therapy*, 47(4), 500-514. doi:<http://dx.doi.org/10.1016/j.beth.2016.01.006>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Wakamatsu, A., Takahashi, N., Takahashi, M., Saito, T., Iizumi, M., Saito, Y., . . . Matsumura, T. (2013). Efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia: a 13-week double-blind study. *European neuropsychopharmacology*, 23, S466. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/768/CN-01024768/frame.html> doi:10.1016/S0924-977X%2813%2970737-5
- Waller, H., Craig, T., Landau, S., Fornells-Ambrojo, M., Hassanali, N., Iredale, C., . . . Garety, P. (2014). The effects of a brief CBT intervention, delivered by frontline mental health staff, to promote recovery in people with psychosis and comorbid anxiety or depression (the GOALS study): study protocol for a randomized controlled trial. *Trials [Electronic Resource]*, 15, 255. doi:<https://dx.doi.org/10.1186/1745-6215-15-255>
- Waller, H., Emsley, R., Freeman, D., Bebbington, P., Dunn, G., Fowler, D., . . . Garety, P. (2015). Thinking Well: A randomised controlled feasibility study of a new CBT therapy targeting reasoning biases in people with distressing persecutory delusional beliefs. *Journal of Behavior Therapy & Experimental Psychiatry*, 48, 82-89. doi:<https://dx.doi.org/10.1016/j.jbtep.2015.02.007>
- Walters, L., & Nel, P. (1981). The addiction potential of benzodiazepines. Application of the results of treatment of alcohol withdrawal syndrome. *South African medical journal*, 59(4), 115-116. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/416/CN-00333416/frame.html>
- Walters, L., & Nel, P. (1981). [The addiction potential of benzodiazepines. Application of the results of treatment of alcohol withdrawal syndrome] Die afhanklikheidspotensiaal van die bensodiasepiene. Toepassing van die resultate van die behandeling van die alkohol-onttrekkingsindroom. *South African medical journal*, 59(4), 115-116. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/414/CN-00255414/frame.html>
- Wamsley, E., Shinn, A., Tucker, M., Ono, K., McKinley, S., Ely, A., . . . Manoach, D. (2013). The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized placebo-controlled trial. *Sleep*, 36(9), 1369-1376. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/677/CN-00873677/frame.html> doi:10.5665/sleep.2968
- Wang, L.-Q., Chien, W. T., Yip, L. K., & Karatzias, T. (2016). A randomized controlled trial of a mindfulness-based intervention program for people with schizophrenia: 6-month follow-up. *Neuropsychiatric Disease and Treatment Vol 12 2016, ArtID 3097-3110*, 12.
- Wang, Y., Roberts, D. L., Xu, B., Cao, R., Yan, M., & Jiang, Q. (2013). Social cognition and interaction training for patients with stable schizophrenia in Chinese community settings. *Psychiatry Research*, 210(3), 751-755. doi:<https://dx.doi.org/10.1016/j.psychres.2013.08.038>
- Watkins, E., Newbold, A., Tester-Jones, M., Javaid, M., Cadman, J., Collins, L. M., . . . Mostazir, M. (2016). Implementing multifactorial psychotherapy research in online virtual environments (IMPROVE-2): Study protocol for a phase III trial

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

of the MOST randomized component selection method for internet cognitive-behavioural therapy for depression. *BMC Psychiatry* Vol 16 2016, ArtID 345, 16.

Watson, P. W., Garety, P. A., Weinman, J., Dunn, G., Bebbington, P. E., Fowler, D., . . . Kuipers, E. (2006). Emotional dysfunction in schizophrenia spectrum psychosis: the role of illness perceptions. *Psychological Medicine*, 36(6), 761-770.

Weber, M., & Wyne, K. (2006). A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. *Schizophrenia Research*, 83(1), 95-101.

Weersing, V., Brent, D. A., Rozenman, M. S., Gonzalez, A., Jeffreys, M., Dickerson, J. F., . . . Iyengar, S. (2017). Brief behavioral therapy for pediatric anxiety and depression in primary care: A randomized clinical trial. *JAMA Psychiatry*, 74(6), 571-578. doi:<http://dx.doi.org/10.1001/jamapsychiatry.2017.0429>

Wehr, A., Hard, M., Weiden, P., & Moltke, L. (2017). A phase 1 study comparing pharmacokinetic and safety profiles of three different dose intervals of aripiprazole lauroxil and subsequent population pharmacokinetic modeling. *Pharmacotherapy. Conference: 2017 annual meeting of the american college of clinical pharmacy, ACCP 2017. United states*, 37(12), e206-e207. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/739/CN-01449739/frame.html> doi:10.1002/phar.2052

Wehring, H., Sullivan, K., McMahon, R., Kearns, A., Heishman, S., Liu, F., . . . Kelly, D. (2015). Minocycline and tobacco craving in schizophrenia. *Schizophrenia bulletin.*, 41, S131. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/801/CN-01087801/frame.html> doi:10.1093/schbul/sbv010

Weiden, P., Kim, E., Bermak, J., Turkoz, I., Gopal, S., & Berwaerts, J. (2017). Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone. *Journal of Clinical Psychiatry*, 78(7), e813-e820. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/337/CN-01405337/frame.html> doi:10.4088/JCP.16m11308

Weiden, P., & Schooler, N. (2012). Long-acting injectable medication maintenance treatment of 'first-episode' schizophrenia-a randomized effectiveness study. *Early intervention in psychiatry*, 6, 8. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/039/CN-01004039/frame.html> doi:10.1111/j.1751-7893.2012.00392.x

Weiden, P., Schooler, N., Weedon, J., Elmouchtari, A., Sunakawa, A., & Goldfinger, S. (2009). A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. *Journal of Clinical Psychiatry*, 70(10), 1397-1406. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/786/CN-00731786/frame.html> doi:10.4088/JCP.09m05284yel

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Weiden, P., Schooler, N., Weedon, J., Elmouchtari, A., & Sunakawa-McMillan, A. (2012). Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study. *Journal of Clinical Psychiatry*, 73(9), 1224-1233. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/075/CN-00879075/frame.html> doi:10.4088/JCP.11m06905
- Weinstein, S., West, A., & Pavuluri, M. (2011). Psychosocial risk factors associated with suicidal events in Paediatric Bipolar Disorder (PBD). *International clinical psychopharmacology*, 26, e32-e33. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/790/CN-01003790/frame.html> doi:10.1097/01.yic.0000400071.67437.5f
- Wezenberg, E., Verkes, R., Ruigt, G., Hulstijn, W., & Sabbe, B. (2007). Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. *Neuropsychopharmacology*, 32(6), 1272-1283. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/229/CN-00586229/frame.html> doi:10.1038/sj.npp.1301257
- Wezenberg, E., Verkes, R. J., Ruigt, G. S., Hulstijn, W., & Sabbe, B. G. (2007). Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. *Neuropsychopharmacology*, 32(6), 1272-1283.
- White, R., Gumley, A., McTaggart, J., Rattrie, L., McConville, D., Cleare, S., & Mitchell, G. (2011). A feasibility study of Acceptance and Commitment Therapy for emotional dysfunction following psychosis. *Behaviour Research & Therapy*, 49(12), 901-907. doi:<https://dx.doi.org/10.1016/j.brat.2011.09.003>
- White, R., Gumley, A., McTaggart, J., Rattrie, L., McConville, D., Cleare, S., & Mitchell, G. (2011). A feasibility study of Acceptance and Commitment Therapy for emotional dysfunction following psychosis. *Behav Res Ther*, 49(12), 901-907. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/115/CN-00851115/frame.html> doi:10.1016/j.brat.2011.09.003
- White, R., Gumley, A., McTaggart, J., Rattrie, L., McConville, D., Cleare, S., & Mitchell, G. (2013). Depression and anxiety following psychosis: associations with mindfulness and psychological flexibility. *Behavioural and Cognitive Psychotherapy*, 41(1), 34-51. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/359/CN-00920359/frame.html> doi:10.1017/S1352465812000239
- White, R. G., Gumley, A. I., McTaggart, J., Rattrie, L., McConville, D., Cleare, S., & Mitchell, G. (2013). Depression and anxiety following psychosis: associations with mindfulness and psychological flexibility. *Behavioural & Cognitive Psychotherapy*, 41(1), 34-51. doi:<https://dx.doi.org/10.1017/S1352465812000239>
- Whittaker, R., Stasiak, K., McDowell, H., Doherty, I., Shepherd, M., Chua, S., . . . Merry, S. (2017). MEMO: an mHealth intervention to prevent the onset of depression in adolescents: a double-blind, randomised, placebo-controlled trial. *Journal of Child Psychology & Psychiatry & Allied Disciplines*, 58(9), 1014-1022. doi:<https://dx.doi.org/10.1111/jcpp.12753>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Whittier, J., Korenyi, C., Haydu, G., & Goldschmidt, L. (1967). Effects of long-acting injectable Prolixin in 23 psychotic patients. *Diseases of the nervous system*, 28(7 Pt 1), 459-461. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/126/CN-00065126/frame.html>
- Wiersma, D., Jenner, J. A., Nienhuis, F. J., & van de Willige, G. (2004). Hallucination focused integrative treatment improves quality of life in schizophrenia patients. *Acta Psychiatrica Scandinavica*, 109(3), 194-201.
- Wiles, N., Thomas, L., Abel, A., Barnes, M., Carroll, F., Ridgway, N., . . . Lewis, G. (2014). Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial. *Health Technology Assessment (Winchester, England)*, 18(31), 1-167, vii-viii. doi:<https://dx.doi.org/10.3310/hta18310>
- Wirgenes, K., Tesli, M., Inderhaug, E., Athanasiu, L., Agartz, I., Melle, I., . . . Djurovic, S. (2014). ANK3 gene expression in bipolar disorder and schizophrenia. *British Journal of Psychiatry*, 205(3), 244-245. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/637/CN-01014637/frame.html>
doi:10.1192/bjp.bp.114.145433
- Wistedt, B., & Palmstierna, T. (1983). Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics. *Journal of Clinical Psychiatry*, 44(10), 369-371. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/923/CN-00032923/frame.html>
- Witte, M., Case, M., Schuh, K., & Ascher-Svanum, H. (2012). Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia. *Current medical research and opinion*, 28(3), 315-323. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/958/CN-00970958/frame.html>
doi:10.1185/03007995.2012.657300
- Wittorf, A., Jakobi, U., Bechdolf, A., Muller, B., Sartory, G., Wagner, M., . . . Klingberg, S. (2009). The influence of baseline symptoms and insight on the therapeutic alliance early in the treatment of schizophrenia. *European Psychiatry: the Journal of the Association of European Psychiatrists*, 24(4), 259-267.
doi:<https://dx.doi.org/10.1016/j.eurpsy.2008.12.015>
- Wittorf, A., Jakobi, U. E., Bannert, K. K., Bechdolf, A., Muller, B. W., Sartory, G., . . . Klingberg, S. (2010). Does the cognitive dispute of psychotic symptoms do harm to the therapeutic alliance? *Journal of Nervous & Mental Disease*, 198(7), 478-485. doi:<https://dx.doi.org/10.1097/NMD.0b013e3181e4f526>
- Wojtalik, J. A., Eack, S. M., Pollock, B. G., & Keshavan, M. S. (2012). Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia. *Psychiatry Research*, 204(2-3), 61-67. doi:<https://dx.doi.org/10.1016/j.psychresns.2012.04.014>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Wolf, D., Satterthwaite, T., Loughead, J., Pinkham, A., Overton, E., Elliott, M., . . . Gur, R. (2011). Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge. *Psychopharmacology*, 218(3), 503-512. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/837/CN-00882837/frame.html> doi:10.1007/s00213-011-2348-7
- Wolwer, W., & Frommann, N. (2011). Social-cognitive remediation in schizophrenia: generalization of effects of the Training of Affect Recognition (TAR). *Schizophrenia Bulletin*, 37 Suppl 2, S63-70. doi:<https://dx.doi.org/10.1093/schbul/sbr071>
- Wright, B., Tindall, L., Littlewood, E., Allgar, V., Abeles, P., Trepel, D., & Ali, S. (2017). Computerised cognitive-behavioural therapy for depression in adolescents: feasibility results and 4-month outcomes of a UK randomised controlled trial. *BMJ Open*, 7(1), e012834. doi:<https://dx.doi.org/10.1136/bmjopen-2016-012834>
- Wykes, T., Hayward, P., Thomas, N., Green, N., Surguladze, S., Fannon, D., & Landau, S. (2005). What are the effects of group cognitive behaviour therapy for voices? A randomised control trial. *Schizophrenia Research*, 77(2-3), 201-210.
- Wykes, T., Newton, E., Landau, S., Rice, C., Thompson, N., & Frangou, S. (2007). Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. *Schizophrenia Research*, 94(1-3), 221-230.
- Wykes, T., Reeder, C., Landau, S., Matthiasson, P., Haworth, E., & Hutchinson, C. (2009). Does age matter? Effects of cognitive rehabilitation across the age span. *Schizophrenia Research*, 113(2-3), 252-258.
doi:<https://dx.doi.org/10.1016/j.schres.2009.05.025>
- Wykes, T., Rose, D., Williams, P., & David, A. (2013). Working alliance and its relationship to outcomes in a randomized controlled trial (RCT) of antipsychotic medication. *BMC Psychiatry*, 13, 28. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/239/CN-00864239/frame.html> doi:10.1186/1471-244X-13-28
- Wyles, D., Rodriguez-Torres, M., Lawitz, E., Shiffman, M., Pol, S., Herring, R., . . . Sulkowski, M. (2014). All-oral combination of ledipasvir, velpatasvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. *Hepatology (baltimore, md.)*, 60(1), 56-64. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/483/CN-00995483/frame.html> doi:10.1002/hep.27053
- Yamaguchi, Y., Mihara, T., Taguri, M., Yamaguchi, O., & Goto, T. (2014). Melatonin receptor agonist for the prevention of postoperative delirium in elderly patients: a randomized, double-blind, placebo-controlled trial. *Intensive care medicine*, 40(1 suppl. 1), S246. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/000/CN-01055000/frame.html> doi:10.1007/s00134-013-3451-5
- Yan, T., Chang, E., Hartry, A., Broder, M., & Greene, M. (2017). Hospitalizations and costs in schizophrenia patients initiating long-acting injectable antipsychotics. *International journal of technology assessment in health care. Conference: 14th annual meeting of the health technology assessment international, htai 2017. Italy*, 33(Supplement 1), 171. Retrieved

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/418/CN-01470418/frame.html>

doi:10.1017/S0266462317003324

- Yang, L., Lo, G., WonPat-Borja, A., Singla, D., Link, B., & Phillips, M. (2012). Effects of labeling and interpersonal contact upon attitudes towards schizophrenia: implications for reducing mental illness stigma in urban China. *Social Psychiatry and Psychiatric Epidemiology*, 47(9), 1459-1473. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/413/CN-00854413/frame.html> doi:10.1007/s00127-011-0452-y
- Yanos, P. T., Vayshenker, B., Pleskach, P., & Mueser, K. T. (2016). Insight among people with severe mental illness, co-occurring PTSD and elevated psychotic symptoms: Correlates and relationship to treatment participation. *Comprehensive Psychiatry*, 68, 172-177. doi:<https://dx.doi.org/10.1016/j.comppsych.2016.04.016>
- Young, S., Khondoker, M., Emilsson, B., Sigurdsson, J., Philipp-Wiegmann, F., Baldursson, G., . . . Gudjonsson, G. (2015). Cognitive-behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: A randomized controlled trial using multi-level analysis. *Psychological Medicine*, 45(13), 2793-2804. doi:<http://dx.doi.org/10.1017/S0033291715000756>
- Youngstrom, E., Hameed, A., Mitchell, M., Freeman, A., Meter, A., Perez, A. G., . . . Meyer, R. (2013). Direct comparison of the psychometric properties of multiple interview and patient-rated assessments of suicidal ideation and behavior in a large inpatient sample. *Neuropsychopharmacology*, 38, S410. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/222/CN-01064222/frame.html> doi:10.1038/npp.2013.280
- Yung, A. R., Phillips, L. J., Nelson, B., Francey, S. M., PanYuen, H., Simmons, M. B., . . . McGorry, P. D. (2011). Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. *Journal of Clinical Psychiatry*, 72(4), 430-440. doi:<https://dx.doi.org/10.4088/JCP.08m04979ora>
- Zanello, A., Mohr, S., Merlo, M. C., Huguelet, P., & Rey-Bellet, P. (2014). Effectiveness of a brief group cognitive behavioral therapy for auditory verbal hallucinations: a 6-month follow-up study. *Journal of Nervous & Mental Disease*, 202(2), 144-153. doi:<https://dx.doi.org/10.1097/NMD.0000000000000084>
- Zhang, Z., Zhai, J., Wei, Q., Qi, J., Guo, X., & Zhao, J. (2014). Cost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study. *BMC Psychiatry*, 14, 212. doi:<https://dx.doi.org/10.1186/s12888-014-0212-0>
- Zhao, Y., Kishi, T., Iwata, N., & Ikeda, M. (2013). Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia. *Neuropsychiatric Disease and Treatment*, 9, 1655-1659. Retrieved from <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/453/CN-01076453/frame.html>

Efficacy of acceptance and commitment therapy (ACT) for schizophrenia spectrum and other psychotic disorders: A systematic review and meta-analysis of randomised controlled trials

- Zheng, Y., & Keenan, A. (2017). The impact of long acting injectable antipsychotics on the health and economic outcomes of schizophrenia patients. *Value in health. Conference: ISPOR 22nd annual international meeting. United states, 20(5)*, A296-a297. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/901/CN-01407901/frame.html>
- Zimmer, M., Duncan, A. V., Laitano, D., Ferreira, E. E., & Belmonte-de-Abreu, P. (2007). A twelve-week randomized controlled study of the cognitive-behavioral Integrated Psychological Therapy program: positive effect on the social functioning of schizophrenic patients. *Revista Brasileira de Psiquiatria, 29*(2), 140-147.
- Zisis, N., Psaras, M., & Lyketsos, G. (1982). Haloperidol decanoate, a new long-acting antipsychotic, in chronic schizophrenics: double-blind comparison with placebo. *Curr-Ther-Res,-Clin-Exp, 31*(4), 650-655. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/742/CN-00178742/frame.html>
- Zonda, T., & Kövári, E. (1992). Use of haloperidol decanoate in psychiatric diseases. *Therapia hungarica (english edition), 40*(2), 64-68. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/345/CN-00089345/frame.html>
- Zuardi, A., Giampietro, A., & Grassi, E. (1983). Double-blind comparison between two forms of haloperidol: an oral preparation and a new depot decanoate in the maintenance of schizophrenic inpatients. *Current therapeutic research, clinical and experimental, 34*(2 i), 253-261. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/498/CN-00240498/frame.html>
- Zwanikken, G. (1973). Penfluridol (R 16341). A long-acting oral neuroleptic, as maintenance therapy for schizophrenic and mentally retarded patients. A placebo-controlled double-blind trial. *Psychiatria, neurologia, neurochirurgia, 76*(2), 83-92. Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/495/CN-00008495/frame.html>
- Zylberman, I., Javitt, D., & Zukin, S. (1995). NMDA RECEPTOR AUGMENTATION THERAPY IN SCHIZOPHRENIA CONFERENCE ABSTRACT - Vth International Congress on Schizophrenia Research Wormsprings, VA, USA 6-12 April 1995. *Schizophrenia research (the vth international congress on schizophrenia research, wormsprings, VA USA. 6th-12th april, 1995.), 1, 2*(171). Retrieved from <http://cochanelibrary-wiley.com/o/cochrane/clcentral/articles/169/CN-00286169/frame.html>